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Abstract 
The interferon (IFN) response is a crucial component of cellular innate 
immunity, vital for controlling virus infections. Dysregulation of the IFN response 
however can lead to serious medical conditions including autoimmune 
disorders. Modulators of IFN induction and signalling could be used to treat 
these diseases and as tools to further understand the IFN response and viral 
infections. We have developed cell-based assays to identify modulators of IFN 
induction and signalling, based on A549 cell lines where a GFP gene is under 
the control of the IFN-β promoter (A549/pr(IFN-β).GFP) and the ISRE 
containing MxA promoter (A549/pr(ISRE).GFP) respectively. The assays were 
optimized, miniaturized and validated as suitable for HTS by achieving Z’ Factor 
scores >0.6. A diversity screen of 15,667 compounds using the IFN induction 
reporter assay identified 2 hit compounds (StA-IFN-1 and StA-IFN-4) that were 
validated as specifically inhibiting IFNβ induction. Characterisation of these 
molecules demonstrated that StA-IFN-4 potently acts at, or upstream, of IRF3 
phosphorylation. We successfully expanded this HTS platform to target viral 
interferon antagonists acting upon IFN-signalling. An additional assay was 
developed where the A549/pr(ISRE).GFP.RBV-P reporter cell line constitutively 
expresses the Rabies virus phosphoprotein. A compound inhibiting viral protein 
function will restore GFP expression. The assay was successfully optimized for 
HTS and used in an in-house screen. We further expanded this assay by 
placing the expression of RBV-P under the control of an inducible promoter. 
This demonstrates a convenient approach for assay development and 
potentiates the targeting of a variety of viral IFN antagonists for the identification 
of compounds with the potential to develop a novel class of antiviral drugs. 
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1. Introduction 
1.1 The interferon system 
The immune system is as ancient as the evolution of bacterial defence 
against bacteriophages and is implicated in inflammatory processes from tissue 
damage repair to protection from, and removal of potentially damaging foreign 
invaders (Kotwal et al., 2012). The interferon (IFN) response is an arm of the 
innate immune system that responds to infective challenge upon a cell, more 
frequently but not exclusively to viruses. Other functions of the IFN response 
include the regulation of cancer cell growth (Caraglia et al., 2013), suppression 
of inflammation (Gonzalez-Navajas et al., 2012) and involvement in 
macrophage differentiation (Hertzog, 2012). Infective challenge is detected by 
pattern recognition receptors (PRRs) present within a cell, which sense 
pathogen associated molecular patterns (PAMPs) (Kumar et al., 2011). These 
PAMPs can take many forms, from bacterial lipopolysaccharide (LPS) to nucleic 
acids and proteins (Yamamoto et al., 2002, Iwasaki, 2012). This crucial non-
discriminatory mechanism of cellular defense is also necessary to abrogate any 
further damage to the cell and its neighbours. Additionally, its activation is a 
necessary step in the induction of the adaptive immune response, which 
instigates more tailored, longer lasting effects (Takeuchi and Akira, 2010). 
IFN was first discovered in 1957 by Lindenmann and Isaacs, and is so 
named for its ability to ‘interfere’ with the course of a viral infection (Isaacs and 
Lindenmann, 1957). Interferons now encompass a group of cytokines that are 
germ line encoded, have far-reaching pleiotropic actions and have been 
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extensively reviewed (Randall and Goodbourn, 2008, Hoffmann et al., 2015, 
Ivashkiv and Donlin, 2014). Since the seminal discovery of IFNs, much work 
has focused on furthering our collective knowledge of the function of these 
chemical messengers and their mechanisms of action. There are numerous 
types of interferon, varying in their receptors and stimuli. The shared goal 
however is the cellular protection from invading pathogens. Type I IFNs 
encompass a group of 18 functional genes, including IFNα with 14 isoforms, β, 
of which there is a single isoform and others including ε, κ and ω (Gonzalez-
Navajas et al., 2012, Ivashkiv and Donlin, 2014). They are ubiquitously 
expressed cytokines and are produced by all nucleated cells. Type II IFN (IFNγ) 
is produced by Natural killer (NK) and T cells and shares many similarities with 
type I IFNs in their mechanism of induction, although they are not produced as 
a direct result in viral infection (Schroder et al., 2004). Type III interferons 
known as IFNλ are more prominently expressed in epithelial cells (Koyama et 
al., 2008, Sommereyns et al., 2008). Although the induction of type III IFNs 
following viral challenge shares many similarities with the regulatory pathways 
of type I IFNs (Onoguchi et al., 2007), they are expressed in response to 
persistent, low-level or repeated infection (Wack et al., 2015, Lazear et al., 
2015). Intriguingly, the more recently discovered IFNλ4 appears to be 
associated with poor clearance of Hepatitis C virus (Prokunina-Olsson et al., 
2013, Hamming et al., 2013). 
IFN production results in increased expression of hundreds of IFN 
stimulated genes (ISGs), including Trim 5α, Myxovirus resistence (Mx) 
GTPases, eukaryotic initiation factor 2α (eIF2α) and oligoadenylate synthase 
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(2’5’ OAS), many of which have direct antiviral actions and potentiate other 
cellular processes such as the induction of apoptosis, triggering dendritic cell 
(DC) maturation, and instigation of other aspects of the innate immune system 
such as the recruitment of NK cells (Baranek et al., 2012). IFNs are ultimately 
responsible for cellular resistance to infection, inducing an antiviral state of 
protection in neighbouring cells in response to, and for the prevention of, further 
spread. Furthermore, they are crucial for the activation and functionality of the 
adaptive immune system (Le Bon and Tough, 2002, Barra et al., 2010). 
1.1.1 Type I IFN induction 
The initial step in the complex IFN induction cascade is the detection of 
foreign material. Although as previously mentioned this stimulus can be LPS, 
for clarity here, the focus will be the detection of nucleic acids with regard to 
viral infection. In this case, the cell recognises self, from non-self using PRRs. 
Membrane bound Toll-like receptors (TLRs) embedded in cell and endosomal 
membranes detect extracellular foreign nucleic acids, whereas cytoplasmic 
PAMPs are recognized by Retinoic acid-inducible gene I (RIG-I) -like receptors 
(RLRs) (Broz and Monack, 2013). The induction of type I IFNs (IFNα/β) through 
TLR- and RLR-dependent signalling will be described below (Figure 1.1). 
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Figure 1.1: TLR3- and RLR-dependent induction of IFNβ  gene expression. 
In response to extracellular and endosomal dsRNA TLR3 recruits TRIF, whereas cytosolic 
dsRNA stimulates RLRs (MDA5, RIG-I), which activate VISA (MAVS/Cardif/IPS-1). Here the 
pathways converge culminating in IRF3 and NF-κB translocation to the nucleus. Binding to their 
respective PRDs in the IFNβ promoter instigates transcription. (Modified from Goodbourn and 
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1.1.1.1 TLR-dependent IFN induction 
TLRs are membrane bound receptors present in two main cellular 
locations; the membranes of immune cells and endosomes (Takeda and Akira, 
2004). TLRs 3, 7 and 9 are found in endosomal membranes and recognise 
double stranded (ds) RNA, single stranded (ss) RNA and unmethylated DNA 
respectively (Akira, 2011). TLR3-dependent IFN induction will be the primary 
focus here, as this study is concerned with IFN induction by dsRNA. The 
recognition of extracellular, endosomal and phagosomal dsRNA by TLR3 
results in its dimerization and tyrosine phosphorylation (Sarkar et al., 2004). 
This leads to the recruitment of Toll-like Interleukin-1 resistance domain-
containing adaptor inducing IFN-β (TRIF) and phosphoinositide 3-kinase (PI3K) 
(Yamamoto et al., 2003), which in turn causes the activation of the IFN 
regulatory factor 3 (IRF3) and nuclear factor κ-light-chain-enhancer of activated 
B cells (NF-κB) branches of the IFN induction pathway (Oshiumi et al., 2003). 
The IRF3 branch of IFN induction is instigated by the recruitment of the 
E3 ubiquitin ligase Tumour necrosis factor receptor-associated factor (TRAF) 3 
by TRIF upon TLR3 activation (Paz et al., 2011). TRAF3 associates with TRAF 
family member-associated NF-κB activator (TANK), which unites with TANK-
binding kinase 1 (TBK-I) (Goubau et al., 2013). TBK-1 and inhibitor of NF-κB 
subunit ε (IKKε) cause the phosphorylation of IRF3, resulting in its dimerization 
and subsequent nuclear translocation in association with Crebb-binding protein 
(CBP)/p300 (Goubau et al., 2013, Perry et al., 2005). Nuclear IRF3 then 
associates with positive regulatory domains (PRDs) present in the IFNβ 
promoter (Panne et al., 2007) 
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The NF-κB branch is also initiated by TRIF, which engages TRAF6 and 
receptor-interacting protein-1 (RIP-I), which are both lysine-63 ubiquitinated 
(Hoesel and Schmid, 2013). The ubiquitination of RIP-I leads to NF-κB essential 
modifier (NEMO) association (Wu et al., 2006). The ubiquitination of both RIP-I 
and NEMO is sensed by the molecular chaperones TAK-binding protein (TAB) 2 
and TAB3 (Kanayama et al., 2004), which instigate the association of 
transforming growth factor β-activated kinase-1 (TAK-I) (Deng et al., 2000). This 
forms the essential complex known as IκB kinase (IKK) (Wu et al., 2006). The 
TAK-I component of IKK causes the phosphorylation of IKKβ at serine 177 and 
181 (Israel, 2010), leading to the ubiquitination and subsequent proteasomal 
degradation of inhibitor of κB (IκB), the suppressor of NF-κB (Li et al., 2000). 
This results in the release of NF-κB, exposing the nuclear localisation signal 
(NLS) present in its P65 (RelA) subunit (Zandi et al., 1997, Hoesel and Schmid, 
2013). Nuclear NF-κB then associates with PRDs present in the IFNβ promoter 
(Panne et al., 2007). 
The detection of endosomal ssRNA and DNA by TLR7 and TLR9 
respectively results in the activation of a similar yet distinct signalling pathway to 
TLR3-dependent IFN induction (Figure 1.2) (Heil et al., 2004, Tabeta et al., 
2004). TLR7 and TLR9 activation recruits the adaptor MyD88 as opposed to 
TRIF, and results in the enrolment of TRAF6, IRAK-1 and IRAK-4 (Reviewed by 
Takeuchi and Akira, 2010, Berke et al., 2013, Kawai and Akira, 2011). TRAF6 
activation results in the release and nuclear localisation of NF-κB through RIP-I 
and TAK-1 signalling as discussed above (Hoesel and Schmid, 2013, Li et al., 
2000). The transcription factor IRF7 is recruited in place of IRF3, and is brought 
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about by the phosphorylation of IRF7 by IRAK-1, a process that is independent 
of TBK-1 and IKKε (Huye et al., 2007). This results in the nuclear translocation 
of IRF7 and as with IRF3, association with the PRDs, subsequently inducing 
IFNα/β transcription. 
 
Figure 1.2: TLR7/9-dependent induction of IFNβ  by ssRNA and DNA 
TLR7 and 9 activation by endosomal ssRNA and DNA respectively initiates the TRAF3 and 
TRAF6-dependent signalling pathways through the adaptor molecule MyD88 (Randall and 
Goodbourn, 2008). 
 
1.1.1.2 RLR-dependent IFN induction 
Foreign nucleic acids that are cytosolic are sensed by helicases. Present 
in three main types, they are classed as the RLRs (Wu and Hur, 2015). RIG-I 
and MDA5 are RNA sensing molecules, which both associate with caspase 
activation and recruitment domains (CARDs) (Goubau et al., 2013). The final 
RLR, LGP2, appears to have a regulatory function, as it is lacking the CARD 
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domain required for IFN induction (Satoh et al., 2010). The subtle difference 
between the two IFN-inducing RLRs is the type of nucleic acids they sense. 
While RIG-I senses short, blunt RNA with a 5ʹ′ triphosphate, MDA5 is thought to 
sense long dsRNA (>2000 nt) although there remains some debate over this 
(da Conceicao et al., 2013, Kato et al., 2006, Baum et al., 2010). An additional 
structure, a 5ʹ′ triphosphate panhandle nucleic acid motif was also discovered to 
activate RIG-I (Schlee et al., 2009). Upon stimulation by nucleic acids, PP1α 
and PP1γ dephosphorylate RIG-I and MDA5 (Wies et al., 2013). Subsequently, 
their CARDs are exposed through conformational change and stimulate 
mitochondrial antiviral signalling protein (MAVS) (also known as VISA, Cardif 
and IPS-I) (Kawai et al., 2005). Upon the enrolment of MAVS, RLR-dependent 
induction follows the same signalling pathway as TLR3-dependent IFNα/β 
induction (Figure 1.1). 
1.1.1.3 STING-dependent IFN induction 
As cytosolic DNA is highly unusual in mammalian cells, detection 
independently of TLRs can also induce IFNα/β production (Ishii et al., 2006). 
Cyclic monophosphates are sensed by cGAMP synthase (cGAS) (Sun et al., 
2013, Burdette et al., 2011), whereas DNA in DCs is sensed by the helicase 
DDX41 (Zhang et al., 2011), and in monocytes and some fibroblasts is detected 
by IFNγ-inducible protein 16 (IFI16) (Unterholzner et al., 2010). In all cases, 
these cytosolic DNA sensors (CDSs) initiate IFNα/β production through IRF3- 
and TBK1-dependent pathways (Figure 1.3) (Tanaka and Chen, 2012). The 
adaptor molecule Stimulator of IFN Genes (STING) is located on the surface of 
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the endoplasmic reticulum, and is essential for cytoplasmic DNA-mediated 














Figure 1.3: STING-dependent induction of IFNβ  by Cytoplasmic DNA 
Cytoplasmic DNA is detected by CDSs, which recruit the adaptor molecule STING, instigating 
the TBK-1 and IRF3-dependent type I IFN induction pathway (Adapted from the InvivoGen 
Insight newsletter, 2012 [http://www.invivogen.com]) 
 
Innate immune responses vary based on the characteristics of both the 
stimulus and the cell that detects the microbe. However, the pathways converge 
on a consensus set of signal transductions resulting in the activation of type I 
IFN responses and other proinflammatory cytokines facilitated by the induction 
of common signalling proteins including NF-κB and CBP (Schroder and 
Tschopp, 2010). 
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1.1.1.4 IFNβ promoter enhanceosome assembly 
Regardless of the stimulus for type I IFN induction, it is heavily reliant on 
various transcription factors such as IRF3 and NF-κB associating with the 
relevant cis regulatory elements, the PRDs (Yang et al., 2004). TLR- and RLR-
dependent signalling cascades result in the nuclear translocation of activated 
transcription factors such as IRF3 and NF-κB. Their association with PRDs 
present in the IFNα/β promoter is a synergistic process resulting in the 
formation of the IFNβ enhanceosome (Figure 1.4), potentiating transcriptional 
activation (Randall and Goodbourn, 2008, Maniatis et al., 1998). To initiate the 
transcription of IFNα/β, either IRF3 associates with PRD I or IRF7 with PRD III, 
whereas NF-κB interacts with PRD II (Panne et al., 2007). To complete 
enhanceosome assembly, activating protein-1 (AP-1) heterodimers composed 






Figure 1.4: The IFNβ  promoter enhanceosome. 
The association of activated transcription factors with the PRDs present in the IFNβ promoter 
occurs in a cooperative manner. IRF subunits bind at PRDI and PRDIII, NF-κB (p50 & RelA) at 
PRDII and AP-1 (ATF-2 & c-Jun) at PRDIV, leading to transcriptional activation (Modified from 
Falvo et al., 2000). 
 
1.1.2 Type I IFN signalling 
Following the induction of type I IFN gene expression and its secretion 
from the cell, it attaches to specific membrane receptors on the cell surface 
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(Kim et al., 1997). All type I IFNs associate with the same IFN α/β receptor 
(IFNAR), minimally composed of two subunits, IFNAR-1 and IFNAR-2 (Figure 
1.5) (Platanias, 2005). Prior to activation by IFN binding, the cytoplasmic tails of 
these membrane-spanning receptors associate with members of a tyrosine 
kinase family, Janus kinases (Jak) (Ivashkiv and Donlin, 2014). IFNAR-1 is 
bound to Tyk2 and IFNAR-2 to Jak1 (Kim et al., 1997). In addition to Jak1, 
IFNAR2 is bound by STAT1, which itself is weakly associated with STAT2 
(Precious et al., 2005, Tang et al., 2007). The STAT1-IFNAR-2 association prior 
to IFN binding appears to occur only when STAT2 is present (Stancato et al., 
1996, Li et al., 1996). Upon IFNα/β binding to the receptor subunits, ligand-
induced dimerization of IFNAR-1 and -2 results in alterations in conformation 
and Janus kinase activation, where Jak1 phosphorylates Tyk2, which in turn 
phosphorylates Jak1 (Gauzzi et al., 1996). The now activate Tyk2 
phosphorylates IFNAR1 at tyrosine 466, which creates a docking site for the 
SH2 domain of STAT2 (Stark et al., 1998, Yan et al., 1996). This facilitates a 
more robust association with STAT2 and subsequently, Tyk2 phosphorylates 
STAT2 at tyrosine 690, disabling its constitutive overriding nuclear export (Stark 
et al., 1998, Frahm et al., 2006). Concurrently, Jak1 phosphorylates STAT1 at 
tyrosine 701, resulting in its dissociation from IFNAR, and the formation of a 
stable heterodimer (Stark et al., 1998, Reich and Liu, 2006). NLS generation 
through SH2 domain interactions potentiates its transport to the nucleus, where 
it remains until it is dephosphorylated (Banninger and Reich, 2004). As a 
consequence of tyrosine phosphorylation, Interferon-stimulated gene factor 3 
(ISGF-3) is formed with the purpose of transcriptional activation of ISGs. This 
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heterotrimeric complex is composed of the phosphorylated STAT1 and STAT2 
proteins, and an additional transcription factor, Interferon Regulatory Factor 9 















Figure 1.5: ISRE and GAS associated ISG induction by type I and type II IFN. 
Although similar, the cascades triggered by type I and type II IFNS are distinct in the expression 
profiles they induce. Furthermore, it can be seen that cross-activation can occur due to STAT1 
being a common component of all both signalling pathways. (Platanias, 2005) 
 
An additional consequence of IFN binding is the IFNAR-2 induced 
activation of CBP/p300, which associates with both STAT2 and protein kinase C 
δ (PKC δ) (Uddin et al., 2002). CBP acetylates the ISGF-3 complex, creating a 
stable binding site for IRF9, which itself is then acetylated, a step crucial to 
ISGF-3-DNA binding (Tang et al., 2007). PKC δ phosphorylates STAT1 at 
	   13 
serine 727, promoting more efficient binding of ISGF-3 to the transcriptional 
apparatus upon nuclear translocation (Bonjardim et al., 2009). Recently 
phosphorylation of S287 in STAT2 was also found to have a regulatory role in 
IFNα/β signalling (Steen et al., 2013). Once in the nucleus, ISGF-3 binds with a 
high degree of specificity to the Interferon stimulated response element (ISRE) 
present in the promoter of ISGs through recognition of DNA sequences 
(Schoggins and Rice, 2011). 
Type II interferons (IFNγ) have distinct receptors whose subunits are 
similarly termed IFNGR-1 and IFNGR-2, although in this case they are weakly 
associated with one another prior to IFN stimulation (Figure 1.5). Here, IFNGR-
1 is associated with Jak1 and IFNGR-2 with Jak2 (Bach et al., 1997, Chen et 
al., 2004). Upon IFNγ binding, the two receptors are brought closer together, 
leading to the activation of Jak2, causing the trans-phosphorylation of Jak1 
(Darnell, 1997). The activated kinases then phosphorylate a tyrosine rich region 
between amino acids 440 and 444 in IFNGR1, which creates binding sites for 
two STAT1 molecules, potentiating their interaction via SH2 domains (Varinou 
et al., 2003). Further phosphorylation of the STAT1 molecules at tyrosine 701 
and serine 727 completes activation, resulting in their dissociation from the 
receptor complex. Dimerization of the STAT1 molecules occurs through 
detection of tyrosine phosphates in the SH2 domains leading to the subsequent 
nuclear translocation of the complex (Boehm et al., 1997). STAT1 homodimers 
bind to a distinct sequence in the promoter of ISGs known as Gamma-activation 
sequence (GAS), which results in their transcriptional induction (Decker et al., 
1991b, Lew et al., 1991). This is separate from the ISRE of ISG promoters and 
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occurs in an IRF-9-independent manner (Takaoka and Yanai, 2006). The 
binding of the STAT1 homodimer and transcriptional activation of ISGs without 
the involvement of IRF-9 can also occur through IFNα/β signalling, which is 
known as the AAF complex (Decker et al., 1991a). Additionally, STAT1 and 
STAT2 can be phosphorylated as a result of both IFNα/β and IFNγ receptor 
binding, leading to “cross-activation”, and represents a certain level of 
convergence of the pathways (Li et al., 1996). STAT1 however is a crucial 
component of both IFNα/β and IFNγ signalling cascades, rendering each type of 
IFN inactive without its presence (Patel et al., 2012). 
1.1.3 The cellular impact of type I IFNs 
The consequences of IFN induction are far reaching and have been 
reviewed extensively (Randall and Goodbourn, 2008, Darnell, 1997, Platanias, 
2005, Takaoka and Yanai, 2006). Several hundred genes are categorised as 
ISGs, and to some extent the IFN response can be tailored, as a cell utilizes 
different sets of ISGs in order to control different viral infections (Bonjardim et 
al., 2009). Some ISGs are enzymes and are synthesised in their inactive form, 
requiring activation to instigate their anti-viral actions. GTPases known as Mx 
are induced by IFN signalling and have been shown to restrict the ability of viral 
components to move within a cell through nucleocapsid recognition (Haller and 
Kochs, 2011). Protein kinase R (PKR) is activated by association with its co-
factors, dsRNA and PKR activator (PACT), leading to the phosphorylation of 
eIF2α (Nakayama et al., 2010, Li et al., 2006). The phosphorylation of eIF2α 
inhibits its action, thus leading to the cessation of translation (Deng et al., 
2004). ISG56 has also been implicated in selectively inhibiting the translation of 
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parainfluenza virus 5 (PIV5) mRNA (Andrejeva et al., 2013). Another enzyme 
that has dsRNA as a co-factor, is 2ʹ′5ʹ′ OAS (Silverman, 2007). Here however, 
the activated enzyme catalyses the oligomerisation of ATP through an unusual 
2ʹ′5ʹ′ phosphodiester bond. The oligoadenylates that result from this catalysis 
cause the activation of RNase L, which digests cellular and viral RNAs and has 
been postulated to lead to amplification of the IFN response through further 
activation of RLRs such as RIG-I and MDA5 (Malathi et al., 2007). Other 
implications of ISRE and GAS stimulation include the induction of a pro-
apoptotic state through the activation of numerous factors including 
procaspases (Maher et al., 2007, Dai and Krantz, 1999, Chin et al., 1997). Cell 
cycle arrest has also been observed through cytostasis at the G1/S interface. 
This has been comprehensively reviewed, and results in the inhibition of E2F 
specific expression, which includes genes crucial to S-phase (Ferrantini et al., 
2007, Ferrantini et al., 2008, Dimova and Dyson, 2005, Asefa et al., 2004). 
The plethora of cellular process affected by type I IFN signalling range 
from the actions of direct antiviral proteins to the limiting of translation and even 
cell cycle arrest. It is therefore not surprising that dysfunction is associated with 
the development of a wide range of diseases. Some of the pathologies 
associated with dysfunctional IFN responses will be discussed below. 
1.1.4 Diseases associated with dysregulation of the IFN system 
As with any biological process, there lies the potential for dysfunction 
within the IFN response. Although a multifactorial disease, it is believed that the 
Systemic Lupus Erythematosus (SLE) phenotype is exacerbated by chronic 
activation of the type I IFN response (Buers et al., 2016, Van Eyck et al., 2015, 
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Oliveira et al., 2015). Additionally, an increasing number of interferonopathies 
have been identified such as STING-associated vasculopathy with onset in 
infancy (SAVI) (Liu et al., 2014) and Aicardi-Goutières syndrome (AGS) (Ahn 
and Barber, 2014, Orcesi et al., 2009, Crow et al., 2006), where gain-of-function 
mutations in STING and MDA5 respectively result in aberrant activation and 
increased levels of type I IFN production (Liu et al., 2014, Oda et al., 2014). 
Although also caused by mutations in the gene encoding MDA5 (Rutsch et al., 
2015), it was recently reported that mutations in the RIG-I encoding DDX58 
gene are responsible for atypical Singleton-Merten syndrome (SMS) (Jang et 
al., 2015). The root of such dysfunction in AGS and SMS is the location of the 
genetic mutations that cause the disease. Both diseases arise from mutations 
located in the helicase domains of the associated RLRs, which are usually 
responsible for RNA binding during activation (Kato and Fujita, 2015, Wu and 
Hur, 2015). AGS is a genetically heterogeneous disorder however as loss-of-
function mutations in enzymes responsible for DNA and RNA editing have also 
been shown to cause the same phenotype (Orcesi et al., 2009, Crow et al., 
2006, Crow, 2015, Rice et al., 2013). As well as RLR-induced dysfunction, 
aberrant signalling in haematopoietic immune cells such as macrophages and T 
cells through TLR3 and TLR4, and subsequently TRIF and TRAM has recently 
been identified as having a causal role in the development of atherosclerosis 
(Lundberg et al., 2013). 
In addition to autoimmune diseases, there is a strongly accepted causal 
link between dysfunctional type I IFN responses and cancer, including tumour 
development (Hosui et al., 2012). For example, phosphorylation events during 
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the activation of NF-κB resulting in atypical and aberrant activity have been 
implicated in solid tumour formation and inflammatory disease (Reviewed by 
Viatour et al., 2005). More specifically, IKKβ has been identified as a link 
between inflammatory responses and tumour formation in myeloid cells using a 
mouse model (Greten et al., 2004). 
Although generally beneficial to the host during acute viral infection, type 
I IFN signalling during persistent infection, e.g. HIV and HCV, can have 
deleterious consequences (Wilson and Brooks, 2013). Due to the importance of 
type I IFN signalling in the recruitment of the adaptive immune response, it is 
increasingly thought of as the root cause of immunosuppression, where chronic 
activation can lead to atypical B and T cell activity and a reduced capacity to 
fight secondary infections (Snell and Brooks, 2015). In addition to 
immunosuppression and secondary infection, it has been shown that HIV 
patients undergoing treatment have heightened susceptibility to diseases linked 
to aberrant immune signalling including the aforementioned atherosclerosis 
(Subramanian et al., 2012, Cha et al., 2014). 
Therefore, it is clear that although a crucial aspect of cellular protection 
against infection, tight regulation of type I IFN induction and signalling is 
necessary to prevent the development of potentially devastating diseases. 
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1.2 Modulating the IFN response 
 As a result of the far-reaching impact of the IFN response on cellular 
physiology, both in terms of viral infection and disease states, the ability to 
modulate the signalling pathways would be advantageous. Antagonism and 
activation of the response holds potential not only for clinical therapeutic 
intervention, but also as a tool to aid research into the IFN induction and 
signalling pathways. Additionally, the potency of the response has caused 
viruses to evolve mechanisms to circumvent both IFN induction and signalling. 
Chemical modification of the IFN response, and the mechanisms by which 
viruses circumvent its actions will be discussed below. 
1.2.1 Chemical modulation of the IFN response 
The interferon response is one of the most heavily studied signalling 
cascades in biology due to its broad ranging effects on cellular activity. As a 
result, it is viewed as an ideal target for the development of treatments for many 
diseases and infections (Theofilopoulos et al., 2005). Molecules that upregulate 
the IFN response for example, could be beneficial as antivirals. In the treatment 
of microbial infections a motive behind targeting a host pathway is the high level 
of drug resistance that can develop quickly when the target is the infecting 
organism. For example, in influenza virus treatment, some of the most 
commonly used drugs target the viral M2 ion channel. However, due to rapidly 
increasing levels of resistance, their use is no longer recommended (Lee and 
Yen, 2012, Jacob et al., 2016). Many current treatments place selective 
pressure directly onto the invading pathogen, increasing the likelyhood of 
resistance developing. Targeting a cellular pathway in the host circumvents this, 
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as it is less likely that the organism will evolve an escape mechanism, or in the 
least, it will occur more slowly (Lee and Yen, 2012). To this end, compounds 
that act as agonists to activate the IFN response could be used as broad-
spectrum antivirals and as supportive therapy for immunocompromised 
patients. 
Conversely, compounds that antagonize the IFN response are beneficial 
for the treatment of inflammatory and autoimmune disorders. A number of such 
molecules have been identified. Inhibitors of type I IFN induction such as TPCA-
1, which inhibits IKKβ in the NF-κB pathway, have the potential for use in the 
treatment of autoimmune diseases such as arthritis (Podolin et al., 2005). It was 
found recently that sodium-potassium ATPase cardiac glycosides, commonly 
used in the treatment of congestive heart failure and arrhythmia, are potent 
inhibitors of IFNβ induction. Bufalin was identified in a cell-based assay to test 
478 compounds for their ability to block the induction of type I IFN. The 
luciferase-based assay highlighted Bufalin as a potent inhibitor that decreased 
the expression of IFNβ by 90% with an IC50 of 43 nM (Ye et al., 2011). 
Molecules targeting type I IFN signalling are also available. The JAK1/2 inhibitor 
Ruxolitinib (Rux) for example, currently approved for the treatment of 
myeloproliferative neoplasms (MPNs), is also in phase II clinical trials to assess 
its use to treat psoriasis and a variety of cancers (Verstovsek et al., 2010, 
Quintas-Cardama et al., 2010, O'Shea et al., 2015). 
Cancerous cells have vastly increased expression of NF-κB, a common 
and crucial component of the IFN response (Hasselbalch, 2012). The result of 
such aberrant over expression of this factor leads to increased and sustained 
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oxidative stress placed on cells. Recent research has found that histone 
deacetylase inhibitors, small molecule drugs widely used in the treatment of 
epilepsy and mood disorders, can have a highly beneficial application to cancer 
treatment (Bridle et al., 2013). This class of enzyme inhibitors has been shown 
to inhibit the transcriptional activation of genes that are typically activated upon 
infection and IFN treatment, resulting in the prevention of autoimmune 
responses. 
Outwith the clinic, inhibitors of both type I IFN induction and signalling 
have been used to facilitate the growth of IFN sensitive viruses. Inhibition of IFN 
induction and signalling in this manner could be utilized in the production of live-
attenuated viral vaccines and the growth of oncolytic viruses (Stewart et al., 
2014, Jackson et al., 2016). Furthermore, their application to basic research 
could potentiate further study of these complex signalling cascades. For 
example, through the use of BX795, a TBK1 and IKKε inhibitor, it was 
demonstrated that serine 172 of TBK1 has a regulatory role in a feedback loop 
controlling its activation (Clark et al., 2009). 
Due to the vast number of effector molecules involved in type I IFN 
induction and signalling, there is potential for novel target identification. 
Additionally, drug discovery could identify molecules that inhibit the IFN 
response, and may also unearth compounds that activate naturally occurring 
host proteins that have inhibitory functions, thus reducing the potential for drug 
associated side effects (Zhang et al., 2004). The complexity of these pathways 
suggests a vast number of yet undiscovered novel targets for the development 
of drugs. There are still many unknowns in the collective knowledge of the 
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molecular mechanisms behind the IFN response, and having the ability to 
transiently or reversibly inhibit the action of an effector molecule could be a 
powerful tool in the researcher’s arsenal. 
1.2.2 Viral antagonism of the IFN response 
The IFN response places a large selective pressure on the ability of a 
virus to replicate and propagate an infection. As a result, nearly every virus has 
evolved at least one mechanism to circumvent the IFN response, highlighting 
the importance and potency of the system (Chen et al., 2010). A plethora of 
viral evasion strategies have evolved as a result of the inherently diverse nature 
of viruses. These will be discussed further, and as the ability of the Rabies virus 
to subvert IFN signalling is of particular importance to this study, it will be 
addressed independently. 
1.2.2.1 The myriad of viral evasion stratagies 
As IFN can elicit autocrine and paracrine actions, the ability of a virus to 
inhibit just one aspect of the IFN response, i.e. either IFN induction or IFN 
signalling, may not be sufficient to facilitate efficient viral replication and spread. 
Subsequently, most viruses have evolved mechanisms to antagonise both 
pathways of the IFN system. The often-multifunctional proteins that viruses 
encode to achieve this are termed IFN antagonists and collectively target every 
aspect of the IFN response (Figure 1.6). Viral antagonism of the IFN system 
can be broadly categorized as acting to (i) conceal PAMPs to prevent activation 
of IFN induction, (ii) inhibit host gene expression and (iii) alter or degrade 
signalling molecules (Reviewed by Ito et al., 2016). The concealment of PAMPs 
is a virus-targeted mechanism of evasion, whereas others that interfere with 
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gene expression and the signalling molecules of the cascades are directed 
against the host. Host-targeted evasion is achieved through 3 main 
mechanisms; (i) direct cleavage of effector molecules by viral proteases, (ii) 
sequestering and relocalisation of effector molecules, and (iii) recruitment of the 
cellular ubiquitin proteasome system (UPS) (Nag and Finley, 2012, Reviewed 
by Hoffmann et al., 2015). 
 
 
Figure 1.6: Viral strategies to evade the IFN response  
Viruses have evolved a plethora of mechanisms to evade every step of the IFN induction and 
IFN signalling pathways, some of which are shown above. (Adapted from McInerney and 
Karlsson Hedestam, 2009) 
 
 
 Viruses have developed many strategies to avoid PAMP detection by 
cellular PRRs. For example, Herpes Simplex virus (HSV) and Influenza A 
viruses (IAV) replicate in the nucleus (Melroe et al., 2004, Weber et al., 2015), 
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endoplasmic reticulum in order to screen their genomes from cytoplasmic 
PRRS (Uchida et al., 2014). Some RNA viruses modify the 5’triphosphate of 
their genome to avoid RIG-I detection. Bunyaviruses (BunV) and Bornaviruses 
for example encode phosphatases that remove two phosphates, leaving an 
undetected 5’monophosphate (Wang et al., 2011b, Habjan et al., 2008), while 
others degrade excess cytoplasmic nucleic acids, such as Human 
Immunodeficiency virus (HIV), which utilises the cellular exonuclease TREX1 
(Yan et al., 2010). Another mechanism to avoid detection by PRRs is to 
disguise the viral genome by ecapsidation in viral proteins such as IAV NS1, 
Ebola virus (EBOV) VP35 and Marburg virus (MAV) VP35 (Hatada and Fukuda, 
1992, Ramanan et al., 2012, Cárdenas et al., 2006). Interestingly, Respiratory 
syncytial virus (RSV) hijacks the cellular protein La to conceal its RNA (Bitko et 
al., 2008). 
Inhibiting the activation of RLR and adaptor molecules such as MAVS is 
also an effective approach to subvert IFN induction. Where some viruses 
directly degrade the PRR through UPS recruitment, such as the NS1 and NS2 
proteins of RSV, others prevent its activation (Goswami et al., 2013). IAV NS1 
for example binds TRIM25, preventing its oligomerization and subsequently 
inhibiting its ability to activate RIG-I through lysine-63 ubiquitination (Gack et al., 
2009). Other viruses simply encode their own deubiquitinating enzymes, such 
as the Foot and mouth disease virus LPro and Kaposi’s sarcoma-associated 
herpesvirus (KSHV) ORF64, which remove the lysine-63-linked ubiquitin from 
PRRs and subsequently inactivate them (Wang et al., 2011a, Inn et al., 2011). 
The ATPase activity of RIG-I is stimulated by PKR and PACT, however the NS1 
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protein of IAV and VP35 of EBOV target the latter to inhibit activation 
(Tawaratsumida et al., 2014, Luthra et al., 2013). The activation of RIG-I and 
MDA5 is also reliant on the dephosphorylation of their CARDs by PP1α and 
PP1γ, a step that is inhibited by Measles virus (MeV) V protein, which has a 
PP1 binding motif to bind and sequester these effector molecules (Davis et al., 
2014). While the inhibition of an RLR such as RIG-I is an effective tactic in 
subverting IFN induction, inhibition of the downstream adaptor molecule MAVS, 
preventing induction from both MDA5 and RIG-I may be a more efficient tactic. 
For example, the 3CPro of Hepatitis A virus (HAV) and NS3-4A of HCV directly 
cleave MAVS, whereas HBV, which does not encode a protease, utilises 
protein X to instigate the UPS mediated degradation of MAVS (Yang et al., 
2007, Li et al., 2005, Wei et al., 2010). Interestingly, MAVS function is also 
impeded by IAV, where the polymerase subunit PB1-F2 causes disruption of 
the mitochondrial membrane, thus inhibiting MAVS activity (Yoshizumi et al., 
2014).  
 Invading viruses frequently target and inhibit downstream signalling in 
the IFN induction pathway. As one of the crucial effector molecules is IRF3 it is 
the focus of many evasion mechanisms. For example, KSHV encoded latency-
associated nuclear antigen impedes IRF3 association with the IFNβ promoter 
by competing for binding (Cloutier and Flamand, 2010). Human 
cytomegalovirus (HCMV) has multiple mechanisms to subvert IRF3-dependent 
signalling using the virally encoded pp65, which has been reported to decrease 
the phosphorylation IRF3 and also prevent its nuclear translocation (Abate et 
al., 2004), a tactic also employed by the ICP0 protein of HCV (Melroe et al., 
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2004). Simple binding and sequestration of cellular proteins is however just as 
effective at circumventing IFN induction. For example, Paramyxoviruses encode 
a multifunctional V protein, which, as well as directly binding to MDA5 to prevent 
its activation, also sequesters IRF3 (Irie et al., 2012). Additionally, some V 
proteins act as a decoy substrate for cellular TBK1 and IKKε and also cause the 
polyubiquitination of these signalling components (Lu et al., 2008). 
 Viruses also circumvent the IFN response by thwarting IFN signalling 
and the action of ISGs. Again, UPS and the subsequent proteasomal 
degradation of signalling effectors is a tactic employed by many viruses, 
including DENV, where NS5 causes the polyubiquitination and subsequent 
elimination of STAT2 (Morrison et al., 2013). The V protein of rubulaviruses in 
the paramyxoviridae family forms a V-degredation complex (VDC) with an E3 
ubiquitin ligase, STAT1 and STAT2 (Ulane and Horvath, 2002). Interestingly, 
although both STATs are required for VDC assembly, only one will ultimately be 
degraded. For example, the VDC formed during PIV5 infection results in STAT1 
degradation, whereas the VDC of PIV2 causes the elimination of STAT2 
(Didcock et al., 1999, Parisien et al., 2001). The V protein of other 
paramyxoviruses such as Nipah virus (NiV) and the C protein of PIV1 sequester 
STAT molecules, although by slightly different mechanisms. Where NiV V 
relocalises unphosphorylated, nuclear STAT1 to the cytoplasm, PIV1 C results 
in the perinuclear aggregation of STAT1 to inhibit its phosphorylation 
(Schomacker et al., 2012, Rodriguez et al., 2002). Interestingly, Sendai virus 
(SeV), another respirovirus of paramyxoviridae appears to have a less specific 
mechanism for STAT inhibition. Although SeV C inhibits the tyrosine 
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phosphorylation of both STAT1 and STAT2 and the serine phosphorylation of 
STAT1, it has also been shown to impede the deactivation of STAT1 through 
disruption of dephosphorylation (Komatsu et al., 2002). The SeV C protein may 
therefore act through a general mechanism of dysregulating phosphorylation 
events. It has been shown that inhibition of the IFN signalling pathway also 
occurs through prevention of its activation. The phosphorylation of STATs is 
crucial to successful IFN signalling. The V protein of MeV blocks the nuclear 
translocation of STATs, but also binds to Jak1 impeding its ability to 
phosphorylate STATs and therefore blocks IFN signalling (Caignard et al., 
2007, Caignard et al., 2009). Similarly, the E6 protein of human papilloma virus 
binds to Tyk2, resulting in a decrease in the phosphorylation of both STAT1 and 
STAT2 (Li et al., 1999). 
1.2.2.2 Rabies and IFN antagonism 
 Rabies virus (RBV) of the lyssavirus genus in the Rhabdoviridae family is 
of particular interest to this study and is of significant global importance. 
Causing in excess of 55,000 human deaths annually, it is classified by the 
World Health Organisation as a neglected zoonotic disease (WHO, 2013, Wilde 
et al., 2016). To circumvent the induction of type I IFN, the N, L and P proteins 
encoded by the negative sense ssRNA genome encase the RNA to conceal it 
from detection by RIG-I (Tian et al., 2016). Additionally, residues 176 to 186 of 
RBV P have been shown to be crucial for the inhibition of IRF3 phosphorylation 
(Rieder et al., 2011). A recent report has demonstrated that the C-terminus of P 
from street strains of RBV inhibits the action of IKKε (Masatani et al., 2016). 
Interestingly, the inhibition of IKKε was not observed in any lab-adapted strains 
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tested. Clearly, the actions of RBV P are effective at inhibiting IFN induction. 
However, the pleiotropic nature of P is better demonstrated through its ability to 
subvert IFN signalling. RBV P only binds to STAT molecules that are tyrosine 
phosphorylated, presumably as it is more important to inhibit an active molecule 
as opposed to its inactive, repressed counterpart (Brzozka et al., 2006). Where 
the N-terminus of full length P (P1) is important for its role in genome 
replication, the C-terminus is crucial for STAT interactions (de Almeida Ribeiro 
et al., 2009, Ito et al., 2016). Additionally, the action of the C-terminus of P 
binding to STAT molecules appears to be conserved among lyssaviruses and is 
crucial for the lethality of RBV infection (Wiltzer et al., 2012, Wiltzer et al., 
2014). N-terminal truncations give rise to 4 other isoforms of P (P2-P5) that 
appear to have distinct roles (Marschalek et al., 2012). For example, P1 and P2 
have an NES which, when bound to phosphorylated STATs, results in their 
nuclear exclusion (Ito et al., 2010, Ito et al., 2016). Furthermore, monomeric P3 
was reported to be nuclear and prevent the function of ISGF3 by preventing 
STATs binding to ISG promoters (Moseley et al., 2007a, Vidy et al., 2007). 
Interestingly, dimeric P3 was shown to prevent the nuclear import of STATs 
through association with microtubules (Moseley et al., 2007b). P1 and P3 have 
also been implicated in the subversion of ISG function by interacting with 
promyelocytic leukemia protein (PML), some isoforms of which have antiviral 
activity (Blondel et al., 2002). 
 It is clear that viruses have evolved a myriad of mechanisms that potently 
inhibit every aspect of the IFN response. Where DNA viruses generally have 
the genome capacity to encode numerous viral IFN antagonists, the limited 
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genomes of RNA viruses has resulted in the production of highly multifunctional 
proteins. This is exemplified through the pleiotropic NS1 protein of IAV, which 
has a plethora of mechanisms by which it subverts both IFN induction and IFN 
signalling. Due to the extent to which IFN antagonists facilitate virus replication, 
they provide an attractive target for clinical intervention. Recombinant viruses 
lacking a functional IFN antagonist could be used as an effective live-attenuated 
vaccine (Wressnigg et al., 2009). Conversely viral PAMPS, or synthetic 
versions, could make potent adjuvants in vaccine preparations (Hoffmann et al., 
2015, Dalpke et al., 2002, Stahl-Hennig et al., 2009). On the other hand, 
compounds that modulate the function of viral IFN antagonists in the course of 
an infection could be developed into a novel class of antiviral drugs (Basu et al., 
2009, Versteeg and García-Sastre, 2010). Furthermore, due to the high degree 
of similarity between the antagonists encoded by viruses of the same family and 
genus, active compounds could have a relatively broad spectrum of activity. 
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1.3 Drug discovery 
 The ever-increasing need for new drugs to treat the multitude of human 
diseases and infections in the clinic has placed enormous pressure on the 
pharmaceutical industry and academic research alike. To develop successful 
candidate drugs, a lengthy and iterative process of drug discovery followed by 
clinical trials is necessary to ensure the efficacy and safety of new therapeutics 
(Figure 1.7) (Hughes et al., 2011). Regardless of the approach used in different 
drug discovery programs, they all follow common themes and have shared 
goals. The overarching aim of all early stage drug discovery campaigns is to 
identify lead compounds that can be developed into candidate drugs to address 
unmet clinical need (Drewry and Macarron, 2010). The pre-clinical stages of the 
drug discovery process and the different approaches utilized will be discussed 
below. The use of high-throughput screening (HTS) and cell-based assays will 
be specifically addressed. 
 
Figure 1.7: The development of a clinically approved drug. 
From the inception of target identification, often from a basic research setting, to the approval of 
a new drug and its availability in the clinic is a lengthy, multistep process involving lead 
discovery, preclinical and clinical development (Hughes et al., 2011). 
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1.3.1 The process of drug discovery 
 The starting point of any drug discovery program is target identification. 
In many cases this is a specific protein, but a target can be any biological entity, 
including genes and RNA (Hughes et al., 2011). Additionally, a phenotypic 
screen can target a whole cellular pathway or process where many potential 
points of intervention may exist (An and Tolliday, 2010). Regardless of the type 
of target identified, they must meet certain criteria. Primarily, the target must be 
directly linked to a disease state, where it can be demonstrated that activation 
or inhibition of its activity will restore functionality and result in a reduction of 
disease-associated symptoms (Hughes et al., 2011). As a direct result of the 
advances in proteomics, genomics and sequencing, most especially with the 
completion of the human genome project in 2003, the number of potential 
targets has dramatically increased (Anderson, 2003). Additionally, the mining of 
biomedical data and direct sequencing of clinical samples has significantly 
increased the collective knowledge of disease-specific targets (Yap et al., 2016, 
Yang et al., 2009). It is estimated that biological space comprises approximately 
30,000 disease-modifying genes, although only 10% of these may be disease 
causing (Overington et al., 2006). There is a great need for the identification of 
novel drug targets however, as all small molecule drugs currently available are 
directed against just 200 distinct protein targets (Bauer et al., 2010). 
 Following the identification of a target, a suitable assay must be 
developed in which the effect of test compounds can be assessed. This assay 
is then used to test different compounds to potentiate lead discovery. A lead is 
defined as a compound that displays the desired level of activity against a 
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specified target (Verlinde and Hol, 1994). Once identified, the lead molecule is 
validated for its potency, specificity and physiological relevance to the target 
(Clemons et al., 2014). As a result of the validation process, lead compounds 
are then chemically optimized, usually to produce a lead series, which provides 
pre-clinical drug candidates, termed new molecular entities (NMEs) (Hughes et 
al., 2011). 
1.3.2 Approaches to drug discovery 
 Historically, lead identification in the 1970’s relied heavily on observation. 
The activity of natural products for example, the side effects of currently 
available medicines, and even research presented at conferences (Kubinyi, 
1995). As a result of advances in structural biology however, this dependence 
on “empirically-based” drug discovery began to decline and structure-based 
drug design (SBDD) emerged (Lipinski et al., 2001). The synthesis and testing 
of compounds on a larger scale was potentiated by developments in both 
combinatorial chemistry and automated robotics platforms (Baum, 1994, Patel 
and Gordon, 1996, Domanico, 1994), and the advent of high-throughput 
screening (HTS) made it possible to screen thousands of compounds in a 
reduced time (Hughes et al., 2011). As target knowledge has increased 
exponentially and NME output from the pharmaceutical industry has not 
followed suit, drug discovery programs are increasingly looking backward to 
historically successful in vivo phenotypic assays in search of innovative 
solutions to increase the productivity of lead discovery. Continued technological 
advances have lead to the development of many different types of HTS, from 
typical biochemical assays to more elaborate whole organism screens and ultra 
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high-throughput screens (uHTS) (Croston, 2002, Zlitni et al., 2009, Zon and 
Peterson, 2005).  
1.3.3 High-throughput screening (HTS)  
 The first article to mention HTS was available on Pubmed in 1991, and it 
took a further 6 years for 10 HTS papers to be published in the same year 
(Macarron et al., 2011). Following target identification, it takes on average 11 to 
13.5 years to develop a clinically approved drug at an estimated cost of $1.5 
billion (Paul et al., 2010). Currently, there are few HTS derived NMEs in late 
stage drug development and clinical trials. This is seen by many as a result of 
the poorly constructed early compound libraries, which largely comprised non-
drug-like molecules with little structural diversity, and were developed with little 
consideration for a compound’s suitability for drug discovery (Bansal and 
Barnes, 2008, Dandapani and Marcaurelle, 2010). The primary purpose of HTS 
is to identify chemical starting points as quickly and efficiently as possible. 
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Figure 1.8: The workflow involved in early stage drug discovery.  
Following validation of a target for drug discovery, compound screening programs including 
HTS aim to identify and optimize potent lead compounds, which are then analysed in secondary 
assays. Following successful characterisation, lead compounds are tested to assess safety and 
efficacy. If a compound successfully passes all these stages, it is deemed a preclinical 
candidate (Hughes et al., 2011). 
 
Significant advances in the synthesis and testing of many thousands of 
compounds paved the way for HTS. Additionally, Lipinski observed that 
increased absorption and permeation of a compound was potentiated when a 
molecule has the following characteristics. (i) ≤ 5 hydrogen bond donors, (ii) ≤ 
10 hydrogen bond acceptors, (iii) a molecular weight (MW) ≤ 500 and (iv), a 
CLogP ≤ 5, which is the logarithm of its partition coefficient, and is used as a 
measure of hydrophilicity (Lipinski et al., 2001). Following Lipinski’s seminal 
publication and the founding of the “Rule of 5” (RO5), the make-up of screening 
libraries began to change, and compound collections were more thoughtfully 
developed (Lipinski, 2004). The continued evolution of screening libraries has 
placed increased emphasis on the use of small, simple molecules. This 
preference is due to the lead optimization process, which inevitably results in an 
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increase in MW and can result in issues with safety and tolerability in later 
stages of the drug development (Perola, 2010). As a result of the increased 
consideration of a compound’s characteristics, two screening strategies have 
developed; (i) fragment-based screening and (ii) diversity screening. 
Fragment-based drug discovery (FBDD) is based on the principle that 
small fragment molecules, although only binding weakly, can have “high quality 
interactions” with the target and so provide a solid basis from which to develop 
potent drugs (Scott et al., 2012). It is believed that hits with weak but 
appropriate binding kinetics are favourable to potent but flawed larger 
compounds. Additionally, classical HTS compound libraries require constant 
upkeep and funding to maintain their quality and diversity. As chemical space in 
the RO5 range (MW≤500) is estimated to be 1060 molecules (Barker et al., 
2013), and there is predicted to be only 107 fragment molecules that are RO3 
compliant (comprising ≤11 atoms) (Fink and Reymond, 2007), FBDD 
immediately increases the range of chemical space that can be covered. FBDD 
relies heavily on molecules binding with high enough affinity to be detected, 
usually between 0.1 and 10 µM (Scott et al., 2012). As a result, screening is 
usually carried out at higher concentrations and requires very sensitive 
detection techniques (Law et al., 2009). As with SBDD, a strong collaboration 
between structural biology and synthetic chemistry is necessary, as is high 
quality 3D data. The fragment approach has proved to be a fruitful one, with the 
development of Zelboraf in 2011 (Murray et al., 2012). This enzyme inhibitor is 
used for the treatment of late-stage melanoma, and was the first FDA approved 
drug born from FBDD (Bollag et al., 2010). In contrast to FBDD, diversity 
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screening is based on classical HTS library composition that obeys Lipinski’s 
RO5, although the focus here is maximization of the range of chemical space 
covered. Libraries are typically composed of a wide variety of chemical 
structures, with little similarity between compounds (Valler and Green, 2000). 
As with SBDD, traditional biochemical HTS begins with a process of 
target identification and assay development. Typically, biochemical HTS assays 
simply test the affinity of a test compounds for the target. Following on from this 
and similarly to SBDD, the iterative process of lead optimization is pursued. In 
contrast to SBDD however, and as HTS can identify chemically distinct hits, 
there is potential for the development of multiple lead series. Furthermore, the 
starting point of biochemical HTS does not require any structural data pertaining 
to the target. Other approaches to HTS include focused, or knowledge-based 
screening, an extension of which has been the development of virtual 
screening. When there is substantial knowledge about a target, including its 
binding site and mode of action, there is the potential to use smaller compound 
collections, comprising molecules likely to have activity (Boppana et al., 2009). 
Knowledge-based screening has potentiated the development of virtual HTS 
(McInnes, 2007). Here, computerised compound sets are screened against a 
target using structure-based approaches that rely on the target structure, or 
ligand-based strategies where the chemistry of molecules known to bind the 
target is exploited (Lavecchia and Di Giovanni, 2013, Nagamani et al., 2011). 
To potentiate HTS, the assay in question must meet certain criteria 
before screening can take place. This process of assay development considers 
the quality of the assay in terms of reproducibility and pharmacological 
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relevance (Zhang et al., 2012). The signal window, typically calculated as 
signal-to-background ratio (S/B), which considers the high and low signal, and 
the levels of variation observed, are used to assess assay quality (Zhang, 
1999). The Z’ factor is now a widely used statistic throughout the screening 
community as it assesses both the signal window of an assay (minimum and 
maximum means) and the variation seen within these populations, expressed 
as the standard deviation (StDev) (Zhang, 1999). The Z’ factor has become the 
gold standard parameter used to gauge the suitability of an assay for HTS. An 
assay achieving a Z’ factor of ≥ 0.5 is deemed an excellent assay, whereas if 
the Z’ factor is between 0 and 0.5, it is viewed as marginal, and although could 
be used in HTS, further assay optimization and development is recommended 
(Clemons et al., 2014). Additionally, assay cost is a crucial aspect of assay 
development, which aims to minimize reagent usage, usually leading to assay 
miniaturization to reduce reagent volumes. 
Regardless of assay format, lead identification (screening) follows 
successful assay development, where primary screening of thousands to 
millions of compounds aims to identify putative hit compounds. Assays targeted 
to antagonist identification are associated with higher initial hit rates as they 
usually detect a decrease in signal, which can also result from compounds that 
interfere with signal generation. A crucial process following primary screening is 
hit triage, which aims to eliminate putative hit compounds that are likely to be 
false positives. Remaining hits are then grouped based on structural similarities 
and secondary assays are carried out the further analyse activity and potency. 
The secondary assay stage of early drug discovery aims to test the potency of 
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lead compound(s) in cell-based assays to demonstrate their activity outwith 
engineered proteins and also identify any structure-activity relationships (SAR). 
Lead optimization, similar to the cyclic process of synthesis, testing and 
structural alteration utilized in SBDD and FBDD, ultimately aims to increase 
specificity and potency. This crucial process is time consuming and associated 
with high failure rates. From a primary HTS testing 200,000 to 1 million 
compounds, hundreds will be taken forward to the hit-to-lead and lead 
optimization phase, which may result in only 1 or 2 clinical candidates (Hughes 
et al., 2011). 
Although the biochemical assays discussed above have been successful 
in generating new NMEs, output has been lower than expected. Lead-to-clinic 
has low numbers and is associated with high attrition rates. This may be for 
numerous reasons. Primarily, the activity of leads identified in traditional 
biochemical assays may not translate to the cellular environment used during 
pre-clinical testing (Clemons et al., 2014). Secondly, biochemical assays may 
not be the best option for targets that are outwith the norm of enzymes and 
receptors due to novel binding kinetics (Swinney, 2006). Historically, many 
successful drug discovery programs were less “target centric” and leads were 
often identified though phenotypic and in vivo assays (Kola and Landis, 2004). 
Furthermore, there was often no knowledge of the specific target or mechanism 
of action. As a result, screening centres and the pharmaceutical industry are 
increasingly looking to use cell-based assays with increased physiological 
relevance. 
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1.3.4 Cell-based assays in HTS 
Biochemical assays used during primary screening simply assess the 
binding of a compound to a specific target. As a result of this, secondary assays 
used during hit validation are often associated with high attrition rates, by which 
time considerable time and money have been invested in the project. To 
overcome this, cell-based and phenotypic assays are increasingly used in early 
stage drug discovery as they not only illustrate the activity of a given compound, 
but also provide preliminary data regarding the ADMET (absorption, distribution, 
metabolism, elimination and toxicity) characteristics of the molecules (Zang et 
al., 2012). Additionally, cell-based assays have the capacity to identify both 
agonists and antagonists in a single screening campaign (Kunapuli et al., 2006, 
Guo et al., 2014). 
Previously published research has provided proof of principle for using 
both a fluorescent cell-based assay and HTS for the identification of novel 
modulators of the IFN response (Enomoto et al., 2000, Guo et al., 2014). For 
example, a red fluorescent protein under the control of the ISRE promoter has 
been used in an HTS to identify immunostimulatory RNA (Nguyen et al., 2009). 
To date, most screens have been luciferase-based assays and utilise relatively 
small compound sets (Chen et al., 2008, Charlaftis et al., 2012, Ye et al., 2011, 
Patel et al., 2012, Zhu et al., 2010). Recently, cell-based HTS was used to 
discover agonists of the IFN response, with a view to developing broad-
spectrum antivirals targeting infections to which there is high level of resistance 
to pre-existing therapies, or no current treatment options (Patel et al., 2012, 
Bedard et al., 2012, Martínez-Gil et al., 2012) 
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To design a cell-based assay for use in HTS, there are a number of 
criteria that need to be considered. Firstly, the target needs to be identified. In a 
cell-based phenotypic assay, this does not need to be a specific protein, but 
can be a signalling pathway as a whole. Secondly, the most appropriate cell 
system needs to be established. Although all cells are amenable to HTS, each 
have pros and cons associated with their use. Immortalized cell lines are simple 
to culture, reproducible and relatively cheap. However, the increased number of 
mutations necessary to render them immortal may alter their biological 
processes beyond physiological relevance (Ebert and Svendsen, 2010, Sharma 
et al., 2010). Primary cell lines and stem cells both produce physiologically 
relevant responses, although they have a limited culture life, and are difficult to 
handle (Ebert and Svendsen, 2010, Zang et al., 2012). Embryonic stem cells 
have an increased capacity for growth and differentiation, although their use is 
associated with moral issues. Chemically induced, pluripotent stem cells 
overcome these issues as they are artificially derived and can also be sourced 
directly from patients with a specific disease (Zang et al., 2012). Additionally, 
whole organism screens using parasites, zebra fish and even plants have been 
carried out (Zon and Peterson, 2005, Baragana et al., 2015, Agee and Carter, 
2009). 
Once an appropriate cell system has been chosen, the assay format 
needs to be addressed. The signal to be detected can range from a functional 
readout such as activation of secondary messengers and fluctuations in 
membrane potential, to phenotypic screens that assess cytokine production and 
cell migration (Zheng et al., 2013, Eggert et al., 2004, Yarrow et al., 2005, Kariv 
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et al., 1999, Chambers et al., 2003). Reporter genes including luciferase, β-
galactosidase, and fluorophores such as green fluorescent protein (GFP) are 
also widely used (Zhang et al., 2012, Beck et al., 2005, Li et al., 2007). The final 
consideration for assay design is the detection method that will be used. 
Although somewhat linked to the format of the assay in terms of signal for 
functional assays, fluorescent-based phenotypic assays can be monitored by 
either uniform well measurements using plate readers or high content screening 
(HCS), where high quality, confocal-level microscopy is used to analyse 
individual cells (Gribbon and Sewing, 2003, Nichols, 2006).  
As with other assays used in HTS, a stringent program of assay 
development and miniaturization is necessary. Although less simple to 
miniaturize compared to biochemical assays, cell-based, fluorescent end point 
assays are amenable to miniaturization as the signal window is not significantly 
affected (Kowski and Wu, 2000, Rudiger et al., 2001). The behaviour of the cell 
line and the assay are assessed at every step of assay development, where 
well-to-well, plate-to-plate, day-to-day and batch-to-batch reproducibility is 
closely monitored. This is achieved by the analysis of screening statistics such 
as the aforementioned S/B ratio, the percentage coefficient of variation (%CV) 
and the Z’ factor (Sittampalam et al., 1997, Zhang, 1999). As cells respond 
rapidly to environmental changes, their sensitivity to the compound solvent, and 
fluctuations in temperature and humidity need to be considered (Zhang et al., 
2012). 
 Following assay development, a pilot screen should be carried out, 
usually of 2,000 to 10,000 compounds to assess the behaviour of the finalized 
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assay (Voter et al., 2016, Clemons et al., 2014). Additionally, the inclusion of a 
reference molecule here is advantageous, although not always possible, 
especially for novel targets (Lu et al., 2015). Hit identification following primary 
HTS is based on the statistical analysis of the results. A predefined signal 
threshold, be it the top 1% of activity, or a fixed percentage minimum allows for 
hit triage, where increased stringency will decrease the number of putative hits, 
but potentially increases the number of false negatives (Malo et al., 2006). It is 
noteworthy that in cell-based HTS assays, off target effects can produce the 
same result as a hit. Additionally, in a phenotypic assay, the same phenotype 
can be achieved through compounds acting at different intervention points 
(Clemons et al., 2014). Putative leads resulting from hit identification are then 
subjected to secondary assays and counter screens designed to assess the 
specificity and potency of their activity. Following this, compounds are deemed 
confirmed hits, and enter the optimization pipeline. This usually involves 
compound set enrichment, where different compounds with chemotypes of high 
similarity to the hits are tested (Varin et al., 2011, Napolitano et al., 2016). 
Confirmed hits with novel structural properties and RO5 compliance are 
favourable as they are less likely to have off-target effects (Lipinski et al., 2001). 
Due to the inherent nature of cells to vary in their responses, hits can give rise 
to ambiguous results in different secondary assays (Burdine and Kodadek, 
2004). 
 Due to the high attrition rates associated with lead optimization following 
biochemical HTS and SBDD, pharmaceutical companies have been searching 
for assays that have built-in hit triage, an unbiased lead identification process, 
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and that give an indication of the biological responses to compounds. Cell-
based assays to provide an answer to this problem, and pharmaceutical 
companies appear to agree, as in 2006, cell-based assays constituted 53% of 
all HTS campaigns (Fox et al., 2006). It is important to note however, that in 
drug discovery there are no short cuts. Although cell-based assays allow for 
earlier focus on lead series that are likely to be successful, a lengthy process of 
lead optimization and preclinical testing will always be involved, regardless of 
the initial approach. 
  
	   43 
1.4 Research aims & objectives 
 The primary aim of this study was the development of a cell-based 
fluorescent assay to identify novel, small molecule modulators of the IFN 
response. Compounds that antagonize the IFN response have potential uses (i) 
as candidate drugs for the treatment of diseases associated with IFN 
dysfunction, (ii) in the production of live-attenuated viral vaccines and oncolytic 
viruses, and (iii) as tools to facilitate basic research. Conversely, compounds 
that agonize and therefore enhance IFN induction could be developed into 
therapeutics to boost the innate immune response in immunocompromised 
patients or for the indirect treatment of viral infections. 
The main aims of this study were as follows: 
• Develop a phenotypic assay to identify modulators of the IFN response 
• Optimize and miniaturize the assay to an automated 384-well format 
• Validate the suitability of the assay for use in an HTS campaign  
• Carry out a diversity screen against 15,667 small molecules at the Drug 
Discovery Unit, University of Dundee 
• Validate any hit compounds identified during screening and confirm their 
specificity 
• Characterize the compounds with preliminary research into the cellular 
target and the mode of action of confirmed hits  
• Expand the assay to enable the identification of molecules that modulate 
the function of the Rabies virus IFN antagonist (RBV-P) and 
subsequently carry out an in-house HTS.  
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2. Materials and Methods 
2.1 Cell-lines, viruses, interferon and antibodies 
2.1.1 Mammalian cell-lines 
 The mammalian cell-lines used in this study were Human embryonic 
kidney cells (293T) (Provided by Prof. Richard Iggo, University of Bordeaux), 
Human adenocarcinomic alveolar epithelial cells (A549) (ECACC 86012804) 
and African green monkey kidney epithelial cells (Vero) (ECACC 84113001). 
The human keratinocyte cell line, HACAT was utilized in the kinase activity 
assay carried out by Jordan Taylor at the University of Dundee. 
In addition to the cell-lines detailed above, the following A549 derivatives were 
used. 
• A549/pr(IFNβ).GFP: A549 cells with an enhanced green fluorescent 
protein (eGFP) gene under the control of the IFNβ promoter (Chen et al., 
2010). 
• A549/pr(ISRE).GFP: A549 cells with an eGFP gene under the control of 
the MxA promoter, which contains multiple Interferon stimulated 
response elements (ISRE) (Stewart et al., 2014). 
• A549/pr.(ISRE).GFP.RBV-P: A549/pr(ISRE).GFP cells that stably 
express N-terminally V5-tagged P protein of Rabies virus (RBV) 
(generated by Dr. Andri Vasou). 
• A549/pr(ISRE).GFP.TetOne-Puro-RBV-P: A549/pr(ISRE).GFP cells that 
express RBV P with an N-terminal V5-tag when induced with doxycycline 
(Dox) treatment. 
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2.1.2 Viruses and interferon 
 Cantell, a strain of Sendai virus (SeV) rich in defective interfering 
particles (DIs) (clarified allantoic fluid at 4000 HA units/ml, Charles River 
Laboratories) was used to stimulate the IFN induction pathway. Unless 
otherwise stated, SeV was used at a concentration of 40 HA units/ml. A 
recombinant Bunyamwera virus lacking the NSs gene (BunVΔNSs), rendering it 
IFN sensitive, was also used in this work (Stewart et al., 2014) (Provided by 
Prof. Richard Elliot, University of Glasgow). Purified IFNα (Roferon) (NHS, UK) 
was used to stimulate the IFN signalling pathway, and unless otherwise stated, 
used at a final concentration of 104 units/ml. 
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2.1.3 Antibodies 
 For the purposes of immunostaining western blot (WB) membranes and 
cell monolayers for immunofluorescent microscopy (IF), the primary and 
secondary-conjugated antibodies used are detailed below (Table 2.1). 
 
Table 2.1: Antibodies used in western blotting and immunofluorescence 
Target 






β-Actin Mouse Sigma-Aldrich 1:10,000 - 
SeV Rabbit Prof. Steve Goodbourn - 1:500 
IRF-3 Rabbit Santa Cruz - 1:200 
pIRF-3 (Ser 396) Rabbit Cell Signalling 1:1000 - 
pSTAT1 (Tyr 701) Goat Santa Cruz 1:150 - 
MxA Rabbit Santa Cruz 1:750 - 
GFP Mouse Roche 1:1000 - 
V5 Mouse Prof. Richard Randall - 1:400 
V5 Rabbit AbD Serotec 1:1000 - 
Secondary Antibodies 
α-Rabbit IRDye680 Goat Li-Cor 1:10,000 - 
α-Mouse IRDye800 Goat Li-Cor 1:10,000 - 
α-Goat HRP1 Donkey Santa Cruz 1:2000 - 
α-Rabbit FITC2 Goat Sigma-Aldrich - 1:200 
α-Rabbit TR3 Donkey Abcam - 1:200 
α-Mouse TR3 Goat AbD Serotec - 1:200 
1 Horseradish Peroxidase (HRP) 
2 Fluorescein isothiocyanate (FITC) 
3 Texas Red (TR) 
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The details of the antibodies used in the TLR3 experiment conducted by Jordan 
Taylor at the University of Dundee are detailed below. 
Table 2.2: Antibodies used in TLR3 dependent kinase activity experiment; conducted at the 
University of Dundee 
Target Raised in Source 




pIKKε (Ser 172) 
pIRF3 (Ser 396) 
GAPDH 
α-Rabbit HRP Goat 
 
2.2 Cloning 
2.2.1 Polymerase chain reaction (PCR) 
 For purposes of gene amplification for sub-cloning into plasmids, all 
PCR reactions were performed using high-fidelity Pfu polymerase (Promega). A 
typical reaction contained the components detailed in Table 2.3 in a total 
volume of 50 µL. The 10× stock Pfu buffer with MgSO4 (200 mM Tris-HCl (pH 
8.8), 100 mM (NH4)2SO4, 100 mM KCl, 1 mg/ml BSA, 1% (v/v) Triton X-100, 20 
mM MgSO4) was used. Details of the primers used throughout this work are 
given in Table 2.6. A thermocycler with heated lid (Biometra®, T-Personal) was 
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Pfu Polymerase 2.5 u/µL 0.05 u/µL 
Pfu buffer 10× 1× 
dNTPs 10 mM 0.4 mM 
Forward primer 100 µM 0.2 µM 
Reverse primer 100 µM 0.2 µM 
DMSO 100% (v/v) 4% (v/v) 
Template DNA 100-500 ng/µL 50 ng 
Water - - 
 
 







Polymerase activation 95 180 1 
Denaturation 95 30 
30 Annealing 55 30 
Extension 
72 120 /kb 
72 600 1 
 
 
Table 2.5: Sources of DNA used in PCR reactions 
Gene Accession Source 
IFNβ EF064725.1 Prof. R Randall 
MxA AK225885.1 Dr D Jackson 
β-Actin NC_000007.14 Amplified from A549 cDNA 
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Table 2.6: Primers used in PCR, qPCR and sequencing reactions 
Name Use Sequence 






























5' EcoRI-V5 (RBV-P) PCR GCGCGAATTCATGGGAAAGCCGATCCCAAACC 
3' BamH1-RBV-P PCR GCGCGGATCCTCAGCAGCTGGTGTATCTGTTCAGG 
pJet 1.2 Forward Seq1 CGACTCACTATAGGGAGAGCGGC 
pJet 1.2 Reverse Seq1 AAGAACATCGATTTTCCATGGCAG 







1 Sequencing reactions (Seq) 
 
2.2.2 DNA gel electrophoresis and extraction 
 To analyse to results of PCR and restriction enzyme digest, DNA was 
separated by agarose gel electrophoresis. PCR reaction samples were mixed 
with the appropriate volume of 10× loading buffer (Bioline) and run on a 1 or 2% 
(w/v) agarose gel (Sigma-Aldrich) in TBE buffer (100 mM Tris base, 100 mM 
Boric acid, 2.5 mM EDTA) containing ethidium bromide (1 µg/ml) (Invitrogen). 
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Samples were loaded into the gel with a molecular weight marker (Bioline, 100 
bp & 1kb) and run in TBE at 90 volts until bands were appropriately resolved. 
Bands of interest were excised from the gel and DNA purified using the 
QIAquick gel extraction kit (Qiagen) following manufacturer’s instructions, with 
the exception of purified DNA elution, where nuclease-free water was used as 
opposed to EB buffer. 
2.2.3 Sub-cloning into pJet shuttle vector 
 To facilitate sequencing and down-stream subcloning of amplified DNA 
fragments, PCR products were cloned into an intermediate vector. Purified PCR 
products were ligated into pJet1.2 (ThermoFischer). This CloneJet system 
allows for the direct ligation of blunt-ended PCR products into the pJet plasmid. 
One microliter of purified PCR product was incubated with 10 µL of 2× Buffer, 1 
µL of pJet1.2 vector and 7 µL of nuclease-free water, and 1µL of T4 DNA ligase 
(5 units) at room temperature (RT) for 5 minutes. For bacterial transformation, 
the ligation reaction was then incubated, on ice, with 50 µL of chemically 
competent DH5α E. coli cells (provided by Dr D Jackson) for 15 minutes. The 
transformation mix was heat-shocked at 42°C for 45 seconds, followed by a 
period of recovery through incubation at 37°C for 30 minutes. The transformed 
DH5α cells were plated onto Lysogeny broth (LB) agar plates containing 
ampicillin (100 µg/ml), inverted and incubated at 37°C for 18 hours. 
Transformed colonies from the agar plates were inoculated into 4 ml of LB 
supplemented with 100 µg/ml ampicillin and incubated at 37°C in an orbital 
shaker (280 rpm) for 18 hours. Plasmid DNA was then extracted from the 
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cultures using QIAprep spin miniprep kit (Qiagen). Miniprep plasmid DNA was 
screened for the cloned insert using diagnostic restriction digest as per 
manufacturer’s instructions (Promega). Briefly, plasmid DNA (3 µL), BglII 
restriction enzyme (5 units), 10× restriction digest buffer D (2 µL) and acetylated 
BSA (2 µg) were incubated at 37°C for 2 hours, followed by DNA gel 
electrophoresis. Gels were visualised under UV light, and plasmid DNA 
displaying the correct banding pattern was sequenced by DNA Sequencing & 
Services (MRCPPU, College of Life Sciences, University of Dundee, 
www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer. 
2.2.4 Sub-cloning into lentiviral transfer vector 
 For construction of the lentiviral vector containing RBV-P, sequence 
verified pJet1.2 vectors and the pLVX-TetOne-Puro destination vector 
(Clontech) were digested with BamHI and EcoRI restriction enzymes 
(Promega). The digested vector was also dephosphorylated using calf intestinal 
alkaline phosphatase (New England Biolabs) to prevent re-ligation of the 
digested vector. Digestion reactions were separated by DNA gel electrophoresis 
followed by DNA extraction of the vector and insert as detailed above (2.2.2). 
Purified insert DNA (5µL) was incubated with 10 µL of 2× Buffer, 1 µL of pLVX-
TetOne-Puro vector and 3 µL of nuclease-free water, and 1µL of T4 DNA ligase 
(5 units) at RT for 5 minutes. For bacterial transformation, the ligation reaction 
was then incubated, on ice, with 50 µL of chemically competent DH10b E. coli 
cells (Provided by Dr M Nevels) for 15 minutes. The transformation mix was 
heat-shocked at 42°C for 45 seconds, followed by a period of recovery through 
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incubation at 30°C for 1 hour. The transformed DH10b cells were plated onto 
LB agar plates containing ampicillin (100 µg/ml), inverted and incubated at 30°C 
for 24 hours. Transformed colonies from the agar plates were inoculated into 4 
ml of LB supplemented with 100 µg/ml ampicillin and incubated at 30°C in an 
orbital shaker (280 rpm) for 24 hours. Plasmid DNA was then extracted from the 
cultures using QIAprep spin miniprep kit (Qiagen). Miniprep plasmid DNA was 
screened for the cloned insert using diagnostic restriction digest as detailed in 
section 2.2.3. where BglII restriction enzyme was substituted by BamHI and 
EcoRI. Following DNA gel electrophoresis, gels were visualised under UV light, 
and plasmid DNA displaying the correct banding pattern was sequenced by 
DNA Sequencing & Services. Upon verification that the recombinant pLVX-
TetOne-Puro vector sequences were correct, miniprep DNA was transformed 
into DH10b E.coli cells, inoculated into 100 ml of LB supplemented with 100 
µg/ml ampicillin and incubated at 30°C in an orbital shaker for 24 hours. To 
achieve higher DNA yield to facilitate transfection for lentivirus production, 
plasmid DNA was extracted from the 100 ml cultures using Qiagen Plasmid 
Maxi Kit as per manufacturer’s instructions with the following alterations; (i) 
following isopropanol addition to precipitate eluted DNA; the reaction was 
incubated at -20°C for 1 hour, (ii) the wash step with ethanol addition to the 
pelleted DNA was carried out twice and (iii) following air-drying of the pellet, 
DNA was dissolved in nuclease-free water. 
2.2.5 Genomic DNA Extraction 
 To verify the successful integration of the transfer vector cassette into the 
host cell chromosome following lentivirus transduction of cells, genomic DNA 
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was extracted. The DNA was then analysed by PCR using primers specific to 
RBV-P (Table 2.6) followed by DNA gel electrophoresis. Genomic DNA 
extraction was achieved using Blood and Cell Culture DNA Kit (Qiagen) and the 
Qiagen Genomic tip 20/G following manufacturer’s instructions with the 
following alteration. Once air-drying of the pellet was complete, DNA was 
dissolved in nuclease-free water. 
 
2.3 Cell culture 
2.3.1 Cell maintenance 
All the cell lines used in this study were maintained as monolayers in 
tissue culture flasks (25, 75, 175 or 225 cm2) in high glucose Dulbecco’s 
modified eagle’s medium (DMEM) supplemented with 10% (v/v) Foetal bovine 
serum (FBS), 30 µg/ml penicillin and 50 µg/ml streptomycin (Pen-strep). Cells 
were incubated at 37°C with 5% CO2. When confluency reached approximately 
90%, cells were passaged with Trypsin-ethylenediaminetetraacetic acid 
(EDTA). For seeding of cells that would later be treated with IFNα, dissociation 
was achieved with 0.48 mM EDTA in phosphate-buffered saline (PBS) to avoid 
trypsin-mediated cleavage of the IFNα/β receptor. 
2.3.2 Cryopreservation & resuscitation of cells 
 Stable cell lines produced by lentivirus transduction were stored as 
stocks in liquid nitrogen. Cell monolayers were maintained as detailed above. 
Once 90% confluency was achieved, cells were trypsinised and centrifuged at 
1200 xg for 5 minutes. The cell pellet was resuspended in cryo-media (60% 
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(v/v) DMEM, 30% (v/v) FBS, 10% (v/v) DMSO) to achieve a concentration of 
1×106 cells/ml. Cells were frozen in 1 ml aliquots at -80°C and transferred to 
liquid nitrogen for long-term storage. To resuscitate cells that had been in liquid 
nitrogen storage, the 1 ml vial was thawed at 37°C and centrifuged at 1200 xg 
for 5 minutes. The resultant cell pellet was resuspended in DMEM 
supplemented with 10% (v/v) FBS and Pen-strep, split 80/20 into two, 25 cm2 
tissue culture flasks and incubated at 37°C with 5% CO2. Where selection was 
required, puromycin (2 µg/ml) was added to culture medium when monolayers 
reached 60% confluency or at first passage. 
2.3.3 Growth of virus stocks 
BunVΔNSs stocks were propagated in T75 cm2 tissue culture flasks 
containing Vero cells at 95% confluency. Cells were infected with virus and 
incubated for 3 days in DMEM supplemented with 2% (v/v) FBS and L-
glutamine (2 mM). Supernatant was collected and centrifuged at 1200 xg for 5 
minutes. BunVΔNSs stocks were stored as 1 ml aliquots at -80°C. 
2.3.4 Stable cell-line production 
 To modify the A549/pr(ISRE).GFP reporter cell line to express RBV-P by 
doxycycline induction, 2nd generation lentivirus technology was used. 
Lentiviruses are produced in 293T cells following transfection with 3 plasmids. 
These plasmids being (i) a transfer vector containing the integration cassette, 
which comprises a puromycin N-acetyl-transferase (PAC) gene, and so gives 
resistance to puromycin, and the gene of interest flanked by long terminal 
repeats, which facilitate integration into the host cell chromosome, (ii) a 
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packaging plasmid encoding Gag, Pol and Rev, and (iii) an envelope plasmid 
encoding the G glycoprotein of vesicular stomatis virus (VSV) (Zufferey et al., 
1997, Naldini et al., 1996). 
2.3.4.1 Lentivirus production 
 293T cells were seeded in T75 tissue culture flasks at 70 to 90% 
confluency for transfection. Using the 3 vector system for lentivirus production, 
10µg of pLVX-TetOne-Puro-V5-RBV-P, 6 µg of pCMVR 8.91 packaging plasmid 
and 6 µg pVSV-G envelope plasmid were added to 1.5 ml of Optimem 
(Invitrogen) and incubated at room temperature for 5 minutes. Separately, 60 µl 
of Lipofectamine 2000 (Invitrogen) was added to 1.5 ml of Optimem. The 
plasmid and Lipofectamine mixes were then combined, and incubated at RT for 
a further 30 minutes to allow DNA containing liposomes to form. Culture 
medium was removed, and the plasmid-Lipofectamine-Optimem solution added 
drop-wise to the 293T cells, which are incubated at 37°C with 5% CO2. Five 
hours post-transfection, 8 ml of antibiotic free DMEM supplemented with 10% 
(v/v) FBS was added. After a 48 hour incubation at 37°C with 5% CO2, lentivirus 
containing media was collected and centrifuged at 3000 ×g for 10 minutes. The 
medium was then filtered through a 0.45 µm syringe filter and divided into 1 ml 
aliquots for storage at -70°C. 
2.3.4.2 Transduction of A549/pr(ISRE).GFP cells 
 A549/pr(ISRE).GFP reporter cells were transduced with lentivirus at 50% 
confluency in T25 tissue culture flasks. Lentivirus preparations were thawed at 
37°C and added to 1 ml of DMEM (serum and antibiotic free) supplemented 
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with polybrene (Sigma), to aid infection, at a final concentration of 8 µg/ml. The 
lentivirus-DMEM-polybrene mix was added to cell monolayers. Flasks were 
then centrifuged at 1000 ×g for 30 minutes and incubated at 37°C with 5% CO2 
for 2.5 hours. Two ml of DMEM supplemented with 10% (v/v) FBS was then 
added to the flasks, which were incubated as above for a further 48 hours. 
Where repeated rounds of lentiviral transduction were required, following 
centrifugation for 30 minutes, cells were incubated for 1 hour. Following 
incubation, the lentivirus containing media was removed, and freshly prepared 
lentivirus-DMEM-polybrene mix applied to the cells as above. This was 
repeated as many times as required. Two ml of DMEM containing 10% (v/v) 
FBS was then added and the cells incubated for 48 hours as above. 
2.3.4.3 Antibiotic selection of transduced cells 
 Following lentivirus transduction, antibiotic selection was used to isolate 
cells that had successfully integrated the transfer vector cassette into the host 
cell chromosome. Puromycin (Sigma) was added to cell culture medium at a 
final concentration of 2 µg/ml. 
2.3.5 Fluorescent activated cells sorting (FACS) 
Following multiple rounds of lentivirus transduction, the 
A549/pr(ISRE).GFP cell line required optimization. The expression of GFP was 
not consistent throughout the population and so was heterogeneous. Therefore, 
the cells were sorted on the basis of GFP expression to produce more 
homogenous expression. Fiona Rossi, of the Centre for Inflammation Research, 
The Queen’s Medical Research Institute in Edinburgh carried this out. 
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The A549/pr(ISRE).GFP cell-lines adapted to include the Dox inducible 
expression of RBV-P required further optimization. To facilitate this optimization, 
FACS was employed to isolate cells expressing the lowest levels of GFP in the 
presence of antagonist. Cells were seeded into T25 tissue culture flasks at 
approximately 25% confluency in the presence or absence of Dox (1 µg/ml) 
(Sigma). Sixteen hours post-Dox treatment, cells were either treated with IFNα 
(104 units/ml) for 24 hours or left untreated. Cells were then trypsinized and 
centrifuged at 1200 xg for 5 minutes and the cell pellet resuspended in 2 ml of 
DMEM supplemented with 2% (v/v) FBS. For FACS analysis, cells were filtered 
into FACS tubes (Round bottom Falcon tubes with cell strainer cap) and 
analysed by flow cytometry in a FACSJazz cell sorter (BD Biosciences). All 
FACS sorting and initial analysis was completed by Dr. Elizabeth Randall. 
Briefly, the cell population to be sorted goes through a process of gating, where 
cell size (Forward Scatter (FSC)) and granularity (Side Scatter (SSC)) are 
assessed to eliminate cell debris, along with trigger pulse width, which removes 
cell doublets from the analysis. Single cells are then sorted on the basis of GFP 
fluorescence using laser excitation of 488 nm and identified by a 530/40 
bandpass filter. Sorted cells are then isolated into 12-well tissue culture dishes 
and maintained for further analysis. 
2.3.6 IFNβ induction assay 
 A549/pr(IFNβ).GFP reporter cells were maintained in tissue culture flasks 
and dissociated with Trypsin-EDTA. Cells were seeded at 9×104 cells/cm2 in 96 
or 384 well tissue culture plates (Corning) and incubated at 37°C with 5% CO2. 
Unless specified, twenty-four hours post seeding, cells were infected with SeV 
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in DMEM supplemented with 10% (v/v) FBS and incubated at 37°C with 5% 
CO2 for 18 hours, unless otherwise stated. Where necessary, prior to SeV 
infection, cells were treated with inhibitors at the indicated concentrations for 2 
hours at 37°C. Cells were fixed with 5% (v/v) formaldehyde at room 
temperature, washed and phosphate buffered saline (PBS) added to each well. 
Cells were then analysed for GFP expression on an Infinite M200 Pro (Tecan) 
or EnVision (Perkin Elmer) plate reader at excitation/emission 484/518 nm or 
485/535 nm respectively. Data was analysed by converting the signal in raw 
fluorescent units (RFU) to a signal-to-background (S/B) ratio of RFU of 
unactived cells and then calculating the mean (µ) and the standard deviation (σ) 
for a group of replicates. This was also used to calculate the Zʹ′ Factor, 
comparing the signal of activated (SeV infected) and unactivated (untreated) 
cells. The formula for this calculation is below (Zhang, 1999). S/B ratio was 
calculated by dividing the mean signal (RFU) of activated cells by that of 
unactivated cells. 
 
Zʹ′ Factor = 1 -  3 × (σActivated + σUnactivated) 
      µActivated - µUnactivated 
2.3.7 IFN signalling assay 
A549/pr(ISRE).GFP reporter cells were maintained in tissue culture 
flasks and dissociated with EDTA for seeding into 96 or 384 well tissue culture 
plates (Corning) at 9×104 cells/cm2, followed by incubation at 37°C with 5% 
CO2. To activate the IFN signalling pathway, cells were treated with 104 Uml-1 of 
IFN-α (Roferon, NHS) in DMEM supplemented with 10% (v/v) FBS 24 hours 
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post seeding. Where necessary, prior to INFα treatment, cells were treated with 
inhibitors at the indicated concentrations for 2 hours at 37°C. Following 
incubation at 37°C with 5% CO2 for 42 hours, unless otherwise specified, cells 
were fixed with 5% (v/v) Formaldehyde at room temperature, washed and PBS 
added to each well. Cellular GFP expression was then analysed as above 
(2.3.6) 
2.3.7.1 A549/pr(ISRE).GFP cells with constitutive antagonist expression 
 A derivative of the A549/pr(ISRE).GFP cell line, which constitutively 
expresses the P protein of Rabies virus (A549/pr(ISRE).GFP.RBV-P) was used 
for in-house HTS (2.4.2). A549/pr(ISRE).GFP.RBV-P cells were used in the IFN 
signalling assay as detailed above (2.3.7). Cells were analysed for GFP 
expression on an Infinite M200 Pro (Tecan) plate reader at excitation/emission 
484/518 nm. As the expression of RBV-P inhibits the IFN signalling assay, GFP 
fluorescence is minimal. Therefore, the S/B ratio and Z’ Factor cannot be used 
for quality control (QC) analysis. In this case, percentage coefficient of variation 
(CV %) was used to monitor fluctuations in the A549/pr(ISRE).GFP.RBV-P cell 
line. 
 
CV % = (σ/µ)*100 
2.3.7.2 A549/pr(ISRE).GFP cells with a doxycycline inducible expression 
system 
Derivatives of the A549/pr(ISRE).GFP cell line were developed, where 
the expression of the P protein of Rabies virus (A549/pr(ISRE).GFP.TetOne-
Puro.RBV-P) is induced with Dox treatment. These cell lines were used in the 
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IFN signalling assay above (2.3.7) with the following amendments. As the half-
life of Dox is 48 hours, it was supplemented into the growth medium and topped 
up every 36 hours. Where appropriate, cells were seeded in the presence of 
Dox, which was also added at the same time as IFNα treatment. Unless 
otherwise stated, Dox was used at a final concentration of 1 µg/ml. 
 
2.4 High-throughput screening 
 In this study, we embarked on 2 separate screening campaigns. The first 
utilized the IFNβ induction assay with the aim of identifying novel modulators 
the IFNβ induction pathway. In this screen we were primarily measuring a 
reduction in GFP expression, which would result from a test compound 
inhibiting the IFNβ induction pathway. The second screen, carried out in-house, 
utilized the IFN signalling assay and A549/pr(ISRE).GFP.RBV-P cells to identify 
novel modulators of RBV-P protein function. In this instance, if a test compound 
were to inhibit RBV-P function, GFP expression would be restored. 
2.4.1 Screening compounds and inhibitors 
IFN induction and signalling inhibitors BX-795, TPCA-1 and Ruxolitinib 
(Rux) (Selleck chemicals) were prepared in dimethyl sulfoxide (DMSO) as 10 
mM stock. CYT387 (Selleck chemicals) was prepared in DMSO as a 20 mM 
stock. Unless otherwise stated, the inhibitors were used at 2 µM. Actinomycin D 
(AMD) and Cycloheximide (CHX) (Sigma), inhibitors of transcription and 
translation respectively, were prepared as 10 mg/ml stocks in DMSO and 
ethanol respectively, and, unless otherwise stated, used at 40 µg/ml. 
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Compounds constituting the Small Diversity Set of the Drug Discovery Unit 
(DDU) at the University of Dundee were stored as 10 mM stocks in DMSO and 
unless otherwise stated, used at 30 µM. Compounds constituting the Maybridge 
screening collection were stored as 10 mM stocks in DMSO and unless 
otherwise stated, used at 11.42 µM. Hit compounds identified during HTS, 
which were named StA-IFN-1 to StA-IFN-5 and compounds with high similarity 
to StA-IFN-1 and StA-IFN-4, and 2 molecules that constitute each half of these 
hit molecules are detailed below (Table 2.7). Compounds were purchased, 
prepared as 10 mM stocks in DMSO and used at 10 µM, unless otherwise 
stated. All compounds were stored at -80°C. 
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Table 2.7: Hit compounds and those with closely related structures  
Name Chemical Name CAS Source 



















methyl- 108-26-9 Enamine 










methyl- 933-76-6 Enamine 
StA-IFN-4-LF 4H-Pyrido[1,2-a]pyrimidin-4-one, 2,8-dimethyl- 30247-64-4 ChemDiv 
 
2.4.2 Diversity and dose response screening at the Drug Discovery Unit 
(DDU) University of Dundee 
A single-point diversity screen of 15,667 compounds was carried out at 
the University of Dundee using the IFNβ induction assay detailed above (2.3.6). 
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The DDU small diversity set was provided in 384-well Echo plates. 
A549/pr(IFN).GFP cells were seeded into clear-bottomed black 384-well plates 
Test compound, at a final concentration of 30 µM (125 nl), was added to 
A549/pr(IFN).GFP cells using an Echo 550 liquid handler (Labcyte). Two hours 
post-compound addition, cells were infected with SeV (40 HA units/ml) for 18 
hours. GFP expression was measured with an EnVision plate reader (Perkin 
Elmer) at excitation/emission 485/535 nm.  
To test the potency of putative hits from the small diversity library, each 
compound was tested in the IFNβ induction reporter assay with and without 
SeV infection, and the IFN signalling assay to generate standard ten-point dose 
response curves. This was achieved through two-fold serial dilutions of test 
compounds added to seeded A549/pr(IFN).GFP or A549/pr(ISRE).GFP cells 
using an Echo 550 and overlord3 robotics software. 
For all data analysis, the RFU of each well was measured, and 
normalised to a percentage effect (% effect) of the positive control, calculated 
as follows. 
 
% Effect = ((RFUUnactivated - RFUTest)/(RFUUnactivated – RFUActivated)) * 100 
 
ActivityBase XE (IDBS) was used for all data processing using % effect, with 
the utilisation of SARgen (IDBS) and Excel (Microsoft). For determination of 
potency, 4-parameter logistic fit (Minimum, maximum, hill slope and IC50) was 
used, being defined in reference to the negative log of the molar value at the 
point of inflection of a sigmoidal dose-response curve (pIC50). Additionally, all 
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assay plates were subject to QC analysis. The QC criteria for the acceptance of 
an assay plate is shown below: 
- S/B Ratio ≥2 
- CV % <8% 
- Z’ ≥0.5 
2.4.3 In-house HTS using the Maybridge library 
 A single-point primary screen of 16,000 compounds was carried out in-
house using the IFN signalling assay detailed above (2.3.7) with the 
A549/pr(ISRE).GFP.RBV-P reporter cell line. The Maybridge compound library, 
loaned by Prof Nicholas Westwood (University of St Andrews), was provided in 
50 384-well plates. Compounds were at a concentration of 10 mM dissolved in 
DMSO and contained in columns 3 to 22. The screen was conducted in 4 
batches; 2 batches of 12, and 2 batches of 13 plates. A549/pr(ISRE).GFP.RBV-
P (columns 1-22) and A549/pr(ISRE).GFP (columns 23 to 24) cells were 
seeded in 384-well clear-bottomed, black tissue culture plates (Greiner Bio-one) 
at 9×104 cells/cm2 and incubated at 37°C with 5% CO2. The following day, cells 
were treated with 11.42 µM of test compound using a MiniTrak V Multi Position 
Dispenser (Perkin Elmer), which replicates the compound plate in the assay 
plate, for 2 hours. To activate the IFN signalling pathway, IFN-α in DMEM 
supplemented with 10% (v/v) FBS was added to cells in columns 2 to 23 
followed by brief centrifugation at 1200 rpm for 1 minute. Following incubation 
at 37°C with 5% CO2 for 42 hours, cells were fixed with 5% (v/v) Formaldehyde 
at room temperature, washed and PBS added to each well. With the exception 
of test compound transfer, all liquid handling was carried out using a Matrix 
	   65 
WellMate microplate dispenser (Thermo Scientific). Cellular GFP expression 
was analysed on an Infinite M200 Pro (Tecan) plate reader at 
excitation/emission 484/518 nm. Additionally, all assay plates were subject to 
QC analysis by monitoring CV % of A549/pr(ISRE).GFP.RBV-P cells and S/B 
ratio, CV % and Z’ Factor of A549/pr(ISRE).GFP cells. All data analysis was 
conducted using Excel (Microsoft) and Prism6 (GraphPad) software. 
 
2.5 Protein expression and modification analysis  
 To facilitate analysis of protein expression and phosphorylation levels 
under different treatment conditions, whole cell lysates were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to 
membranes for western blotting. For different experiments, initial cell treatments 
post-seeding differ, however they converge on a standard set of techniques 
detailed below. 
2.5.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 The procedures common to all experiments requiring SDS-PAGE are 
detailed here. A549 cells were seeded into 6-well plates at 4×104 cells/cm2. 
Where appropriate the following day, cells were treated with compound for 2 
hours. To activate the IFN induction pathway cells were infected with SeV. To 
induce the IFN signalling pathway, cells were treated with IFNα. Cells were 
lysed in disruption buffer (6M Urea, 4% (w/v) sodium dodceyl sulphate (SDS), 2 
M β-mercaptoethanol), and to ensure denaturation of proteins were pulse 
sonicated at 10 amplitude microns (23kHz) for 10 seconds and heated to 95°C 
for 5 minutes. Cell lysates were separated by SDS-PAGE. Ten percent (v/v) 
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acrylamide gels were hand-cast using 30% (w/v) Protogel, Stacking buffer and 
Resolving buffer (National Diagnostics), the components of the gels are detailed 
below (Table 2.8). Gels were run at 100 volts for approximately 2 hours in 1× 
TGS buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS, pH8.3). 
 
Table 2.8: Components of hand-cast SDS-PAGE gels 
Reagent 10 % (v/v) Resolving Gel 
4% (v/v) 
Stacking Gel 
30% (w/v) Acrylamide (ProtoGel) 8.3 ml 1.3 ml 
Resolving Gel Buffer 
(0.375 M Tris-HCl, 0.1% (w/v) SDS, pH 8.8) 
6.3 ml - 
Stacking buffer 
(0.125 M Tris-HCl, 0.1% (w/v) SDS, pH 6.8) 
- 2.5 ml 
10% (w/v) Ammonium persulfate (APS) 250 µl 100 µl 
TEMED (Tetramethylethylenediamine) 25 µl 10 µl 
Water 8.5 ml 6.1 ml 
Total Volume (for four gels) 25 ml 10 ml 
 
Cell treatment conditions varied depending on the aim of individual 
experiments. The specifics of these different experiments following cell seeding 
and leading up to cell lysate collection are detailed below. 
• Detection of phosphorylated IRF3 (pIRF3): Cells were treated with 
compound for 2 hours, followed by SeV infection for 3. 
• Detection of phosphorylated STAT1 (pSTAT1): Cells were treated with 
compound for 2 hours, followed by IFNα treatments for 15 minutes. 
• Validation of the A549/pr(ISRE).GFP.RBV-P cell line: 
A549/pr(ISRE).GFP and A549/pr(ISRE).GFP.RBV-P cells were treated 
with IFNα for 18 and 44 hours. 
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• Validation of RBV-P protein expression from the pLVX-TetOne-
Puro-RBV-P vector: 293T cells were transfected with plasmid DNA 
using the Lipofectamine transfection protocol detailed in section 2.3.3.1, 
followed by incubation with Dox for 16 hours. 
• Validating the functionality of RBV-P in the A549/pr(ISRE).GFP. 
TetOne-Puro-RBV-P cell line: A549/pr(ISRE).GFP and 
A549/pr(ISRE).GFP. TetOne-Puro-RBV-P cells were seeded in the 
presence or absence of Dox and treated with IFNα for 40 hours. 
2.5.2 Western blotting and immunostaining of membranes 
Following separation by SDS-PAGE, proteins were transferred to 
polyvinlidene difluoride (PVDF) membranes, activated in 100% (v/v) methanol 
(Thermo), using TransBlot Turbo semi-dry transfer system (Bio-Rad) in Towbin 
transfer buffer (25 mM Tris, 192 mM Glycine, 20% (v/v) methanol, pH8.3) at 1.3 
Amps, 25 volts for 20 minutes. Membranes were blocked in blocking buffer 
(PBS, 0.1% (v/v) tween-20 and 5% (w/v) skimmed dried milk powder) and 
incubated with primary antibody (Table 2.1) at room temperature for 1 hour or 
overnight at 4°C. Membranes were then washed in 0.1% (v/v) tween-20 (PBS) 
and incubated with secondary antibody conjugated to a fluorophore or HRP 
(Table 2.1). Membranes were washed as above and protein detection 
performed using an Odyssey CLx near-infrared scanner (Licor) for fluorescently 
tagged secondary antibodies or enhanced chemiluminescence (ECL) for HRP-
conjugated secondary antibodies.   
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2.6 Off-target effects of hit compounds 
 Following HTS and selection of hits to follow up, compounds were 
repurchased. We instigated a campaign of hit validation to confirm that the 
inhibition in GFP expression observed through screening was due to the action 
of a compound on the IFN induction pathway, and not through off-target, non-
specific effects. This was achieved through assessing cell viability, cellular 
protein synthesis and virus infection and replication in the presence of hit 
compound. 
2.6.1 Cell-viability assay 
 To assess the effect of compound on cell viability, the AlamarBlue (AB) 
reagent (Life Technologies) was used. A549 cells were seeded in 96-well plates 
and treated with a 10 point, 2-fold serial dilution of compound from 50 to 0.1 µM 
for 48 hours at 37°C with 5% CO2. AB reagent (Life technologies) was added to 
cells to a final concentration of 10% (v/v) and incubated in the dark for 4 hours. 
Fluorescence was measured on an Infinite M200 Pro (Tecan) plate reader at 
excitation/emission 545/590 nm. The percentage reduction in AB used to 
assess cell viability is calculated by using 0% reduced (DMEM+AB) and 100% 
reduced (cells+DMEM+AB) controls. 
2.6.2 Cellular and viral protein synthesis analysis 
 To assay cellular protein synthesis in the presence and absence of hit 
compounds, A549 cells were incubated with 10 µM of hit compound or the 
transcriptional inhibitor AMD for 24 and 48 hours. Cells were then metabolically 
labelled with L-[35S]Met/Cys pro-mix (500 Ci mmol-1, Perkin Elmer) for 1 hour. 
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After labelling, cells were lysed in disruption buffer containing 28 units/ml 
benzonase (Sigma) and proteins separated by SDS-PAGE (2.6.1). Gels were 
fixed, washed and imaged via coomassie brilliant blue stain. Bands were 
quantified using a FLA-5000 phosphoimager and Image Gauge software 
(FujiFilm). Down stream data analysis used Prism 6 (GraphPad) software. 
 To assess viral protein synthesis in the presence of hit compound, A549 
cells were incubated with 10 µM of hit compound for 2 hours, followed by SeV 
infection for 18 hours. Metabolic labelling and processing of whole cell lysates 
was carried out as detailed above. 
 
2.7 Analysis of IFNβ  and MxA gene expression 
 To establish the activity of hit compounds out-with the GPF based 
reporter assays, their effect on IFNβ and MxA gene expression was assessed. 
This was achieved through total RNA extraction of compound treated, SeV 
infected cells, followed by reverse transcription of messenger RNA (mRNA) and 
quantitative PCR (qPCR) of the resultant complementary DNA (cDNA). 
2.7.1 RNA extraction 
 A549 cells were seeding into 6-well plates at 3x105 cells/ml (2 ml/well) 
and incubated at 37°C with 5% CO2. The following day, confluent cell 
monolayers were treated with compound for 2 hours followed by either a 3-hour 
SeV infection or an 18-hour IFNα treatment. Total RNA was then extracted from 
the cells by standard Phenol-Chloroform extraction using TRIzol 
(ThermoFisher). Briefly, 1 ml of TRIzol reagent is added to each well to lyse the 
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cells. Cell lysates were collected and mixed with 200 µl of chloroform. To 
separate RNA, DNA and protein, the TRIZol-chloroform lysates were 
centrifuged at 12,000 ×g for 15 minutes at 4°C. The RNA-containing aqueous 
phase was then removed from the separated lysates. RNA was then mixed with 
1µl of GlycoBlue coprecipitant (ThermoFisher) and 500 µl of isopropanol (IPA) 
and incubated at -20°C for up to 1 hour to aid RNA precipitation. The RNA-IPA 
was then centrifuged at 12,000 ×g for 10 minutes at 4°C and the resultant RNA 
pellet washed twice in 1 ml of 75% (v/v) ethanol (EtOH). The EtOH supernatant 
was removed from the RNA pellet, which was then air-dried and dissolved in 
nuclease-free water overnight at 4°C. The RNA was then used directly in cDNA 
synthesis or stored at -70°C. 
2.7.2 Complementary DNA synthesis 
 Reverse transcription of purified RNA was completed using RevertAid 
First Strand cDNA Synthesis Kit (ThermoFisher), which utilizes a recombinant 
M-MuLV reverse transcriptase. Manufacturer’s instructions were followed and 
are outlined below. 
 Total RNA (3 µg) was added to 1.5 µl of Oligo d(T)18 primer (12.5µM) 
and nuclease-free water on ice and incubated at 65°C for 5 minutes. Once back 
on ice, 5× reaction buffer, RiboLock RNase inhibitor (20 units), and dNTPs (1 
mM of each) and RevertAid M-MuLV Reverse Transcriptase (200 units) were 
added to the reaction. Following an hour’s incubation at 42°C, the reaction was 
terminated by a 5-minute incubation at 70°C. Resultant cDNA was used directly 
in qPCR or stored at -70°C. 
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2.7.3 Quantitative PCR 
 Quantitative PCR is a highly sensitive technique that allows accurate 
determination of transcript levels within a given sample. In this study, qPCR was 
used to compare the levels of IFNβ mRNA in samples taken from cells treated 
with hit compounds and subsequently infected with SeV to activate the IFNβ 
induction pathway. MxA mRNA levels in samples from cells that had been 
treated with hit compound and subsequently incubated with IFNα to activate the 
IFN signalling pathway were also assessed. In this instance, absolute 
quantitation was used, as opposed to relative quantitation. To potentiate 
absolute quantitation, a DNA standard, of known concentration, matching the 
sequence to be amplified in the qPCR reaction is required. A 10-fold serial 
dilution of the standard allows the cycle threshold (Ct) values to be used to 
construct a standard curve, from which the quantity of DNA in the test samples 
can be calculated. The details of this process and the qPCR are given below. 
2.7.3.1 Standard curve generation 
 Plasmids containing gene fragments of IFNβ, MxA and β-Actin to be 
amplified in the qPCR reactions were used to create a standard curve of known 
concentration against Ct value using a 6-point 10-fold serial dilution of DNA 
from 1 ng to 0.01 pg. These reactions are carried out in the same 96-well plate 
as the corresponding test sample reactions, detailed below. The qPCR results 
for the IFNβ standard are shown in figure 2.1. In addition to the internal controls 
in the qPCR reaction detailed below, the standard curve also potentiates 
assessment of the efficiency of the reaction through the R2 value generated 
(Figure 2.1A). An example of the amplification plots generated for the DNA 
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standards is also shown (Figure 2.1B). The dissociation curve created during 
each reaction displays one clear peak (Figure 2.1C), suggesting high specificity 
of the primers and an absence of primer dimer formation. Standard and 
dissociation curves for the MxA and β-Actin primer sets are shown in Appendix 
1. 
2.7.3.2 qPCR of test samples 
Primers specific to IFNβ (nt 40-155), MxA (nt 570-931) and Actin (nt 257-
640) (Table 2.6) were used at 100 nM to assay cDNAs generated by reverse 
transcription (2.7.2) in qPCR reactions. In this study MESA Blue qPCR 
mastermIx (Eurogentec) containing SYBR Green I, an intercalating dye that 
fluoresces upon binding to DNA, and Rox, a reference dye that acts as an 
internal control to normalise any variations in mastermix concentration or 
reaction volume, were used. PCR reactions were set (Table 2.9) and were 
carried out in a Stratagene Mx3005P real-time PCR thermocycler using the 
specified cycling conditions (Table 2.10). Conversion of Ct value to DNA 
quantity (ng) was carried out by MxPro software (Stratagene). Further data 
analysis was carried out on Excel (Microsoft) and Prism6 (Graphpad). 
	   73 
 
Figure 2.1: Data output of qPCR reactions using IFNβ  standard template DNA. 
pJet1.2 IFNβ nt 40-155 was used to create a 6-point standard curve using a 10-fold serial 
dilution from 1 ng to 0.01 pg, giving an R2 value of 0.999 (A). The amplification plots for each of 
the 6 DNA concentrations show even spacing, with the highest DNA concentration 
corresponding to the lowest Ct value (B). The corresponding dissociation curve display a single 
































R2 = 0.999 
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MESA Blue Mastermix 2× 1× 
Forward primer 100 µM 100 nM 
Reverse primer 100 µM 100 nM 
cDNA - 1 µl 
Nuclease-free Water   
 







1 – Activation 
60 120 Activates Mastermix 
95 600 Activates polymerase 
2 – qPCR1 
95 15 Denatures 
50 60 Anneals 
72 60 Extends2 
3 – Dissociation 
curve 
95 60 Denatures 
50 30 Anneals 
95 30 Denatures3 
1 Step 2 repeated through 40 cycles 
2 Fluorescence read at the end of each extension step 
3 Fluorescence read at each degree between 50 and 95°C during ramp 
 
2.8 Immunofluorescent microscopy 
 Immunofluorescent microscopy was used to analyse the nuclear 
localisation of IRF3 during SeV infection, in the presence or absence of hit 
compounds. It was also used to assess the impact of hit compounds on SeV 
infection itself. A549 cells were grown on 10 mm coverslips (Scientific 
Laboratory Supplies) and treated with inhibitors for 2 hours at 37°C. Cells were 
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then infected with SeV and processed as detailed below for the two different 
experiments. Details of the antibodies used can be found in table 2.1. Images 
were collected on a Nikon Microphot-FXA microscope at ×40 magnification with 
Imsol imaging software and processed using ImageJ64 software. 
2.8.1 IRF-3 localisation analysis 
At 4 hours post infection, cells were fixed (5% (v/v) formaldehyde in PBS) 
for 15 minutes, permeabilised (0.5% (v/v) NP-40, 10% (w/v) sucrose) for 10 
minutes and washed (1% (v/v) FBS in PBS). Coverslips were incubated for 1 
hour with anti-IRF3 antibody, followed by Texas red-conjugated secondary 
antibody and DAPI (Sigma). For quantification of nuclear translocation, images 
were anonymized and Dr Andri Vasou counted cells displaying nuclear or 
diffuse cytoplasmic staining of IRF3. The number of cells showing IRF3 nuclear 
localisation was converted to a percentage of total cells counted for each 
image. 
2.8.2 Sendai virus infection analysis 
Two hours post-compound treatment, cells were infected with SeV for 18 
hours followed by fixation (5% (v/v) formaldehyde in PBS) for 15 minutes, 
permeabilisation (0.5% (v/v) NP-40, 10% (w/v) sucrose) for 10 minutes and 
washed (1% (v/v) FBS in PBS). Coverslips were incubated for 1 hour with anti-
SeV antibody, followed by FITC-conjugated secondary antibody. 
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2.9 Plaque assays 
 In order to assess the growth of an IFN sensitive virus in the presence of 
hit compounds, plaque assays were performed, which allow quantification of 
viral replication. A549 cells were seeded into 12-well plates at 2.5×105 cells/ml. 
The following day, confluent monolayers were treated with compound for 2 
hours where appropriate, and then infected with 100 µl of 10-6 BunVΔNSs in 
PBS supplemented with 2% (v/v) foetal calf serum (FCS). Following a 1 hour 
incubation at 37°C for adsorption, the inoculum was replaced with Avicel 
overlay (1× MEM, 1× GlutaMAX, 2% (v/v) newborn calf serum (NCS), 0.4% 
(v/v) NaHCO3 and 0.6 % (w/v) Avicel), which, where appropriate also contained 
hit or control compound. Plaque assays were incubated for 3 days at 37°C with 
5% CO2 followed by fixation with 5% (v/v) formaldehyde in PBS for 1 hour at 
4°C. Cells monolayers were washed with water and plaques visualised by 
Coomassie Brilliant Blue stain (0.1% (w/v) Coomassie R250, 10% (v/v) Glacial 
acetic acid and 40% (v/v) Methanol). To facilitate quantification of plaque size, 
plates were scanned at 600 d.p.i. and images amplified to 400%. PixelStick 
(Plum Amazing) was used to measure plaque size. The plaque size in pixels 
was normalized to the DMSO + SeV control to illustrate fold-increase. 
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3. Development of a cell-based assay to identify 
modulators of the type I IFN response 
3.1 Introduction 
 Two GFP reporter cell lines, A549/pr(IFNβ).GFP and 
A549/pr(ISRE).GFP, previously generated in the lab provide a simple method to 
detect activation of the IFN response through fluorescence. These cells lines 
have previously been used to monitor the activity of known inhibitors of the IFN 
induction and signalling pathways (Stewart et al., 2014). We sought to 
demonstrate that these cell lines could be utilized in an automated HTS to 
identify novel compounds that modulate the IFN response. In order to execute a 
robust screen and have confidence in the results obtained, the assay in 
question requires optimization to (i) maximize the signal-to-background (S/B) 
ratio, (ii) minimize variation between replicates and (iii) minimize the timescale 
of the assay. In collaboration with the Drug Discovery Unit (DDU) at the 
University of Dundee, we instigated a campaign of assay development in which 
we sought to optimize every step in both the IFN induction assay, utilizing the 
A549/pr(IFNβ).GFP reporter cell line and the IFN signalling assay, utilizing the 
A549/pr(ISRE).GFP cell line. Following this period of optimization, both assays 
were validated for their ability to identify novel modulators of the IFN response 
by using compounds known to inhibit various components of the pathways. 
Following successful assay validation, the assays were miniaturized and 
automated to a 384-well HTS format to generate final assay parameters, which 
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illustrated that both GFP reporter assays had been successfully optimized for 
use in HTS. 
 
3.2 Results 
3.2.1 IFN induction assay development 
The IFN induction assay utilizes the A549/pr(IFNβ).GFP cell line, which 
has an eGFP gene under the control of the IFNβ promoter. When 
A549/pr(IFNβ).GFP cells are infected with a Sendai virus (SeV) stock rich in 
defective interfering (DI) particles to activate the IFN induction pathway, GFP is 
expressed (Figure 3.1A). Using a fluorescent plate reader, the signal expressed 
in raw fluorescent units (RFU), potentiates quantification of GFP fluorescence. 
By normalizing the RFU of activated cells to that of unactivated cells 
(background fluorescence), S/B ratio can be established (Figure 3.1B). A 
compound that enhances or inhibits the IFN induction pathway would result in 
increased or decreased GFP expression respectively. With the aim of 
developing a high-throughput automated assay to identify molecules that 
modulate IFNβ induction, we sought to optimize a cell-based assay using the 
A549/pr(IFNβ).GFP reporter cell line. To achieve this, we assessed the 
following parameters; (i) SeV inoculum concentration, (ii) SeV infection length, 
(iii) length of cell seeding prior to infection, (iv) length of formaldehyde fixation of 
cells following infection and (iv) seeding density of cells. As each parameter 
was optimized, it was taken forward for use in the next step of the optimization 
campaign. 
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Figure 3.1: A cell-based assay to monitor the IFN induction pathway 
The A549/pr(IFNβ).GFP cell line, with a GFP gene under the control of the IFNβ promoter 
proveds a straightforward method to monitor the IFN induction pathway. Upon infection of the 
A549/pr(IFNβ).GFP cell line with a DI rich stock of SeV, the IFN induction pathway is activated 
resulting in expression of GFP (A). This fluorescence provides a parameter by which the 
activation of the IFNβ promoter can be monitored and quantified using a fluorescent plate 
reader at excitation and emission wavelengths of 484 and 518 nm respectively (B). Data 
represents 3 independent repeats each conducted in quadruplicate (n=4) and error bars display 
standard deviation (StDeV). 
 
The initial step in the optimization process was to determine the optimal 
concentration of SeV for maximal activation of the IFNβ promoter and thus GFP 
expression, whilst minimizing reagent usage. To achieve this, 
A549/pr(IFNβ).GFP cells were infected with a 2-fold dilution series of virus for 
20 hours. Fluorescence was measured following formaldehyde fixation on a 
Tecan Infinate Pro plate reader at excitation/emission of 484/518nm. Maximal 
GFP expression was observed between 200 and 12.5 HA units/ml, after which 
S/B ratio begins to reduce in a dose-dependent manner (Figure 3.2A). As 
maximal GFP expression is required without wasting reagents, an SeV 
inoculum concentration of 40 HA units/ml was deemed to be the most 
appropriate for this assay; it is a convenient dilution to perform (1:100) and does 
not approach the stage at which S/B ratio begins to reduce. 
SeV is cytopathic in cell culture as it induces programmed cell death 
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disruption during infection (Iseni et al., 2002). We therefore sought to ascertain 
the point at which GFP expression was optimal during infection. We assume 
that when S/B ratio is at its highest, the cell monolayer has undergone minimal 
disruption from the SeV infection and as such the maximum number of cells 
expressing GFP are present. A549/pr(IFNβ).GFP cells were infected with SeV, 
and following 8, 12, 16 and 19 hours of infection, cells were fixed and GFP 
expression measured. S/B ratio is significantly increased at 16 and 19 hours 
post-infection (p<0.0001) (Figure 3.2B). As an aim of this optimization was to 
minimize the timescale of the assay where possible, a 16-hour infection was 
deemed most appropriate as incubation with SeV for 3 hours longer did not 
significantly impact GFP expression. 
The length of time that cells are given to recover following trypsinisation 
prior to infection may also be a factor that impacts the level of SeV induced cell 
death. To investigate this, A549/pr(IFNβ).GFP cells were seeded and incubated 
for 18 and 24 hours. Cells were then infected with SeV for 16 hours, fixed and 
GFP fluorescence measured. From the levels of GFP expression observed, a 
24-hour incubation following cell seeding prior to infection was optimal (Figure 
3.2C). Although slight, a significant increase in S/B ratio is observed when 
compared with cells that were incubated for 16 hours before SeV addition 
(p<0.0002). By assessing the impact of SeV inoculum concentration, cell 
seeding length prior to infection and infection length itself, variability observed 
within the assay resulting from SeV induced cell death was reduced, whilst also 
optimizing S/B ratio. 
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Figure 3.2: Optimization of the IFN induction reporter assay. 
A549 reporter cells with a GFP gene under the control of the IFNβ promoter were used to 
optimize an assay for HTS. The level of eGFP reporter gene expression is presented as signal-
to-background ratio (S/B ratio). Optimization steps aimed to maximize S/B ratio and minimize 
the time-scale of the assay. SeV input was assessed in A549/pr(IFNβ).GFP reporter cells using 
a 2-fold dilution series of SeV and fluorescence was monitored (A). Length of SeV infection was 
assessed (B), as was the incubation period between cell seeding and infection (C). By fixing 
cells for various lengths of time 16 hours post-infection, the effect of formaldehyde fixation on 
GFP signal was assessed (D). Reporter cells were seeded at various cell densities and infected 
with SeV. Fluorescence was measured 18 hours post-infection (E). Data is representative of 
three independent experiments that were each conducted in quadruplicate (n=4) and error bars 
indicate StDev. Statistical significance was assessed using one-way ANOVA to compare the 
S/B ratios achieved under differing assay conditions (*** p<0.0001, ** p<0.0002).  
 
Additional factors unrelated to SeV infection may also impact the 
variability and S/B ratio observed in the IFN induction assay. Owing to the scale 
of HTS, batches of multiple 384-well plates will be processed at the same time. 
To ensure that the cells and virus infection are consistent, and that GFP 
expression is comparable between plates, fixation is necessary. Therefore, we 
aimed to assess the impact of formaldehyde fixation on GFP fluorescence. To 
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study this, A549/pr(IFNβ).GFP cells were seeded and infected with SeV. Cells 
were then fixed with a final concentration of 5% formaldehyde in PBS for 15, 30 
and 45 minutes. We observed that S/B ratio was significantly reduced following 
45 minutes of formaldehyde fixation (p<0.0001) (Figure 3.2D). Furthermore, an 
increase in variability was observed when cells were fixed for longer than 30 
minutes. As the assay development process aims to minimize the timescale 
and variability of the assay where possible, and no significant difference in S/B 
ratio is observed between formaldehyde incubations of 15 and 30 minutes, a 
fixation length of 15 minutes was considered optimal. 
In order for cells to respond to treatment with a physiologically 
representative response, they must be at a density at which they are functioning 
as normal. Furthermore, in a cell-based assay S/B ratio is inherently linked to 
the cell-number in each well. To assess how cell density may impact GFP 
expression in our assay, A549/pr(IFNβ).GFP cells were seeded at 3, 6 and 
9×104 cells/cm2 of cell growth area for 24 hours. Following SeV infection and 
formaldehyde fixation, GFP was measured to assess S/B ratio and associated 
variability between replicates. S/B ratio is not significantly increased when cell 
density doubles from 3×104 to 6×104 cells/cm2 (Figure 3.2E). However, when 
cells are seeded at a density of 9×104 cells/cm2 of growth area, a statistically 
significant increase in S/B ratio is observed (p<0.0001). Interestingly, variability 
also appears to increase slightly with each increase in cell density, although the 
increase in S/B ratio more than compensated for this. 
Owing to this campaign of assay development, the optimized assay 
resulted in a S/B ratio of 2.6±0.06 from cell seeding at 9×104 cells/cm2 of growth 
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area, 24 hours prior to infection with 40 HA units/ml of SeV for 16 hours 
followed by 15 minutes of formaldehyde fixation. As such, S/B ratio was 
successfully optimized whilst minimizing assay variability and timescale. 
In order to validate the IFN induction assay for use in HTS, we needed to 
verify its ability to identify novel inhibitors of the IFNβ induction pathway. To 
achieve this, chemical compounds reported to inhibit components of the IFN 
induction pathway were used in the IFN induction reporter assay. BX795, which 
inhibits TBK1 in the course of IRF3 activation (Clark et al., 2009), and TPCA-1, 
an IKKβ inhibitor acting during NF-κB activation (Podolin et al., 2005) were 
used. A549/pr(IFNβ).GFP cells were seeded into 96-well plates. Twenty-four 
hours post-seeding, cells were treated with a 2-fold serial dilution of either 
BX795, TPCA-1, or the equivalent volumes of DMSO for 2 hours followed by a 
SeV infection. Cells were fixed and GFP expression measured. Percentage 
inhibition in GFP expression was calculated by converting the RFU signal of 
DMSO treated cells that were unactivated (uninfected), with that of DMSO 
treated, activated (infected) cells to normalize to 100% and 0% inhibition 
respectively. The equation used to calculate percentage inhibition in GFP 
expression can be found in chapter 2 (2.4.1). A clear dose-dependent inhibition 
of GFP expression was observed in the presence of both inhibitors (Figure 3.3). 
BX-795 completely inhibited GFP expression at 25 µM with an IC50 of 5.2 µM, 
displaying a classic sigmoidal dose-response curve. TPCA-1 on the other hand 
achieved a lower maximum GFP inhibition of 72% at 25 µM, however it also has 
a lower IC50 of 3.1 µM.  
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Figure 3.3: Inhibition of IFNβ  promoter driven GFP expression by chemical antagonists. 
Small molecules BX795 and TPCA-1, reported to inhibit the TBK1 and IKKβ in the course of IFN 
induction were used to verify the A549/pr(IFNβ).GFP reporter assay. The IFN-induction pathway 
and hence GFP expression was activated by SeV infection. GFP expression in the presence of 
a 2-fold serial dilution of BX795 and TPCA-1 was measured 16 hours post-infection. Data 
represents 3 independent repeats each conducted in quadruplicate (n=4); error bars display 
StDev. 
 
The inhibition of GFP expression observed in activated 
A549/pr(IFNβ).GFP cells treated with BX795 and TPCA-1 validates this assay 
and provides proof-of-principle that it can used in HTS. Due to proof-of-principle 
confirmation and the encouraging results obtained through the assay 
development campaign, it was believed that an HTS to identify novel 
modulators of IFN induction would be successful. 
3.2.2 IFN signalling assay development 
The IFN signalling assay utilizes the A549/pr(ISRE).GFP cell line, which 
has an eGFP gene under the control of an MxA promoter, which contains 
ISREs. When A549/pr(ISRE).GFP cells are treated with purified IFNα, the IFN 
signalling pathway is activated, and results in GFP expression (Figure 3.4). 
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appears more heterogeneous (Figure 3.4A) with a lower S/B ratio (Figure 3.4B) 
than that observed in the A549/pr(IFNβ).GFP cell line (Figure 3.1). To facilitate 
successful assay development and subsequent HTS of a cell-based assay, we 
required a S/B ratio of at least 2. Therefore, maximizing the S/B ratio in the 
A549/pr(ISRE).GFP cell line was necessary to render it more amenable to 
assay development and potentiate the use of the IFN signalling assay in HTS. 
 
 
Figure 3.4: A cell-based assay to monitor the IFN signaling pathway 
To monitor activation of IFN signalling, an A549 reporter cell line with an eGFP gene under the 
control of the ISRE containing MxA promoter had been previously generated. Upon treatment of 
the A549/pr(ISRE).GFP cell line with purified IFNα, the IFN signaling pathway is activated 
resulting in expression of GFP (A). This fluorescence provides a parameter by which the 
activation of the MxA promoter and thus ISG expression through IFN signaling can be 
monitored, and quantified using a fluorescent plate reader at excitation and emission 
wavelengths of 484 and 518 nm respectively (B). Data represents 3 independent repeats each 
conducted in quadruplicate (n=4) and error bars display StDeV. 
 
We sought to optimize GFP expression in the A549/pr(ISRE).GFP 
reporter cell line through multiple rounds of transduction with lentivirus 
containing the pr(ISRE).GFP integration cassette. Parental A549/pr(ISRE).GFP 
cells, generated previously to this study, had undergone a single round of 
lentivirus transduction followed by fluorescent activated cell sorting (FACS) to 
isolate cells expressing the highest levels of GFP following IFNα treatment. We 
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integration events with the pr(ISRE).GFP expression cassette would 
significantly increase GFP expression in A549/pr(ISRE).GFP cells without 
having a detrimental affect on the cells. This was achieved by transducing the 
parental A549/pr(ISRE).GFP cell line 3 times with lentivirus, followed by 
incubation for 72 hours to allow the cells to recover. The cells were then 
transduced a further 4 times to produce the A549/pr(ISRE).GFP.L8 cell line. 
GFP expression and intensity of fluorescence was increased dramatically 
between cells that have a single integration compared to those that have 8 
(Figure 3.5A). In an effort to produce a cell line that exhibits more homogenous 
expression of GFP with more consistent levels of fluorescence throughout the 
population, these cells were analysed by FACS. Fiona Rossi at The Queen’s 
Medical Research Institute, Edinburgh, carried out this work. The 
A549/pr(ISRE).GFP cells that had undergone a total of 8 lentiviral transductions 
were left untreated (unactivated) or treated with IFNα for 20 hours to activate 
the IFN signalling pathway (activated). From the population of cells activated 
with IFNα, those expressing the highest levels of GFP were isolated. The flow 
cytometry profiles of untreated and IFN-treated A549/pr(ISRE).GFP.L8 cells 
and the sorted cell population (A549/pr(ISRE).GFP.L8F) are shown (Figure 
3.5B). 
To assess the impact that repeated rounds of lentivirus transduction with 
the pr(ISRE).GFP integration cassette and FACS had in the context of the IFN 
signalling assay, A549/pr(ISRE).GFP, A549/pr(ISRE).GFP.L8 and 
A549/pr(ISRE).GFP.L8F cells were seeded into 96-well plates and left 
untreated or treated with IFNα. Following IFNα treatment to activate the IFN 
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signalling pathway, cells were fixed with 5% formaldehyde and GFP expression 
measured. Surprisingly, the level of GFP expression observed in 
A549/pr(ISRE).GFP.L8 cells was only slightly higher than that of the parental 
A549/pr(ISRE).GFP cell line. Following FACS however, a dramatic increase in 
S/B ratio was seen (Figure 3.5C). From the data presented here, we 
successfully increased GFP expression in the IFN signalling assay by repeated 
rounds of lentivirus transduction in the A549/pr(ISRE).GFP cell line. The S/B 
ratio was dramatically improved upon FACS to select against cells that, in the 
presence of IFNα, had low levels of GFP expression. Overall, this optimization 
process increased the S/B ratio from 1.5 to 2.3. For the remainder of this 
chapter, and all other chapters, the A549/pr(ISRE).GFP.L8F cell line was used. 
For simplicity, it will be referred to as A549/pr(ISRE).GFP. 
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Figure 3.5: Optimization of the A549/pr(ISRE).GFP reporter cell line through multiple 
lentivirus transductions and FACS 
To maximize the S/B ratio of GFP expression in A549/pr(ISRE).GFP reporter cells, repeated 
lentivirus transductions were performed, followed by cell sorting on the basis of GFP 
fluorescence. A549/pr(ISRE).GFP cells were transduced a further 7 times with lentivirus with an 
integration cassette containing the MxA promoter and GFP gene. (A) Parental 
A549/pr(ISRE).GFP (1) and multiply transduced (8) cells were treated with IFNα to activate the 
IFN signaling pathway, and visualized to assess GFP expression compared to untreated 
A549/pr(ISRE).GFP cells. (B) To establish the signal window of the IFN signaling assay when 
cells are activated and unactivated, A549/pr(ISRE).GFP cells that had undergone multiple 
transductions were analyzed for GFP expression following incubation with and without IFNα by 
flow cytometry. Cells were then subjected to FACS on the basis of GFP fluorescence. Activated 
cells expressing the highest levels of GFP were sorted and isolated (A549/pr(ISRE).GFP.L8F). 
(C) The GFP expression levels of sorted cells (A549/pr(ISRE).GFP.L8F) was compared to 
unsorted cells that had also undergone multiple lentivirus transductions 
(A549/pr(ISRE).GFP.L8) and the parental A549/pr(ISRE).GFP cell line following IFNα treatment 
was assessed. Data represents 3 independent repeats, each conducted in quadruplicate (n=4). 
Error bars display StDev. 
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To identify molecules that modulate IFN signalling, we sought to optimize 
a cell-based assay using the A549/pr(ISRE).GFP reporter cell line. To achieve 
this, we aimed to investigate the impact the following parameters; (i) 
concentration of IFNα treatment, (ii) use of dissociation reagent, and (iii) length 
of IFNα treatment. As each parameter was optimized, it was taken forward for 
use in the next step of the optimization process. The previously optimized 
parameters for cell density, seeding length and formaldehyde fixation gained 
from development of the IFN induction assay were also used here. 
The initial step in the optimization process was to determine the 
concentration of IFNα required for optimal activation of the IFN signalling 
pathway and thus GFP expression, whilst minimizing reagent usage. To 
achieve this, A549/pr(ISRE).GFP cells were treated with a 2-fold dilution series 
of IFNα. Fluorescence was measured following formaldehyde fixation on a 
Tecan Infinite Pro plate reader at excitation/emission of 484/518nm. Maximal 
GFP expression was observed between 40,000 and 20,000 units/ml, after 
which S/B ratio begins to decline in a dose-dependent manner (Figure 3.6A). As 
maximal GFP expression is required without wasting reagents, an IFNα 
concentration of 10,000 units/ml was deemed to be the most appropriate for the 
assay. Although maximal S/B ratio is no achieved at this concentration, 
variability is lower; it is a convenient dilution to perform (1:100) and does not 
approach the point at which S/B ratio dramatically decreases. 
To activate the IFN signalling pathway, IFNα binds to the IFNα/β 
receptor found on the surface of cells. Trypsin is routinely used in cell culture for 
passage and seeding of cells into multi-well plates. If trypsin cleaves the IFNα/β 
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receptor, the potential exists for a reduction in receptor numbers, which would 
have a negative impact on IFNα binding and thus activation of the IFN 
signalling pathway. The ExPASy website PeptideCutter 
(http://web.expasy.org/peptide_cutter/) predicts 54 trypsin cleavage sites in the 
IFNα/β receptor protein sequence (Accession: CAA42992.1). As such, this 
could impact the S/B ratio of the IFN signalling assay. To investigate this 
further, we made single cell suspensions of A549/pr(ISRE).GFP cells by 
treating cell monolayers with either trypsin-EDTA or EDTA alone and then 
compared their ability to respond to IFNα. Cells were left untreated or treated 
with IFNα for 24 hours. GFP expression was measured following formaldehyde 
fixation. The use of trypsin did not impact the background signal or variability of 
unactivated A549/pr(ISRE).GFP cells (Figure 3.6B). However, following 
treatment with IFNα, there was a significant increase in GFP expression in cells 
that had been seeded following EDTA treatment alone, compared to cells 
treated with trypsin-EDTA (p<0.0001). This suggests that trypsin does cleave 
the IFNα/β receptor, leading to a lower level of IFN signalling pathway activation 
in the presence of IFNα. 
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Figure 3.6: Optimization of the IFN signaling assay. 
A549 reporter cells with a GFP gene under the control of the ISG containing MxA promoter 
were used to optimize an assay for HTS in successive steps. The level of GFP reporter gene 
expression is presented as signal-to-background ratio (S/B ratio). Optimization steps aimed to 
maximize S/B ratio and minimize the time-scale of the assay. IFNα input was assessed in 
A549/pr(ISRE).GFP reporter cells using a 2-fold serial dilution of IFNα and fluorescence was 
monitored (A). The method of monolayer dissociation prior to cell seeding was assessed for its 
impact on GFP expression. A549/pr(ISRE).GFP reporter cells were dissociated with either 
trypsin or EDTA (0.48 mM) before seeding and IFNα treatment (B). The length of IFNα 
incubation was assessed (C). Data represents three independent experiments that were each 
conducted in triplicate (n=3) and error bars indicate StDev. Statistical significance was 
assessed using one-way ANOVA to compare the S/B ratios achieved under differing assay 
conditions (*** p<0.0001). 
 
Following the discovery that trypsin treatment prior to cell seeding 
negatively impacts S/B ratio, we next assessed the length of IFNα treatment 
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that results in optimal GFP expression. To achieve this, A549/pr(ISRE).GFP 
cells were treated with IFNα, and 24 and 48 hours post-IFNα treatment, GFP 
expression was measured. There was a dramatic increase in S/B ratio at 48 
hours post-treatment (Figure 3.6C). As the aim of this assay development was 
to maximize S/B ratio, a 48-hour IFNα incubation was deemed most appropriate 
as it increased GFP expression by 0.5-fold above that of a 24-hour treatment 
length. Owing to this process of development, the optimized assay included cell 
seeding at a density of 9×104 cells/cm2 following treatment with EDTA only, and 
treating cells with 10,000 units/ml of IFNα for 48 hours, and achieved a S/B 
ratio of 2.2. 
In order to validate the IFN signalling assay for use in HTS, we needed to 
verify that it could be used to identify novel inhibitors of the IFN signalling 
pathway. To achieve this, Ruxolitinib (Rux), and CYT387, which both inhibit 
JAK1/2 in the course of STAT activation (Quintas-Cardama et al., 2010, 
Pardanani et al., 2009) were tested in the IFN signalling assay. Twenty-four 
hours post-seeding, A549/pr(ISRE).GFP cells were treated with a 2-fold serial 
dilution of either Rux, CYT387, or the equivalent volumes of DMSO for 2 hours 
followed by IFNα treatment. The percentage inhibition in GFP expression was 
calculated as before (3.2.1). A clear dose-dependent inhibition of GFP 
expression was observed in the presence of both inhibitors (Figure 3.7). Both 
compounds completely inhibited GFP expression at 25 µM. Rux had an IC50 of 
0.53 µM and CYT387 had an IC50 of 2.03 µM. 
The inhibition in GFP expression seen in activated A549/pr(ISRE).GFP 
cells treated with Rux or CYT387 validated this assay and provides proof-of-
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principle that it can be used successfully in HTS to identify novel modulators of 









Figure 3.7: Inhibition of ISRE driven GFP expression by chemical antagonists. 
Small molecules Ruxolitinib and CYT387 have been reported to inhibit the Jak1 component of 
the IFN-signaling pathway. The compounds were used to verify the A549/pr(ISRE).GFP 
reporter assay. The IFN-signaling pathway and hence eGFP expression was activated by IFNα 
treatment. GFP expression in the presence of Ruxolitinib and CYT387 at various concentrations 
was measured post-IFNα treatment. Data represents 3 independent repeats each conducted in 
quadruplicate (n=4); error bars display StDev. 
 
 
3.2.3 Final assay parameters 
 The assay development campaigns detailed above for both the IFN 
induction and the IFN signalling assays were carried out in St Andrews with the 
aim of subsequently using automated liquid handling at the DDU at the 
University of Dundee. For this, we needed to miniaturize the assays from a 96- 
to a 384-well plate format, which is more amenable to HTS as it reduces the 
necessary plate number by 75%. It also facilitates reduction of the assay 
volume from 120 µl to 60 µl, allowing for conservation of valuable reagents. To 
achieve this, both assays were assessed at the DDU after automating as much 
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which can accurately transfer as little as 2.5 nl of test compound. Cell seeding, 
addition of SeV and IFNα were carried out with a Matrix WellMate microplate 
dispenser. Initially, washing of fixed plates wasto be carried out using a BioTek 
ELx405 Select CW microplate washer. However, troubleshooting of inconsistent 
washing, revealed high levels of variability. Therefore, the wash step was the 
only high throughput aspect of the assays that was done manually. Following 
miniaturization and automation of the IFNβ induction and IFN signalling reporter 
assays at the DDU, their performance was compared to pre-set QC parameters 
set by the DDU (Table 3.1). Both assays performed well, with each assay 
parameter well within its associated QC limits. This provided confidence that we 
had successfully developed robust and reproducible assays as the S/B ratio 
was above 2.8 in both cases. A powerful statistic used to assess the overall 
performance of an assay, which gives an indication of its suitability to HTS is 
the Z’ factor (Zhang, 1999). This statistic takes into consideration both the 
signal window (S/B ratio) and the variability of the assay. As such, it provides a 
convenient statistic that describes the critical aspects of an assay’s behaviour. 
The closer the Z’ factor is to 1 (and above 0.5), the more robust and reliable an 
assay. In this case, a Z’ factor above 0.6 was achieved, indicating a high level 
of reproducibility and that both assays were robust. 
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Table 3.1: Performance of the IFN induction and signaling assays compared to pre-set 
QC standards. Following assay development, the reporter cell lines were optimized for HTS. 
The performance of the A549/pr(IFNβ).GFP IFN induction and A549/pr(ISRE).GFP IFN 
signalling assays following optimization to an automated 384-well format were compared to pre-








Z’ Factor > 0.5 0.67 ± 0.03 0.7 ± 0.05 
S/B ratio > 2 3.1 ± 0.53 2.8 ± 0.06 
Activated CV (%) < 8 6.7 ± 0.59 4.9 ± 0.93 
Unactivated CV (%) < 8 3.1 ± 0.53 2.5 ± 0.66 
 
3.3 Summary 
 Through extensive assay development, we successfully optimized two 
fluorescent cell-based assays for use in HTS. Furthermore, through the use of 
known chemical antagonists of IFN induction and signalling, these assays were 
validated for their suitability to identify novel modulators of the two pathways. 
Activation of the IFN induction pathway in the A549/pr(IFNβ).GFP assay is 
dependent upon SeV infection. Although the DI rich Cantell strain of SeV used 
in this study is a very potent inducer of IFN, its inherent properties such as PCD 
induction meant that close optimization was necessary. This was achieved 
through assessing general assay conditions such as seeding density, and 
closely monitoring the impact of SeV induced cell death by studying the effect of 
infection length and inoculum concentration. The IFN signalling assay, utilizing 
the A549/pr(ISRE).GFP reporter cell line required additional optimization prior to 
general assay development, to maximize the GFP signal window. This was 
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achieved by multiple lentivirus transductions of the parental cell line followed by 
FACS selection of the most responsive cells. This signal optimization, followed 
by subsequent assay development successfully maximized S/B ratio while 
minimizing variation. As a result of the optimization campaigns on both the IFN 
induction and IFN signalling assay, their behaviour was highly reproducible. 
Furthermore, the assays were validated for their ability to identify chemical 
modulators of the pathways, and successfully miniaturized to an automated 
384-well plate format amenable to HTS. 
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4. High-throughput screening to identify novel 
modulators of the IFN response 
4.1 Introduction 
 As a result of the successful assay development and validation carried 
out in St Andrews, and the subsequent miniaturization of the IFN induction and 
IFN signalling assays at the DDU, an HTS campaign was pursued. At this point 
either assay could be taken forward for HTS, and the IFN induction pathway 
was chosen. There are already many commercially available inhibitors of the 
IFN signalling pathway, and although commercial inhibitors of the IFN induction 
pathway are also available, they are mainly focused on inhibition of the kinases 
involved in IFN activation. Therefore, the potential exists to identify compounds 
that modulate novel targets. As such, we proposed that there was greater 
scope for discovery of novel modulators of IFN induction and so pursued a 
single-point diversity screen utilizing the IFN induction assay and 
A549/pr(IFNβ).GFP cell line. 
The small diversity set of the DDU compound library, consisting of 
15,667 small molecules, was used at an initial screening concentration of 30 
µM. Following successful primary screening, putative hit compounds were taken 
forward to dose-response screens. This screening aimed to determine the 
potency of a given hit compound. Dose-response screening utilized a 10-point 
2-fold serial dilution of compound, in this case from 50 µM to 0.1 µM, to 
construct a 4-parameter logistic fit using % inhibition in GFP expression. This 
facilitates determination of potency through the construction of a dose-response 
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curve by using minimum and maximum % inhibition in GFP expression, hill 
slope and XC50. Where the term XC50 is used, ‘X’ denotes a compound where 
activity is either antagonistic (inhibition, IC50) or agonistic (enhancement, EC50). 
During dose-response screening, XC50 values are routinely reported as pXC50, 
where the negative log of the molar concentration is used. As such, the higher 
pXC50 value, the lower the molar XC50 concentration. For reference, a 
conversion table is provided (Table 4.1). 
 
















Three dose-response screens were carried out to investigate the activity 
of hit compounds in (i) inhibition of IFN induction, (ii) enhancement of IFN 
induction and (iii) assess their specificity. This screening aimed to determine the 
potency of putative hit compounds in the IFN induction assay, but also 
eradicate false positives by eliminating hits that fail to produce a curve from the 
parameters detailed above. This process is beneficial as it allows for timely 
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reduction in compound numbers, allowing further studies to focus on a smaller 
number of confirmed hits.  
 Following dose-response screening, a confirmed hit warranting further 
investigation was first analysed by liquid chromatography-mass spectrometry 
(LC-MS) to assess the purity and confirm the identity of the compound used in 
screening. Confirmed hit compounds that passed LC-MS were repurchased and 
investigated further through a campaign of hit validation, aiming to re-test the 
compound from a fresh stock to confirm its direct action on the IFN induction 
pathway and also eliminate false-positives acting through off-target effects. 
 
4.2 Results 
4.2.1 Diversity HTS to identify compounds that modulate the IFN induction 
pathway 
 The successful optimization and validation of the IFN induction assay 
detailed in chapter three provided confidence that a diversity screen to identify 
novel modulators of the IFN induction pathway could be successfully 
completed. As such, we embarked on a screening campaign using the Small 
Diversity Set (15,667 compounds) of the compound library at the DDU. This 
compound collection is composed of small molecules selected as appropriate 
starting points for drug discovery that all comply with Lipinski’s rule of 5 (Lipinski 
et al., 2001). For HTS, A549/pr(IFNβ).GFP cells were seeded into clear-
bottomed black 384-well plates laid out as shown (Figure 4.1A). Cells in 
columns 1 to 22 were treated with test compound. SeV infection of columns 1 to 
22 and column 24 followed. Column 24 was untreated but infected with SeV 
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(activated) provide a 0% inhibition control. Column 23 was left untreated and 
uninfected (unactivated) to provide a 100% inhibition control. GFP expression 
was measured using an Envision plate reader. Screening was carried out in 4 












Figure 4.1: Single point diversity HTS to identify compounds that modulate the IFN 
induction pathway 
A single point diversity screen using the A549/pr(IFNβ).GFP reporter assay and the DDU small 
diversity set (n = 15,667 compounds) was performed at a compound concentration of 30 µM. 
(A) A schematic of 384-well plate layout; wells in columns 1-22 contain a single test compound 
and SeV infected cells, wells in column 23 contain uninfected cells that represent maximum 
eGFP inhibition (100%, Unactivated) and wells in column 24 contain untreated SeV infected 
cells that represent baseline eGFP inhibition (0%, Activated). (B) Plot of Z’ factor and S/B ratio 
for each assay plate in the primary screen. Dotted lines indicate QC approval limits for Z' factor 
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Table 4.2: Screen statistics of the IFN induction assay, measured as Z’ factor, S/B ratio, and % 






Z’ Factor > 0.5 0.6 ± 0.1 
S/B > 2 1.6 ± 0.2 
Activated CV (%) < 8 4.4 ± 1.8 
Unactivated CV (%) < 8 2.4 ± 1.4 
 
The behaviour of the screen in terms of QC statistics was monitored 
between plates and between batches. The screen performed as expected with 
the exception of a dramatic drop in S/B ratio (Table 4.2). Assay development 
saw a consistent S/B ratio of 3.1±0.53, while this fell during primary screening to 
1.6±0.2. Although not inconsequential, the Z’ factor remained at 0.6 and % CV 
for both activated and unactivated cells was consistently below 4.5%. Although 
the unexpected drop in S/B ratio may call into question the validity of the 
screen, the consistency of the arguably more important Z’ factor suggests that 
the screen remained robust (Figure 4.1B). Percentage effect of GFP inhibition 
for each compound was calculated using fluorescence, in RFU, of uninfected 
cells to set the 100% maximum (Unactivated) and untreated, SeV infected cells 
to set the 0% baseline (Activated). Of the 15,667 compounds tested, 
percentage effect of inhibition in GFP expression produced a normal distribution 
of results, centred at 10 to 20% inhibition (Figure 4.2A). A compound resulting 
in less that -50% inhibition in GFP expression and being 2 standard deviations 
outside of the test well average for the plate was considered a putative 
enhancer of IFN induction (Figure 4.2B). Likewise, a compound achieving 50% 
or more inhibition in GFP expression and being 2 standard deviations away 
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from the test well average for the plate was considered a putative inhibitor of 
IFN induction (Figure 4.2C). 
 
 
Figure 4.2: Percentage inhibition in GFP expression of compounds tested in a single 
point diversity HTS to identify modulators the IFN induction pathway 
(A) Screen output is represented as % inhibition of eGFP expression and plotted as a frequency 
distribution of all compounds tested. (B) Compounds that inhibit GFP expression from -50 to -
150% were designated as potential enhancers of IFN induction and plotted as a frequency 
distribution. (C) Compounds that inhibit GFP expression by 50% or more were designated 
potential inhibitors of IFN induction and plotted as a frequency distribution. 
 
 From these initial selection criteria, 264 of the 15,667 compounds 
screened were considered putative hits. A compound that was duplicated was 
withdrawn, along with any that had shown possible toxicity in past DDU 
screens. The information regarding compound toxicity was established by using 
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legacy data at the DDU. This data is compiled from all screens carried out in the 
department. One such example of how this data was used can be seen in an 
historical screen carried out at the DDU investigating compound action on 
intracellular parasites. In the course of this screen, mammalian host cell number 
was monitored. As such, information regarding a compounds impact on cell 
number was available. If a putative hit compound from our screen had caused a 
reduction in cell number in the previous screen, it was likely to be toxic to the 
mammalian host cell and as such was eliminated from further analysis. This 
process of hit triage reduced our putative hit compound number to 245, 
composed of 200 inhibitors and 45 enhancers of GFP expression. Therefore, 
the primary screening campaign yielded an initial hit rate of 1.56%.  
 With the aim of identifying novel compounds that modulate the IFN 
induction pathway we utilized the A549/pr(IFNβ).GFP reporter cell line and 
successfully carried out an automated HTS campaign with 15,667 test 
compounds, which identified 245 putative hits. Although a drop in S/B ratio was 
observed, the Z’ factor remained comparable to that achieved during assay 
development, reinforcing the integrity of the primary screen, which had a 
respectable hit rate of 1.56%. 
4.2.2 Dose response screening of putative hit compounds that modulate 
the IFN induction pathway 
 In order to confirm the activity of putative hit compounds identified during 
primary diversity screening, we embarked on a campaign of dose-response 
screening. The purpose of dose-response screening is 2-fold in that it not only 
allows the establishment of potency of putative hit compounds, but can also 
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facilitate the identification of false-positive hits. In this case, there were 245 
putative hit compounds to test. Primary diversity screening sought to identify 
compounds that modulate the IFN induction pathway, which could therefore 
result in either inhibition or enhancement of GFP expression. In order to 
maximize the information gained from dose-response screening, we carried out 
3 separate screens. The classical IFN induction assay with SeV infection 
facilitated the study of inhibitors of IFN activation (i), while the IFN induction 
assay without SeV infection allowed for greater scrutiny of putative hits that may 
enhance pathway activation (ii), and to aid in the elimination of false positives, 
putative hit compounds were also subjected to a specificity screen (iii) in the 
IFN signalling assay utilizing the A549/pr(ISRE).GFP cell line. A compound that 
is active in both the IFN induction and signalling assays is either acting through 
non-specific, off-target means or could have dual activity. The plate layout used 
in all 3 of the screens is shown (Figure 4.3A), where columns 1 to 10 and 13 to 
22 contain a 10-point 2-fold serial dilution of test compound from 50 µM to 0.1 
µM. As with the primary screen, a 100% inhibition control of untreated, 
unactivated cells (in columns 11 and 23) and a 0% inhibition baseline control of 
untreated, activated cells (in columns 12 and 24) was included. 
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Figure 4.3: Secondary dose-response screening using the IFN induction and signalling 
reporter assays. 
Putative hit compounds were subjected to secondary screening in the A549/pr(IFNβ).GFP and 
A549/pr(ISRE).GFP reporter assays to generate 10-point dose-response curves for potency 
determination. (A) A schematic of 384-well plate layout; wells in columns 1-10 and 13-22 
contain a single test compound in a 2-fold dilution series from 50 to 0.1 µM and SeV infected or 
IFNα treated cells, wells in column 11 and 23 contain uninfected cells that represent maximum 
eGFP inhibition (100%, Unactivated) and wells in column 12 and 24 contain untreated SeV 
infected or IFNα treated cells that represent baseline eGFP inhibition (0%, Activated). (B-D) 
Plots of Z’ factor and S/B ratio for each assay plate in the 3 secondary dose-response screens. 
Dotted lines indicate QC approval limits for Z' factor and S/B. All 245 putative hit compounds 
were analyzed in the A549/pr(IFNβ).GFP reporter assay with (B) and without (C) SeV infection 
to confirm the activity of compounds that inhibited or enhanced GFP expression during primary 
screening respectively. To eliminate false positive hits, compounds were also tested in the 
A549/pr(ISRE).GFP reporter assay (D) where SeV infection is replaced by IFNα treatment.  
 
The IFN inhibitor dose-response screen followed the IFN induction assay 
protocol using the A549/pr.(IFNβ).GFP reporter cell line with SeV infection of 
wells containing test compound. The purpose of this was to further investigate 
compounds that resulted in a reduction in GFP expression in the primary 
Test wells Media only Virus only 
50µM 50µM 0.1µM 0.1µM 
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screen. The IFN inhibitor screen behaved exceptionally with clear restoration of 
the S/B ratio to above 3, and each plate passing both the S/B ratio and Z’ factor 
QC approval limits (Figure 4.3B). 
The IFN enhancer dose-response screen was used to further investigate 
putative hits that enhanced GFP expression. This assay utilized the 
A549/pr.(IFNβ).GFP reporter cell line following the same protocol as the IFN 
induction assay with one exception; wells containing test compound (columns 1 
to 10 and 13 to 22) were not infected with SeV. Here the 0% enhancement 
baseline control was untreated, uninfected (unactivated) cells in columns 11 
and 23 and the 100% enhancement control was untreated, infected (activated) 
cells in columns 12 and 24. As was observed in the IFN inhibitor dose-response 
screen, each plate passed both the S/B ratio and Z’ factor QC approval limits 
(Figure 4.3C). Although a slight drop in S/B ratio was seen in comparison, it 
remained above the QC approval limit of 2. 
To aid in the identification of any non-specific hits, a specificity screen 
utilizing the IFN signalling assay and A549/pr.(ISRE).GFP reporter cell line was 
carried out. Here, wells containing test compound were treated with IFNα. A 
putative hit compound that resulted in reduced GFP expression in this assay is 
likely to be activating through off-target actions. It is possible however that a 
compound with activity in both the IFN induction and IFN signalling assays is 
real, and as such, these dual inhibitors should not be disregarded completely. 
This screen followed the same plate layout as the IFN inhibitor dose-response 
screen, where SeV infection was substituted with IFNα treatment. The screen 
behaved as expected, where the S/B ratio averaged 2.2 and Z’ factor was 0.68. 
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Thus, it was a robust screen as each plate passed the S/B ratio and Z’ factor 
QC approval limits (Figure 4.3D). The dose-response screening performed to 
further investigate the 245 putative hit compounds behaved well, with each QC 
approval limit, including % CV being cleared (Table 4.3). 
 
Table 4.3: Screen statistics for the 3 dose-response screens performed, measured as robust Z’ 










Z’ Factor > 0.5 0.8 ± 0.02 0.7 ± 0.05 0.7 ± 0.07 
S/B > 2 3.6 ± 0.1 2.2 ± 0.1 2.5 ± 0.1 
Activated CV (%) < 8 5.4 ± 0.9 4.0 ± 0.5 5.2 ± 1.8 
Unactivated CV (%) < 8 3.9 ± 0.8 4.0 ± 1.6 5.1 ± 0.8 
 
At this stage of the screening process, to be considered a confirmed hit, 
a compound’s activity must result in the production of a dose-response curve 
that allows pXC50 determination. As such, it must achieve clear maximum and 
minimum effects in the assay. The hill slope of a dose-response curve is an 
important indication of the potency of a molecule. A steeper hill slope (≥1) 
indicates that a compound has higher potency. Therefore, to designate a hit as 
confirmed, it must also produce an acceptable hill slope around 1. The 
determination of a compound’s pXC50 value potentiates efficient hit 
characterization, allowing the elimination of compounds that fail to produce a 
dose-response curve. A compound with a pXC50 value of 4.3, equivalent to 50 
µM, and the highest concentration tested, was designated as inactive and as 
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such, a false-positive. Any compound achieving a pXC50 of 5 or above (≤10 µM) 
was categorized as a confirmed hit warranting further study. Although a 
compound with a pXC50 value between 4.4 and 5 is not disregarded as inactive, 
it is deemed as less potent, and so further investigation may not be worthwhile. 
This procedure potentiates efficient triage of hit compounds, using rational 
parameters to reduce the number of compounds warranting further 
investigation. Analysis of the pIC50 values generated for each compound in the 
IFN inhibitor dose-response screen identified a 109 putative hits that failed to 
produce a dose-response curve, with a pIC50 of 4.3 (Figure 4.4A). From the 200 
potential inhibitors of IFN induction, 41 had a pIC50 of 5 or more. Therefore, the 
IFN inhibitor dose-response screen identified 20% as confirmed hits indicating 
good levels of potency. The IFN enhancer dose-response screen identified all 
but 3 compounds (242) as inactive, having pEC50 values of 4.3 (Figure 4.4B). 
The 3 compounds that successfully produced dose-response curves had a 
pEC50 value between 4.5 and 4.7, suggesting a lack of potency. The specificity 
screen, carried out to facilitate elimination of false-positive hits and identify any 
potential dual inhibitors of both pathways identified 83 putative hits with no 
activity (pIC50 values of 4.3) and 63 compounds with a pIC50 of 5 or more 
(Figure 4.4C). 
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Figure 4.4: pIC50 and pEC50 values generated through secondary dose-response 
screening using the IFN induction and signalling reporter assays. 
Potency determination of putative hit compounds derived from the dose-response curves 
generated in the A549/pr(IFNβ).GFP reporter assay with (A) and without (B) SeV infection to 
generate pIC50 and pEC50 values respectively, and the A549/pr(ISRE).GFP reporter assay (C) 
to give pIC50. Hits with a pXC50 of 4.3 (IC50 50 µM) were deemed inactive (dotted line) and hits 
with a pXC50 ≥ 5 (IC50 ≤10 µM) were deemed favorable (dashed line). pIC50 values derived from 
dose-response curves generated for each hit tested in the A549/pr(IFNβ).GFP with Sev 
infection and A549/pr(ISRE).GFP reporter assays were plotted against one another. Boxed hits 
represent confirmed hit compounds that specifically inhibit the IFN-induction pathway (dashed 
line) or those that show comparable activity in both the A549/pr(IFNβ).GFP and 
A549/pr(ISRE).GFP reporter assays (dotted line) and have a pIC50 ≥ 5 (IC50 ≤10 µM). Dose 
response curves, pIC50 values and statistics were generated using ActivityBase XE software. 
 
Taken alone, the information provided by the specificity screen is limited. 
The aim of this screen was to see whether putative hits inhibiting IFN induction 
were specific. Therefore, the pIC50 value generated for each compound in the 
IFN inhibitor dose-response screen was plotted against the corresponding value 
generated in the specificity screen (Figure 4.4D). This provides a 
straightforward method for identifying hits specific to the IFN induction pathway, 
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with pIC50 values above 5, but showed no activity in the IFN signalling pathway, 
achieving pIC50 values in the specificity screen of 4.3. Hits achieving very 
similar levels of inhibition in both assays could be false positives, or compounds 
that have dual activity in the both pathways, and so could warrant further 
investigation. 
As a result of the dose-response screening, 41 compounds were 
designated as confirmed hits, inhibiting IFN induction with pIC50 values of 5 or 
above. Of these 41 hits, 6 achieved pIC50 values in the specificity screen of less 
than 5. Therefore, dose-response screening focused further investigation of 41 
confirmed inhibitors of IFN induction down to 6, which are more likely to be real 
hits, specific to the pathway we are aiming to target. These confirmed hit 
compounds were designated StA-IFN-1, -2, -3, -4, -5, and -6, and their 
associated pIC50 values are shown (Table 4.4). In this case, dose-response 
screening was also an effective tool for eliminating hits that are unlikely to yield 
results further down the validation pipeline. The IFN enhancer dose-response 
screen identified 3 compounds with dose-dependent activity, although the levels 
of potency achieved were not convincing enough to warrant further 
investigation. Overall, the dose-response screening campaign was effective at 
focusing further investigative efforts on hit compounds with levels of potency 
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Table 4.4: pIC50 values of 6 confirmed hit compounds that specifically inhibit IFNβ promoter 















A549/pr(IFNβ).GFP 5.5 5.6 5.8 5.0 5.0 5.3 
A549/pr(ISRE).GFP 4.3 - 4.3 4.4 4.3 4.7 
 
 
4.2.3 Validation of novel hit compounds that inhibit the IFN induction 
pathway 
 As a result of the dose-response campaign that followed the primary 
diversity screen, 6 compounds were identified as specifically inhibiting GFP 
expression in the IFN induction assay. To ensure that the molecules used 
during screening were correct, the purity and identity of the compounds 
required verification. Therefore, all 245 putative hit compounds were subjected 
to LC-MS at the DDU. Compounds StA-IFN-3 and StA-IFN-6 did not pass this 
stage of testing, as LC-MS of these molecules failed to produce a mass ion. 
Therefore, investigation of these compounds was not carried forward. 
To further scrutinize the 4 confirmed hit compounds that passed LC-MS, 
they were repurchased from commercial sources and their activity verified. This 
was achieved by re-testing the compounds in the IFN induction and IFN 
signalling reporter assays. Cells were treated with a 9-point, 2-fold serial dilution 
of compounds StA-IFN-1, StA-IFN-2, StA-IFN-4 or StA-IFN-5 or the equivalent 
volume of DMSO. Following pathway activation for the appropriate length of 
time, GFP expression was measured. The activity of StA-IFN-1 (Figure 4.5A) 
and StA-IFN-4 (Figure 4.5B) remained specific for the IFN induction pathway, 
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as they failed to produce an adequate dose-response curve in the IFN 
signalling assay. Conversely, StA-IFN-2 (Figure 4.5C) and StA-IFN-5 (Figure 
4.5D) did not exhibit specificity, where the dose-response curves observed in 
the IFN induction and IFN signalling assays are comparable. As a result, StA-
IFN-2 and StA-IFN-5 were not carried forward to further hit validation studies. 
StA-IFN-1 and StA-IFN-4 maintained their specific activity upon repurchase and 
re-testing, reinforcing the validity of these compounds as specifically inhibiting 
the IFN induction pathway. The activity of these compounds is broadly 
comparable to that of TPCA-1, a known inhibitor of IKKβ, bearing in mind that 
StA-IFN-1 and StA-IFN-4 are small druggable molecules, designed to be 
starting points for medicinal chemistry and optimization (Table 4.5). 
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Figure 4.5: Potency and specificity of confirmed hit compounds in the IFN induction and 
signalling reporter assays. 
Confirmed hit compounds were repurchased and tested in the A549/pr(IFNβ).GFP and 
A549/pr(ISRE).GFP reporter assays. Cells were treated with a 9-point, 2-fold serial dilution of 
StA-IFN-1 (A), StA-IFN-4 (B), StA-IFN-2 (C) and StA-IFN-5 (D) for 2 hours prior to stimulation of 
A549/pr(IFNβ).GFP and A549/pr(ISRE).GFP cells with SeV or IFNα respectively. Data 




Table 4.5: Dose response curve parameters of repurchased hit compounds, StA-IFN-1 and 
StA-IFN-4, retested in the A549/pr(IFNβ).GFP reporter assay and compared to those of the 
IKKβ inhibitor, TPCA-1. 
 Max (%) Min (%) IC50 (µM) Hill Slope 
StA-IFN-1 61 -5 4.1 1.4 
StA-IFN-4 77 -5 6.7 1.5 
TPCA-1 88 -6 1.1 0.9 
 
 Up to this point, compound activity had been assessed using GFP 
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been designated as specific through their lack of potency in the IFN signalling 
reporter assay. It was therefore necessary to verify that the activity of StA-IFN-1 
and StA-IFN-4 was not due to other potential off-target effects. Additionally, it 
was necessary to validate the hit compounds by assessing their effect on 
cellular markers for IFN induction.  
 To eradicate the possibility that StA-IFN-1 and StA-IFN-4 had off-target 
effects that would mimic IFN induction pathway inhibition, we aimed to analyse 
cellular processes in the presence and absence of hit compounds. To achieve 
this, we studied levels of protein synthesis in A549 cells treated with DMSO, the 
transcriptional inhibitor actinomycin D (AMD), StA-IFN-1 or StA-IFN-4. Cells 
were metabolically labelled with 35S cysteine/methionine mix to assess the 
levels of 35S incorporation (Figure 4.6A). As expected, quantification of band 
intensity clearly showed AMD inhibiting cellular protein synthesis (Figure 4.6B). 
However, no such reduction in the levels of 35S incorporation were observed 
following treatment with StA-IFN-1 or StA-IFN-4, suggesting they were not 
acting through inhibition of cellular protein synthesis. We also aimed to assess 
cell viability in the presence of these compounds. To achieve this, A549 cells 
were treated with DMSO, the translational inhibitor cycloheximide (CHX), StA-
IFN-1 or StA-IFN-4 and an AlamarBlue cell viability assay carried out. As 
expected, cells exhibit a dose-dependent reduction in viability following CHX 
treatment. In contrast to this, cells treated with StA-IFN-1 (Figure 4.6C) and 
StA-IFN-4 (Figure 4.6D) only exhibited a reduction in viability at the highest 
concentration tested (50µM). This further supported the theory that hit 
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compounds StA-IFN-1 and StA-IFN-4 do not elicit inhibitory effects on the IFN 
induction pathway through non-specific off-target effects. 
 
 
Figure 4.6: Elimination of off-target effects associated with hit compounds StA-IFN-1 and 
StA-IFN-4 impacting cell viability  
Cellular protein synthesis in the presence of StA-IFN-1 and StA-IFN-4 was assessed with the 
use of the transcriptional inhibitor AMD as a control. A549 cells were treated with compound for 
24 or 48 hours and labeled metabolically with [35S]Met/Cys promix. Whole cell lysates were 
visualized (A) by SDS-PAGE followed by coomassie brilliant blue stain and phosphoimage 
analysis to quantitate levels of global protein synthesis compared to the DMSO control (B). The 
effect of StA-IFN-1 (C) and StA-IFN-4 (D) on cell viability was assessed with an AlamarBlue 
Assay and the translational inhibitor CHX as a control. A549 cells were treated with compound 
for 48 hours prior to AlalmarBlue reagent addition and viability assessed by fluorescence. Data 
is representative of three independent experiments that were each conducted in quadruplicate 
(n = 4). Error bars indicate StDev. 
 
 There is a possibility that StA-IFN-1 and StA-IFN-4 may be appearing as 
IFN induction inhibitors by acting on the SeV used to activate the pathway. If 
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this were the case, inhibition of SeV entry into the cells and subsequent 
reduction in cellular PAMPs would result in dose-dependent inhibition of the IFN 
induction pathway. To investigate this, immunofluorescence was carried out on 
compound treated, infected cells to detect viral proteins. No viral proteins were 
detected in mock-infected cells (Figure 4.7A). However, in cells treated with 
DMSO or either of the hit compounds, viral proteins were clearly seen. The 
staining of SeV proteins appeared comparable between the DMSO control and 
compound treated cells, suggesting that there was no impact on SeV entry into 
cells. This implied that StA-IFN-1 and StA-IFN-4 were not effecting SeV 
infection in the IFN induction assay. 
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Figure 4.7: Elimination of off-target effects associated with hit compounds StA-IFN-1 and 
StA-IFN-4 impacting SeV  
The effect of StA-IFN-1 and StA-IFN-4 on SeV infection and replication was assessed. A549 
cells were treated with compound and infected with SeV for eighteen hours. Cells were then 
fixed, permeabilized and probed with anti-SeV antibody followed by FITC-conjugated secondary 
antibody. Cells were visualized with a Nikon Microphot-FXA microscope at 40x magnification 
(A). A549 cells were treated with compound and infected with SeV. Eighteen hours post-
infection cells were labeled metabolically with [35S]Met/Cys promix. Whole cell lysates were 
visualized by SDS-PAGE and coomassie brilliant blue followed by phosphoimage analysis (B) 
to quantitate SeV nucleoprotein (NP) levels (C). NP band intensity was normalized to a host cell 
protein and quantified relative to the DMSO control, set at 100%. Data represents the mean of 
three independent experiments (n=3); error bars indicate StDev.  
 
To further investigate compound effect on viral replication, A549 cells 
were treated as above and metabolically labelled with 35S cysteine/methionine 
mix to assess the levels of 35S incorporation. SeV nucleoprotein (NP) was 
clearly visible (Figure 4.7B), and from the associated quantification (Figure 
7.7C), NP was undetectable in mock treated cells. However, it was easily 
quantified in DMSO treated, SeV infected cells. The same levels of SeV NP 
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difference was seen. Therefore, taking both the immunofluorescence images 
and the NP expression levels into consideration, it was clear that neither StA-
IFN-1 nor StA-IFN-4 target SeV. This gives further confidence that they act to 
inhibit the IFN induction pathway specifically. 
 To investigate cellular markers of IFN induction, the expression of IFNβ 
mRNA resulting from pathway activation was assessed by qRT-PCR. 
Quantitative RT-PCR using RNA extracted from cells treated with DMSO, 
TPCA-1, StA-IFN-1 or StA-IFN-4 and subsequently infected was used to 
monitor expression levels. As was expected, TPCA-1, the IKKβ inhibitor, 
significantly reduced the levels of IFNβ mRNA by 78% (p<0.005) (Figure 4.8A). 
StA-IFN-1 reduced IFNβ mRNA expression to a lesser extent, showing levels of 
45% compared to the DMSO, SeV control (p<0.005). Interestingly, in the 
presence of StA-IFN-4, greater inhibition of the induction pathway was 
observed, with only 13% of IFNβ mRNA expressed compared to SeV infection 
alone. The clear inhibition of IFNβ mRNA expression in the presence of StA-
IFN-1 and StA-IFN-4 further validated them as inhibitors of IFN induction, 
outwith the GFP reporter cells used thus far. 
In order to ensure pathway specificity, StA-IFN-1 and StA-IFN-4 were 
assessed for activity in the IFN signalling pathway. We utilized qRT-PCR to 
analyse MxA mRNA expression in cells treated with DMSO, the Jak inhibitor 
Rux, StA-IFN-1 or StA-IFN-4 and subsequently treated with IFNα to activate 
IFN signalling. Rux reduced MxA mRNA expression by almost 99% compared 
to IFNα treatment in the absence of inhibitors (p<0.0001) (Figure 4.8B). 
Conversely, StA-IFN-1 and StA-IFN-4 had no significant impact upon MxA 
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mRNA expression following IFN signalling pathway activation. Taken together, 
the data obtained from qRT-PCR provided further evidence that compounds 
StA-IFN-1 and StA-IFN-4 inhibit the induction of IFNβ, exhibiting pathway 
specificity, as they have no activity on the IFN signalling pathway. 
 
 
Figure 4.8: Hit compounds StA-IFN-1 and StA-IFN-4 effect on IFNβ and MxA transcript 
levels 
The effect of StA-IFN-1, StA-IFN-4 and known inhibitory compounds on IFNβ and MxA mRNA 
levels was assessed. A549 cells were treated with compound 2 hours prior to activation. Three 
hours post-SeV infection and 18 hours post-IFNα treatment, total cellular RNA was extracted 
and reverse transcribed. The resultant cDNA was used to qPCR amplify either IFNβ (A) or MxA 
(B) sequences using appropriate primers. Ct values were subjected to absolute quantitation 
using a 6-point standard curve with DNA of known concentration and converted into % cDNA of 
controls. Data represents the mean of three independent experiments, each conducted in 
triplicate (n=3); error bars indicate StDev. Statistical significance was assessed using One-way 
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and IFN signalling assays facilitated an HTS campaign to identify novel 
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small diversity set at the DDU, comprising 15,667 small molecules. The 
diversity screen was carried out in an automated 384-well format utilizing the 
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ratio to 1.6 compared to 3.1 following assay development. The Z’ factor was 
consistent however at 0.67, indicating that the screen remained robust. Of 
15,667 compounds screened, 245 were identified as putative hit molecules, 200 
showing inhibitory activity and 45 enhancing GFP expression, yielding a primary 
hit rate of 1.56%. To validate these hit compounds and determine their potency, 
we embarked on a campaign of dose-response screening. Using 2-fold serial 
dilutions of hit compounds, construction of 10-point dose-response curves 
facilitated XC50 determination.  
Three screens were performed. 
I. IFN inhibitor screen to further investigate putative hit compounds with 
inhibitory activity 
II. IFN enhancer screen using the IFN induction assay without SeV 
infection to study possible enhancers of IFN induction 
III. Specificity screen using the IFN signalling assay to identify 
compounds with dual activity or non-specific, off-target effects 
Of the 200 putative inhibitors of IFN induction, 6 showed activity specific 
to the IFN induction pathway, as they were shown to lack potency in the 
specificity screen. All but 3 of the potential enhancers of IFN induction were 
deemed inactive. Following LC-MS to confirm the identity and purity of the 
screening compounds, the remaining 4 most promising hits were repurchased 
for further testing. Two of these hit compounds, StA-IFN-2 and StA-IFN-5 failed 
to display specificity to the IFN induction pathway following retesting. StA-IFN-1 
and StA-IFN-4 however continued to exhibit activity specific to IFN induction. 
Additionally, we excluded the possibility that this inhibition was due to off-target 
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effects such as SeV inhibition or by compromising cell viability. Furthermore, we 
confirmed that StA-IFN-1 and StA-IFN-4 have direct activity on the inhibition of 
IFN induction as RT-qPCR saw a significant decrease in IFNβ mRNA 
expression in their presence. 
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5. Characterization of novel compounds that inhibit the 
IFN induction pathway 
5.1 Introduction 
 As a result of successful diversity screening, dose-response studies and 
hit validation, two compounds, StA-IFN-1 and StA-IFN-4, were identified as 
having specific activity to the inhibition of IFN induction. To further investigate 
the action of these compounds in the IFN induction pathway, we instigated 
studies to identify the cellular target of these compounds, assess any structure-
activity relationships regarding their activity and determine whether StA-IFN-1 
and StA-IFN-4 can increase the growth of IFN sensitive viruses. 
The activity of StA-IFN-1 and StA-IFN-4 in the IRF3 branch of the IFN 
induction pathway was investigated in a number of different ways: (i) 
Immunofluorescent microscopy was utilized to determine the levels of IRF3 
nuclear translocation in the presence and absence of the compounds. (ii) IRF3 
phosphorylation is critical for its activation and we therefore assessed the levels 
of phosphorylated IRF3 in the presence of hit compounds following SeV 
induced pathway activation. (iii) To further scrutinize the activity of the 
compounds in this pathway, which is heavily dependent on the activity of 
cellular kinases, StA-IFN-1 and StA-IFN-4 were tested for activity on kinases 
that act upstream of IRF3 phosphorylation. 
To characterize specific aspects of the structures of StA-IFN-1 and StA-
IFN-4 that may be important for their activity, we carried out an investigation into 
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any previous publications that may include these compounds, or substructures 
within the molecules. Web-based database searches suggested that the 
compound activity observed in our study was novel. Subsequently, we 
instigated studies using compounds with a high level of similarity to StA-IFN-1 
and StA-IFN-4 and components of the molecules that have structural identity to 
distinct portions of the original hit compounds. As we have previously shown 
that inhibitors of the IFN response can increase the growth of BunVΔNSs, an 
IFN sensitive virus (Stewart et al., 2014), we sought to assess the activity of 
StA-IFN-1 and StA-IFN-4 in the broader context of the IFN response. Effective 
replication of BunVΔNSs in the presence of StA-IFN-1 and StA-IFN-4 would 
suggest that these compounds are blocking the IFN response. 
 
5.2 Results 
5.2.1 Mode of action studies 
 As StA-IFN-1 and StA-IFN-4 were identified through phenotypic 
screening, the mechanism of action of these compounds remains unknown. We 
therefore sought to determine their cellular target(s). Firstly, we measured the 
impact of StA-IFN-1 and StA-IFN-4 on the nuclear translocation of activated 
IRF3, a crucial step in the induction of IFN. To achieve this, we used 
immunofluorescent microscopy to assess IRF3 localisation in SeV infected 
A549 cells incubated in the presence, or absence, of the compounds (Figure 
5.1A). In the absence of infection, IRF3 is primarily cytoplasmic. Following 
DMSO treatment and SeV infection however, 60% of the cells exhibited clear 
nuclear staining (Figure 5.1B). Strikingly, StA-IFN-4 caused a highly significant 
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inhibition of IRF3 translocation, approaching 100% (p<0.0001). As was 
expected, BX795, which inhibits TBK1 in the course of IRF3 activation, 
significantly reduced nuclear IRF3 to 20% (p<0.0001), although very high levels 
of variation were observed. StA-IFN-1 resulted in a significant (p<0.005) 20% 
reduction in nuclear translocation of IRF3 compared to the DMSO control. 
Although StA-IFN-1 caused a significant reduction in IRF3 translocation, the 
level of inhibition seen by StA-IFN-4 is far superior, even compared to that of 
BX795. 
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Figure 5.1: Effect of StA-IFN-1 and StA-IFN-4 on nuclear translocation of IRF3. 
The effect of StA-IFN-1, StA-IFN-4 and BX795 on the translocation of IRF3 following SeV 
infection. A549 cells were treated with compound for 2 hours, followed by infection with SeV for 
3 hours. Cells were fixed, permeabilized and incubated with anti-IRF3 antibody, followed by 
Texas red-conjugated secondary antibody. Cells were visualized with a Nikon Microphot-FXA 
microscope at 40x magnification (A). Images were annonymized and the number of cells 
displaying diffuse cytoplasmic and nuclear staining quantified by Dr Andri Vasou (B). Data is 
presented as percentage of cells displaying nuclear staining of IRF3 and is representative of 3 
individual repeats (n=3). Error bars display StDev and the statistical significance of cells 
exhibiting nuclear IRF3 following compound treatment compared to the DMSO + SeV control 
using one-way ANOVA (***=p<0.0001, *=p<0.005). 
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 The translocation of IRF3 is a consequence of its phosphorylation and 
subsequent homodimerization, which exposes a nuclear localization signal. A 
reduction in IRF3 phosphorylation would suggest the compounds are acting 
upstream in the pathway, where no decrease in levels of phosphorylated IRF3 
(pIRF3) would suggest compound activity is targeted to inhibit dimerization or 
nuclear translocation. Therefore we assessed the impact of StA-IFN-1 and StA-
IFN-4 on levels of pIRF3 following activation of the IFN induction pathway 
(Figure 5.2A). The most dramatic reduction was observed following treatment 
with StA-IFN-4, where the level of pIRF3 decreased by 92% (p<0.0001). BX795 
resulted in a 56% reduction in pIRF3 compared to the control, although again, 
high levels of variation were observed (Figure 5.2B). StA-IFN-1 results in a 
small yet significant decrease in IRF3 phosphorylation of 32% (p<0.005). It was 
necessary to ensure that the action of StA-IFN-1 and StA-IFN-4 upon pIRF3 
was not due to a global inhibition of phosphorylation. The phosphorylation of 
STAT1 is a crucial step in the IFN signalling pathway, distinct from 
phosphorylation events in the IFN induction pathway. Therefore, we 
investigated the impact of StA-IFN-1 and StA-IFN-4 on the levels of 
phosphorylated STAT1 (pSTAT1) (Figure 5.2C). As was expected, Rux, a 
Jak1/2 inhibitor, resulted in a dramatic 85% decrease in pSTAT1 (p<0.0001) 
(Figure 5.2D). Conversely, no such impact on the levels of pSTAT1 following 
StA-IFN-1 or StA-IFN-4 treatment was observed, suggesting that the hit 
compounds are not acting as general inhibitors of phosphorylation. 
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Figure 5.2: Effect of StA-IFN-1 and StA-IFN-4 on phosphorylation of IRF3. 
The effect of StA-IFN-1, StA-IFN-4 and BX795 on the phosphorylation of IRF3 following SeV 
infection. A549 cells were treated with compound for 2 hours, followed by infection with SeV to 
activate the IFNβ induction pathway for 3 hours. Whole cell lysates were subjected to SDS-
PAGE and western blot. Membranes were probed with anti-pIRF3 and anti-βActin antibodies 
followed by IRDye680 or IRDye800-conjugated secondary antibody respectively (A). Bands 
were visualized and quantified as % pIRF3 relative to actin (B). The effect of StA-IFN-1, StA-
IFN-4 and Rux on the phosphorylation of STAT1 following IFNα treatment was also assessed. 
A549 cells were treated with compound for 2 hours, followed by incubation with IFNα to activate 
the IFN signalling pathway for 15 minutes. Whole cell lysates were subjected to SDS-PAGE and 
western blot. Membranes were probed with anti-pSTAT1 or anti-βActin antibodies followed by 
HRP or IRDye800-conjugated secondary antibody respectively (C). Bands were visualized and 
quantified as % pSTAT1 relative to actin (D). Data representative of 3 individual repeats (n=3). 
Error bars display StDev and statistical significance of pIRF3 and pSTAT1 levels compared to 
the DMSO + SeV or IFNα control was determined by one-way ANOVA (***=p<0.0001, 
*=p<0.005). 
 
Taken together, we have shown that StA-IFN-4 significantly reduces the 
phosphorylation and subsequent nuclear translocation of IRF3. This suggests 
that StA-IFN-4 is not acting upon the dimerization or translocation of IRF3, but 
either directly upon its phosphorylation, or further upstream in the IFN induction 
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experiments, it may have more potent activity elsewhere in the IFN induction 
pathway. 
IRF3 is activated by phosphorylated kinases, TBK1 and IKKε. In an effort 
to further scrutinize the activity of StA-IFN-1 and StA-IFN-4 in IRF3-dependent 
IFN induction, we instigated studies to assess their action on TBK1 and IKKε. 
Philip Cohen has a well-established assay to investigate compounds with 
inhibitory activity against kinases (Clark et al., 2009). Therefore, in collaboration 
with Philip Cohen, hit compounds StA-IFN-1 and StA-IFN-4, were studied for 
their ability to inhibit the phosphorylation of TBK1 (pTBK1) and IKKε (pIKKε) 
following TLR3 activation by Poly(I:C). In contrast to the results we obtained, 
where IFN was induced through SeV activated RIG-1 (Figure 5.2), no reduction 
in pIRF3 levels were observed in the presence of either StA-IFN-1 or StA-IFN-4 
(Figure 5.3). Indeed, here the data suggests that neither compound causes a 
reduction in the phosphorylation of IRF3, TBK1 or IKKε following TLR-induced 
activation. 
  









Figure 5.3: Effect of hit compounds on TLR3 induced kinase activity 
The activity of StA-IFN-1 and StA-IFN-4 on TLR3 activation of the IFN induction pathway. 
HACAT cells were incubated with 10 µM of compound. Two hours post-compound treatment, 
cells were treated with 10 µg/ml of Poly(I:C) for 1 hour to activate TLR3. Whole cell lysates were 
subjected to SDS-PAGE and western blot. Membranes were probed with anti-pTBK1, anti-
TBK1, anti-pIKKε, anti-pIRF3 and anti-GAPDH antibodies followed by goat anti-rabbit HRP-
conjugated secondary antibody. Jordan Taylor carried out this work in the lab of Philip Cohen at 
the university of Dundee. 
 
 From this study, we have identified that StA-IFN-4 causes a significant 
reduction in the phosphorylation of IRF3 and its subsequent translocation to the 
nucleus following RIG-I mediated IFN induction by SeV infection. StA-IFN-1 on 
the other hand exhibited lower levels of activity that were less significant. 
However, no such reduction in pIRF3 was observed through TLR3 dependent 
IFN induction with Poly(I:C). The disparity in the levels of pIRF3 observed in 
experiments using different activators of IFN induction suggests that StA-IFN-1 
and StA-IFN-4 may be acting upstream of the TBK1/IKKε activation step, where 
induction of the pathway is distinct between different PAMPs. 
5.2.2 Structure-activity relationships (SAR) 
 To further characterize hit compounds StA-IFN-1 and StA-IFN-4, we 
hoped to gain an understanding of the structural components of the molecules 
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that are important for inhibition of IFN induction. We first endeavoured to 
identify if these molecules had previously been characterized. If they have 
shown activity in previous studies, we could gain an understanding of any 
structure-activity relationships relating to these compounds. To investigate this, 
the SciFinder database (American Chemical Society, scifinder.cas.org) was 
utilized. Searches based on the chemical structures of StA-IFN-1 and StA-IFN-4 
were carried out to identify any substructures within the compounds that have 
shown activity similar to that observed in our study. This investigation 
suggested that the compounds were novel as no previous compound 
characterization was identified. 
 StA-IFN-1 obeys Lipinski’s rule of 5 with a molecular weight of 255.3, 1 
hydrogen bond acceptor and 5 hydrogen bond donors. SciFinder database 
searches identified a compound with 82% similarity (StA-IFN-1-82S). StA-IFN-1 
(Figure 5.4A) has an acetyl group, whereas this is missing in StA-IFN-1-82S 
(Figure 5.4B). The chemical structure of StA-IFN-1 can be broadly divided into 
two smaller compounds, an acetyl indole group (StA-IFN-1-LF) (Figure 5.4C) 
and a pyrazolone (StA-IFN-1-SF) (Figure 5.4D). We sought to investigate the 
activity of StA-IFN-1-82S, StA-IFN-1-LF and StA-IFN-1-SF in relation to StA-
IFN-1. To achieve this, the compounds were used in the IFN induction reporter 
assay to assess inhibition of GFP expression. StA-IFN-1 had far superior 
activity, showing the highest levels of inhibition (38%) (Figure 5.4E). StA-IFN-1-
LF was the only other compound tested that exhibited activity, reducing GFP 
expression by 13%. Both StA-IFN-1-82S and StA-IFN-1-SF resulted in no 
inhibition of GFP expression, exhibiting the same trend as DMSO. Interestingly, 
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both StA-IFN-1 and StA-IFN-1-LF have the acetyl indole structure, suggesting 
that it may be important for inhibition of IFN induction. 
 
 
Figure 5.4: Investigating StA-IFN-1 structure-activity relationships 
The activity of compounds with structural similarity to StA-IFN-1 were analysed in the IFN 
induction reporter assay. The chemical structure of StA-IFN-1 (A), an 82% similar molecule 
(StA-IFN-1-82S) (B), and molecules representing large (StA-IFN-1-LF) (C) and small (StA-IFN-
1-SF) (D) fragments of the original compound are shown. A549/pr(IFNβ).GFP cells were treated 
with compounds 2 hours prior to infection with SeV. Eighteen hours post infection, cells were 
fixed and GFP expression analyzed (E). Data represents 2 independent replicates, each 
conducted in triplicate (n=6) where errors bars show StDev. 
 
 StA-IFN-4 obeys Lipinski’s rule of 5 with a molecular weight of 337.2, 6 
hydrogen bond acceptors and no hydrogen bond donors. SciFinder database 
searches identified a compound with 85% similarity (StA-IFN-4-85S). StA-IFN-4 
is composed of a pyridoprymindine and a dichloro pyridazinone (Figure 5.5A), 
whereas the pyridoprymidine is substituted for an imidazolprymindine in StA-
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divided into two smaller compounds, the pyridoprymidine (StA-IFN-4-LF) 
(Figure 5.5C) and the dichloro pyridazinone (StA-IFN-4-SF) (Figure 5.5D). We 
sought to investigate the activity of StA-IFN-4-85S, StA-IFN-4-LF and StA-IFN-
4-SF in relation to StA-IFN-4. Initially, the compounds were used in the IFN 
induction reporter assay to monitor inhibition of GFP expression. StA-IFN-4 had 
the highest level of activity, resulting in over 60% inhibition (Figure 5.5E). StA-
IFN-4-85S exhibited a slight decrease in activity compared to the parental 
compound, although still achieved 40% inhibition in GFP expression. 
Surprisingly, the smallest molecule, StA-IFN-4-SF, also appeared to be active in 
inhibiting IFN induction, causing a 28% decrease in GFP expression. StA-IFN-
4-LF did not significantly inhibit GFP expression, exhibiting the same trend as 
DMSO. Interestingly, StA-IFN-4, StA-IFN-4-85S and StA-IFN-4-SF all have the 
same dichloro pyridazinone structure and although to varying degrees, all inhibit 
IFN induction. 
In order to further investigate the activity of the StA-IFN-4-like molecules 
independently of the GFP reporter assay, qRT-PCR was used to assess the 
level of IFNβ mRNA expression following compound treatment and activation of 
the IFN induction pathway. As expected, BX795, a TBK1 inhibitor, significantly 
reduced the levels of IFNβ mRNA present by 99% (p<0.0001) (Figure 5.5F). 
Treatment with StA-IFN-4 at 10 µM exhibited similar levels of IFNβ mRNA as 
shown previously (Figure 4.8A). Furthermore, when treated with 20 µM, 
inhibition is increased to 97% (p<0.0001). The 3 compounds with high levels of 
similarity to StA-IFN-4 showed significantly less inhibition at 10 µM compared to 
20 µM (Figure 5.5F). IFN-4-85S significantly decreased IFN induction, achieving 
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73% at 10 µM (p<0.001) and 52% at 20 µM (p<0.0001). In contrast to the 
results of the IFN induction reporter assay, both of the fragment compounds, 
StA-IFN-4-LF and StA-IFN-4-SF, achieved similar levels of IFNβ mRNA 
expression. However here, StA-IFN-4-LF yielded more significant decreases in 
IFNβ mRNA expression. 
 
Figure 5.5: Investigating StA-IFN-4 structure-activity relationships 
The activity of compounds with structural similarity to StA-IFN-4 was analysed. The chemical 
structures of StA-IFN-4 (A), a molecule with 85% similarity (StA-IFN-4-85S) (B), and molecules 
representing large (StA-IFN-4-LF) (C) and small (StA-IFN-4-SF) (D) fragments of the original 
compound are shown. A549/pr(IFNβ).GFP cells were treated with compound 2 hours prior to 
SeV infection. Eighteen hours post-infection GFP expression was analyzed (E). Compound 
effect on IFNβ mRNA levels was assessed. A549 cells were treated with compound for 2 hours. 
Three hours post infection, total cellular RNA was extracted and reverse transcribed. The 
resultant cDNA was used to qPCR amplify IFNβ sequences using appropriate primers. Ct 
values were subjected to absolute quantitation using a 6-point standard and converted into % 
cDNA of controls (F). Data represents 2 independent repeats, each conducted in triplicate 
(n=6). Errors bars show StDev. Statistical significance was assessed using One-way ANOVA to 
compare compound treatment with the DMSO + SeV control (*** = p<0.0001, **=p<0.001, 
*=p<0.005). 
 
We endeavoured to investigate how the structure of hit compounds StA-
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molecules with high levels of similarity to the parental compound, and 
compounds constituting distinct structures within StA-IFN-1 and StA-IFN-4, we 
have learnt that the acetyl indole of StA-IFN-1 (StA-IFN-1-LF) appears to be 
crucial for its activity. Conversely, the dichloro pyridazinone of StA-IFN-4 (StA-
IFN-4-SF) showed more activity in the inhibition of IFN induction in the GFP 
reporter assay. However, both StA-IFN-4-LF and StA-IFN-4-SF showed 
similarly low levels of inhibition in the RT-qPCR assay. 
5.2.3 Inhibition of IFN induction and the growth of an IFN sensitive virus 
 We have previously demonstrated that inhibitors of the IFN response can 
restore the replication of an IFN sensitive virus in A549 cells (Stewart et al., 
2014). BunVΔNSs is IFN sensitive and so replicates poorly in cell culture as a 
result of the deletion of NSs, the gene encoding its viral IFN antagonist. 
Therefore, we wanted to assess the growth of BunVΔNSs in the presence of 
StA-IFN-1 and StA-IFN-4. To achieve this, plaque assays were carried out on 
A549 cells treated with compound. As is clear, BunVΔNSs produces pinpoint 
plaques when inhibitory compounds are not present (Figure 5.6A). In 
agreement with previously published work (Stewart et al., 2014), the size of 
BunVΔNSs plaques is significantly increased by 6-fold in the presence of the 
Ikkβ inhibitor TPCA-1 (p<0.0001) (Figure 5.6B). Interestingly, StA-IFN-1 caused 
a 2-fold increase in plaque size (p<0.0005). However, StA-IFN-4 did not have a 
potent impact on plaque size, although a slight increase was observed (p<0.04). 
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Figure 5.6: Effect of hit compounds on the replication of an IFN sensitive virus 
The effect of StA-IFN-1 and StA-IFN-4 on the growth of an IFN sensitive virus, BunVΔNSs, was 
assessed. A549 cells were treated with compound and infected with BunVΔNSs for 1 hour. 
Plaque size was visualized by crystal violet staining 3 days post-infection (A). Plaque sizes 
were measured and are presented as fold increase above that of the DMSO-only control (B). 
Data represents 2 independent experiments (n≥53). Statistical significance was determined by 
one-way ANOVA where each condition was compared to the DMSO-only control (***=p<0.0001, 
**=p<0.0005, *=p<0.04). 
 
As StA-IFN-4 exhibited such low levels of activity in the plaque assays, 
we postulated that this could be a result of compound degradation. Therefore, 
we assessed the stability of StA-IFN-1 and StA-IFN-4. To achieve this, culture 
media containing the compounds was incubated alone or with A549 cells, and 
media samples containing StA-IFN-1 and StA-IFN-4 were used in the IFN 
induction reporter assay. The level of GFP inhibition observed for StA-IFN-1 
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does not differ between samples incubated in media alone or in the presence of 
cells, however the extent of GFP inhibition begins to decline 3-days post-
treatment (Figure 5.7A). In contrast to this, when StA-IFN-4 was incubated in 
the presence of cells, activity dropped dramatically after 24-hours, whereas in 
media alone, activity was retained (Figure 5.7B). To further investigate the 
reduction in StA-IFN-4 activity, media samples were also used to assess pIRF3 
levels (Figure 5.7C). Through quantification of band intensity, we observed that 
StA-IFN-4-mediated inhibition of pIRF3 dramatically decreased when incubated 
with A549 cells (Figure 5.7D). Conversely, it remained potent at inhibiting IRF3 
phosphorylation when incubated in media alone. This suggests that the 
compound is stable for up to 8 days in cell culture media. However, StA-IFN-4 
loses activity when A549 cells are present, suggesting that it is metabolised 
rapidly in cell culture. This indicates that the small plaque size observed in the 
presence of StA-IFN-4 is not necessarily due to lack of activity, but instead a 
result of compound instability in cell culture. StA-IFN-1 on the other retains 
activity for up to 4 days regardless of the presence of cells. 
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Figure 5.7: Stability of hit compound activity 
By incubating compounds in media alone or in the presence of A549 cells the stability of StA-
IFN-1 and StA-IFN-4 was assessed. Media samples were taken for up to 8 days. 
A549/pr(IFNβ).GFP cells were treated with the samples of StA-IFN-1 (A) or StA-IFN-4 (B) for 2 
hours, prior to infection with SeV. Eighteen hours post infection, cells were fixed and GFP 
expression analyzed. Data is representative of 2 independent experiments each conducted in 
triplicate (n=3). Error bars indicate StDev. Monitoring phosphorylation of IRF3 also assessed 
the activity of IFN-4. A549 cells were treated with compound samples for 2 hours, followed by 
infection with SeV to activate the IFNβ induction pathway for 3 hours. Whole cell lysates were 
subjected to SDS-PAGE and western blot (C). Membranes were probed with anti-pIRF3 and 
anti-βActin antibodies followed by IRDye680 or IRDye800-conjugated secondary antibody 
respectively. Bands were visualized and quantified as % pIRF3 relative to actin (D). Data is 




 As a result of HTS and associated hit validation, two compounds, StA-
IFN-1 and StA-IFN-4 were identified as inhibitors of the IFN induction pathway. 
In order to further characterize the inhibitory activity of these compounds, we 
sought to determine their mechanism of action in the IFN induction pathway. 
Through assessment of nuclear translocation and phosphorylation of IRF3, we 
observed that StA-IFN-4 significantly reduced both of these events. Although 
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still significant, StA-IFN-1 exhibited much lower levels of activity. This 
suggested that StA-IFN-4 acts at, or upstream of IRF3 phosphorylation. The 
activity of these compounds appears to be specific to SeV-induced RIG-1 
activation of IFN induction however, as no inhibition in the phosphorylation of 
IRF3, TBK1 or IKKε was observed following TLR3-dependent, Poly(I:C) 
stimulation of the IFN induction pathway. 
To gain an insight into how the structures of StA-IFN-1 and StA-IFN-4 
impact their activity, we conducted preliminary structure-activity relationship 
studies. Compounds with a high degree of structural similarity to, or 
substructures from within, the parental compounds were tested in the IFN 
induction reporter assay. Here, we learnt that the acetyl indole of StA-IFN-1 was 
important for activity. This work also suggested that the dichloro pyridazinone of 
StA-IFN-4 was important for inhibition of the IFN induction pathway, although 
these results were not definitive. In order to assess the activity of the 
compounds in the context of the IFN response as a whole, we sought to 
determine if StA-IFN-1 and StA-IFN-4 increased the growth of an IFN sensitive 
virus. Plaque assays using the IFN sensitive BunVΔNSs were carried out. StA-
IFN-1 and StA-IFN-4 resulted in a small increase in BunVΔNSs plaque size. As 
the increase in plaque size resulting from StA-IFN-4 treatment was small, we 
postulated that compound degradation might be the cause. Indeed, by 
assessing compound stability in cell culture and media alone, we observed that 
StA-IFN-4 is rapidly metabolised by cells in culture, although it remains stable 
when incubated in media alone. From this work, we have successfully gained 
an insight into the cellular target of StA-IFN-4 in the IFN induction pathway, and 
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ascertained which aspects of both molecules may be more important for their 
inhibitory activity. Furthermore, we have successfully shown that these 
compounds can inhibit the cellular IFN response, resulting in slightly increased 
growth of an IFN sensitive virus. 
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6. An assay to screen for novel antiviral compounds 
6.1 Introduction 
 Due to the potency of the cellular IFN response, viruses have evolved 
strategies to circumvent its actions. One way in which viruses achieve this is 
through the expression of viral IFN antagonists, which are often multi-functional 
proteins. Owing to the importance of functional IFN antagonists to the 
establishment of a viral infection, they present an attractive target for antiviral 
drug discovery. A virus that does not have a functional IFN antagonist is 
severely restricted in its ability to replicate (Stewart et al., 2014). Therefore, a 
compound that renders the viral IFN antagonist non-functional will aid the 
cellular IFN response in controlling an infection and prevent virus spread. With 
the aim of identifying candidate molecules with antiviral activity, we postulated 
that the IFN signalling reporter assay presents a simple platform to facilitate this 
work. To this end, a derivative of the A549/pr(ISRE).GFP cell line was 
generated to constitutively express the phosphoprotein of Rabies virus (RBV-
P). Following validation of the A549/pr(ISRE).GFP.RBV-P cell line it was used 
in an in-house diversity HTS with the aim of identifying compounds that 
modulate RBV-P function, resulting in restoration of GFP expression. 
 As the A549/pr(ISRE).GFP.RBV-P cell line used in screening 
constitutively expresses RBV-P, the assay was complex, as it was necessary to 
include the parental A549/pr(ISRE).GFP cell line in assay plates. In an effort to 
streamline this assay and optimize it for use in future screening campaigns, we 
instigated a campaign of assay development in which RBV-P was under the 
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control of an inducible promoter. Following validation of the functionality of 
RBV-P under Dox inducible expression, we aimed to optimize the cell line using 
multiple rounds of lentivirus transduction and FACS. 
 
6.2 Results 
6.2.1 Assay validation 
The IFN antagonist of Rabies virus, RBV-P, blocks the IFN signalling 
pathway by sequestering STATs in the cytoplasm, thus preventing their nuclear 
accumulation. To target RBV-P, Dr Andri Vasou generated a derivative of the 
parental A549/pr(ISRE).GFP cell line that constitutively expresses RBV-P. To 
validate this cell line, we first compared GFP expression in the parental 
A549/pr(ISRE).GFP and A549/pr(ISRE).GFP-RBV-P cell lines in the IFN 
signalling reporter assay. A549/pr(ISRE).GFP.RBV-P cells do not respond to 
pathway activation. Regardless of IFNα concentration, GFP expression remains 
the same as untreated cells (Figure 6.1A). This suggests that the RBV-P 
expressed is functional and successfully blocks the IFN signalling pathway. To 
confirm this, the expression levels of the ISG, MxA, were assessed. 
A549/pr(ISRE).GFP cells stimulated with IFNα expressed high levels of GFP 
and MxA, indicating successful activation of the IFN signalling pathway (Figure 
6.1B). Where RBV-P is expressed, the expression of GFP and MxA remains 
undetectable, irrespective of IFNα treatment. This confirms that the expression 
of RBV-P results in functional protein that is effective at blocking the IFN 
signalling pathway. 
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Figure 6.1: IFN signaling pathway inhibition by Rabies virus P protein  
To assess the functionality of RBV-P, A549/pr.(ISRE).GFP and A549/pr.(ISRE).GFP.RBV-P cell 
lines were used in the IFN signalling reporter assay. (A) Cells were seeded and treated with a 
2-fold serial dilution of IFN-α (40,000 to 39 U/mL) for 18 and 44 hours. Cells were then fixed and 
fluorescence measured using the Tecan Infinate Pro plate reader. Data is representative of 2 
independent repeats, each conducted in quadruplicate (n=4). Error bars display StDev. (B) 
Cells were treated with or without IFNα for 18 and 44 hours. Total cell lysates were collected 
and subject to SDS-PAGE followed by western blot. Membranes were probed with primary anti-
bodies raised against MxA, GFP, V5 tag and β-Actin, followed by IRDye800 and IRDye680 
conjugated secondary antibodies. Data shown is representive of 2 independent repeats. 
 
6.2.2 In-house HTS 
Successful validation of the A549/pr(ISRE).GFP.RBV-P cell line 
demonstrated that is was suitable for use in an in-house HTS to identify small 
molecules that modulate the function of RBV-P. We embarked on a screening 
campaign using the Maybridge Screening Collection (16,000 compounds), 
comprising small molecules selected as appropriate starting points for drug 
discovery as they all comply with Lipinski’s rule of 5 (Lipinski et al., 2001). As 
A549/pr(ISRE).GFP.RBV-P cells display the same level of fluorescence 
irrespective of IFNα stimulation, the parental A549/pr(ISRE).GFP cell line was 
included in each assay plate as an internal control, allowing us to monitor GFP 
expression (Figure 6.2A). As such, A549/pr(ISRE).GFP cells in column 23, 
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24 was left untreated and unactivated to provide a 0% restoration control. This 
also allows for QC parameters to be determined for each assay plate, as if the 
A549/pr(ISRE).GFP cell line produces results that do not pass the QC criteria, 
the A549/pr(ISRE).GFP.RBV-P cells are also likely to fail. 
A549/pr(ISRE).GFP.RBV-P cells were seeded into columns 1 to 22 and 
A549/pr(ISRE).GFP cells into columns 23 and 24 in clear-bottomed black 384-
well plates. In column 1, A549/pr(ISRE).GFP.RBV-P cells were left untreated 
and unactivated, whereas in column 2, cells were untreated and activated with 
IFNα. This allowed us to monitor the behaviour of the A549/pr(ISRE).GFP.RBV-
P cell line in the absence of test compound. 
  















Figure 6.2: Performance of a single point HTS to identify compounds that modulate RBV-
P protein function 
 A single point HTS using the A549/pr(ISRE).GFP and A549/pr(ISRE).GFP.RBV-P cell lines 
against the Mayrbidge compound library (n=16,000 compounds) at a concentration of 11.42 µM 
was performed. (A) A schematic of the 384-well plate layout used for screening; wells in 
columns 1-22 contain the A549/pr(ISRE).GFP.RBV-P cell line and 23-24 contain 
A549/pr(ISRE).GFP cells. Columns 3-22 were treated with a single test compound and IFNα, 
wells in columns 1 and 24 were untreated (Unactivated) and wells in columns 2 and 23 contain 
IFNα treated cells (Activated). (B) Plate metrics representing Z’ Factor and S/B ratio for 
A549/pr(ISRE).GFP cells, plotted for each plate of the HTS compared to preset quality control 
standards (dotted lines). 
 
The behaviour of the screen in terms of QC statistics was monitored both 
between plates and between batches. The screen was performed successfully, 
behaving as expected (Table 6.1). The consistency of the S/B ratio and Z’ factor 
of A549/pr(ISRE).GFP cells (Figure 6.2B), and the percentage CV of both cell 
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for each compound was calculated using fluorescence, in RFU of each test well 
normalized to that of activated A549/pr(ISRE).GFP.RBV-P cells. Fold change in 
GFP expression produced a very narrow normal distribution of results for the 
16,000 compounds tested, centred at 1 to 1.25-fold increase (Figure 6.3A). To 
verify the shape of the frequency distribution, a narrower range of fold change 
was also used (Figure 6.3B). A compound resulting in a fold increase in GFP 
expression that was 2 standard deviations away from the test well average for 
the plate resulted in it being considered a putative hit. From these initial 
selection criteria, 56 of the 16,000 compounds screened were considered 
putative hits yielding an initial hit rate of 0.35%. Unlike the IFN inhibitor 
screening campaign, the toxicity of a compound was less relevant, as a 
compound causing a restoration in GFP expression is unlikely to have toxic 
effects on the cells. 
 
Table 6.1: Primary screen statistics of the RBV-P IFN signalling assay represented as Z’ factor, 
S/B ratio and coefficient of variation (CV) compared to preset quality control standards. Screen 







Z’ Factor > 0.5 0.54 ± 0.06 
S/B > 2 2.04 ± 0.18 
Activated CV (%) < 8 6.85 ± 1.32 
Unactivated CV (%) < 8 1.74 ± 0.49 
A549/pr(ISRE).GFP. 
RBV-P 
Activated CV (%) < 8 2.28 ±0.97 
Unactivated CV (%) < 8 2.00 ± 0.73 
 
















Figure 6.3: Data output from a single point HTS to identify compounds that modulate 
RBV-P protein function 
Data obtained during the single point HTS was analyzed by comparing the fluorescence of 
A549/pr(ISRE).GFP.RBV-P cells to the parental A549/pr(ISRE).GFP cell line. Raw data (RFU) 
was converted to fold increase in GFP expression where IFNα treated (activated) 
A549/pr(ISRE).GFP.RBV-P cells set the background level (1). Screen output is plotted as a 
frequency distribution of the fold increase in GFP expression of all compounds tested 
(n=16,000) (A) and a smaller range of expression levels demonstrate the normal distribution of 
results (B). 
 
 With the aim of identifying novel compounds that modulate the function 
of RBV-P in the IFN signalling pathway we utilized the 
A549/pr(ISRE).GFP.RBV-P reporter cell line and successfully carried out an 
automated HTS against 16,000 test compounds, which identified 56 putative 
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hits. By utilizing the A549/pr(ISRE).GFP reporter cell line during screening, we 
were able to monitor GFP expression. The Z’ factor remained above 0.5 and a 
S/B ratio >2 was consistently observed, reinforcing the integrity of the primary 
screen. 
6.2.3 Dose response screening of putative hit compounds 
 In order to confirm the activity of putative hit compounds, determine their 
potency and identify any false-positive hits, we embarked on a campaign of 
dose-response screening. In this case, 56 putative hit compounds were tested 
using a 9-point 2-fold serial dilution of test compound from 25 µM to 0.1 µM. As 
compounds modulating RBV-P function would result in restoration of GFP 
expression, we needed to be aware that compounds with autofluorescent 
properties could be identified as hits. To identify false positives that exhibit 
autofluorescence, three dose-response screens were carried out. We tested 
each compound in the A549/pr(ISRE).GFP.RBV-P cell line (i) with and (ii) 
without IFNα treatment to activate the IFN signalling pathway and (iii) in A549 
cells lacking a GFP reporter gene. If a compound exhibits the same levels of 
fluorescence in the absence of IFNα to activate IFN signalling and in a cell line 
without a GFP gene, they are autofluorescent and therefore false positive hits. 
The 3 dose-response screens performed to further investigate the 56 
putative hit compounds behaved well, with each assay achieving a percentage 
CV well below that of the 8% approval limit (Figure 6.4A). Unfortunately, all 56 
putative hit compounds tested were either inactive or exhibited some degree of 
autofluorescence. As such, the compounds were categorized into 3 groups; 
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compounds displayed (i) high-level autofluorescence (Figure 6.4B), (ii) low-level 
autofluorescence (Figure 6.4C) or (iii) inactivity (Figure 6.4D).  
 
Figure 6.4: Dose-response screening of putative hit compounds using A549 cells and the 
A549 pr.(ISRE).GFP.RBV-P reporter assay 
Compounds showing activity during primary HTS screening were subjected to secondary 
screening to generate a 9-point dose response curve using a 2-fold serial dilution from 25 to 0.1 
µM in the A549/pr.(ISRE).GFP.RBV-P reporter cell-line with (+IFN) or without (-IFN) IFNα 
treatment and A549 cells lacking a GFP gene (A549). Between-plate screen statistics showing 
coefficient of variation (CV) of the 3 conditions used, compared to preset quality control 
standards (Dotted line) (A). Compounds were categorized as displaying high-level auto-
fluorescence (B), low-level auto-fluorescence (C) or as being inactive (D), where a 
representative example of each is shown. 
 
 With the aim of identifying compounds that modulate the antagonistic 
activity of RBV-P in the IFN signalling pathway, diversity HTS against 16,000 
compounds at 11.42 µM resulted in the identification of 56 putative hits. These 
compounds were taken forward to secondary dose-response screening to 
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determine potency. All 56 putative hit compounds displayed either no activity or 
autofluorescence, and as such were broadly characterized as being inactive, 
highly autofluorescent or exhibiting low-level autofluorescence. 
6.2.4 An inducible expression assay 
 A limitation of the HTS performed was the constitutive expression of 
RBV-P. As such, to ascertain the possible S/B ratio in this assay and the level 
of potential restoration in GFP expression a compound could achieve, it was 
necessary to include the parental A549/pr(ISRE).GFP cell line in screening. 
Therefore, we hypothesized that using an inducible expression system to 
express the IFN antagonist target would produce an assay requiring a single 
cell line that, under different treatment conditions, would provide all the 
necessary controls. Primarily, working with a single cell line would greatly 
simplify the assay, thus decreasing the potential for variation. Additionally, 
comparisons of signal and variation would have increased validity if all results 
were derived from the same cell line. Secondly, we theorized that the high 
levels of RBV-P expression in the constitutive cell line were saturating the IFN 
signalling pathway, decreasing the potential for hit identification. To this end, we 
aimed to develop an assay in which RBV-P was expressed under the control of 
an inducible promoter. This would enable maximum and minimum levels of GFP 
expression to be determined and allow greater control over the expression 
levels of RBV-P. Successful development of such an assay would provide 
proof-of-principle for its application to HTS. Further to this, we aimed to optimize 
the assay to maximize the signal window achieved when the IFN antagonist is 
or is not expressed. 
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6.2.4.1 Assay development 
 To generate a derivative of the parental A549/pr(ISRE).GFP cell line, 
which contained the RBV-P gene under the control of a Dox inducible promoter, 
we utilized the LVX-Tet-One transfer vector. The expression of V5-tagged RBV-
P from the newly constructed transfer vector was tested in transiently 
transfected 293T cells. RBV-P is clearly expressed in cells transfected with the 
transfer vector containing the gene and subsequently treated with Dox (Figure 
6.5). The pLVX-Tet-One vector tightly regulates expression from the inducible 
cassette, as no RBV-P is detected in transfected cells where Dox treatment was 








Figure 6.5: An IFN signaling reporter assay to incorporate the inducible expression of the 
Rabies virus phosphoprotein 
A transient transfection of the pLVX-Tet-One-RBV-P plasmid was performed in 293T cells 
followed by treatment of the cells with Dox. Total cell lysates were subjected to separation on 
SDS-PAGE gel followed by western blot. Membranes were probed for N-terminally V5 tagged P 
protien to ensure successful expression from the plasmid. 
 
 Following verification that the pLVX-Tet-One-RBV-P plasmid was 
functional and resulted in the expression of V5-tagged RBV-P, lentivirus stock 
produced with this transfer vector was used to transduce parental 
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cell line. To verify that the Tet-One-RBV-P cassette was integrated into the 
A549/pr(ISRE).GFP chromosome, we amplified the RBV-P sequence from 
genomic DNA (gDNA) extracted from A549/pr(ISRE).GFP.Tet-One-RBV-P cells 
and  used the pLVX-Tet-One-RBV-P plasmid as a control (Figure 6.6). The 
RBV-P sequence is not present in gDNA extracted from parental 
A549/pr(ISRE).GFP cells. This suggested that the V5-tagged RBV-P gene had 








Figure 6.6: Confirmation of RBV-P gene integration into chromosomal DNA 
Following transduction of the target cells with lentivirus, genomic DNA was extracted and PCR 
amplified to confirm chromosomal integration of the Rabies P gene. Lanes contain the following; 
MM – Mastermix only, NTC – No template control (primers only), NPC – No primer control 
(template only), Template – parental lentiviral plasmid, ISRE – parental A549/pr(ISRE).GFP 
cells (untransduced), CMV-IE1 – control cell line transformed using the same lentivirus 
technology and RBV-P – resultant A549/pr(ISRE).GFP.Tet-One-RBV-P cell line following 
lentiviral transduction. 
 
 Although we had confirmed that the A549/pr(ISRE).GFP.Tet-One-RBV-P 
cell line contained the RBV-P gene, we needed to verify that the protein was 
expressed and that it was functional. To achieve this, A549/pr(ISRE).GFP and 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells were used in the IFN signalling 
reporter assay. Untreated A549/pr(ISRE).GFP and A549/pr(ISRE).GFP.Tet-
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6.7A). When treated with a 2-fold serial dilution of IFNα however, 
A549/pr(ISRE).GFP and A549/pr(ISRE).GFP.Tet-One-RBV-P cells exhibit 
comparable dose-dependent expression of GFP as a result of successful IFN 
signalling pathway activation. In the presence of Dox and IFNα, 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells exhibit greatly reduced S/B ratio in 
comparison to cells treated only with IFNα. Although suggesting that induction 
of RBV-P expression by Dox treatment is successful and results in the 
production of functional protein, GFP expression is not completely inhibited. To 
investigate the effect of Dox concentration on RBV-P expression, 
A549/pr(ISRE).GFP and A549/pr(ISRE).GFP.Tet-One-RBV-P cells were again 
used in the IFN signalling assay, and  treated with a 2-fold serial dilution of Dox. 
In the presence of IFNα, low Dox concentrations (0.03 to 0.06 µg/ml) result in 
comparable levels of GFP expression in A549/pr(ISRE).GFP.Tet-One-RBV-P 
and A549/pr(ISRE).GFP cells (Figure 6.7B). At higher Dox concentrations, GFP 
expression in A549/pr(ISRE).GFP.Tet-One-RBV-P cells is reduced by up to 
50% compared to the parental A549/pr(ISRE).GFP cell line. However, a 
reduction in S/B ratio is also observed in the A549/pr(ISRE).GFP cell line as 
Dox concentrations increase. 
 Thus far, assessment of RBV-P functionality has been carried out in the 
IFN signalling reporter assay. We therefore endeavoured to evaluate the effect 
of RBV-P in the context of the IFN signalling pathway itself by comparing the 
levels of MxA and GFP expression in both A549/pr(ISRE).GFP and 
A549/pr(ISRE).GFP.Tet-One-RBV-P cell lines. Dox treatment does not impact 
the IFN signalling pathway as A549/pr(ISRE).GFP cells exhibit the same levels 
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of MxA and GFP expression irrespective of Dox (Figure 6.7C). Strong 
expression of MxA and GFP was also observed in IFNα treated 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells. Upon Dox induction, RBV-P is 
strongly expressed, and there is a marginal decrease in GFP expression, but 
not MxA, which remains unaltered. This suggests that RBV-P does not 
successfully inhibit the IFN signalling pathway. 
Variation in RBV-P expression within the cell population was investigated 
using immunofluorescent microscopy of A549/pr(ISRE).GFP and 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells. Dox treatment does not impede the 
expression of GFP following IFNα treatment in A549/pr(ISRE).GFP cells (Figure 
6.7D). In the absence of Dox, both cell lines express comparable levels of GFP, 
indicating successful activation of the IFN signalling pathway. 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells treated with both Dox and IFNα show 
clear expression of both GFP and RBV-P. Interestingly, cells that express GFP 
do not appear to express RBV-P, and in cells where RBV-P is detected, GFP is 
not expressed. This suggests that although RBV-P is successfully expressed 
and functional, the cell population is heterogeneous and therefore there are 
cells present that do not contain the inducible RBV-P gene. 
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Figure 6.7: Assessing the functionality and expression of Rabies virus phosphoprotein in 
an inducible reporter assay 
Following generation of the A549/pr(ISRE).GFP.Tet-One-RBV-P cell line, the functionality of the 
expressed protein was assessed. The IFN signaling assay using A549/pr(ISRE).GFP and 
A549/pr(ISRE).GFP.Tet-One-RBV-P cell lines was performed using a 2-fold dilution series of 
IFN-α (A) or Dox (B) to assess GFP expression in the presence and absence of Rabies 
phosphoprotein. Cellular expression levels of GFP, Rabies phosphoprotein and the ISG MxA 
were assessed in the presence and absence of IFN-α and Dox by SDS-PAGE separation and 
western blotting of whole cell lysates (C). To further investigate the expression of GFP and 
phosphoprotein in the cell population, immunofluorescent microscopy was utilized. 
A549/pr(ISRE).GFP and A549/pr(ISRE).GFP.Tet-One-RBV-P cells were seeded onto coverslips 
and either left untreated, incubated with IFN-α only or with Dox followed by IFN-α treatment. 
Cells were fixed and probed with α-V5 primary and Texas red-conjugated secondary antibodies 
and DAPI (D). Data is representative of 3 independent repeats, each conducted in triplicate 
(n=3). Error bars display StDev. 
 
 To reduce the heterogeneity of the population and maximize RBV-P 
mediated inhibition of GFP expression, further optimization of the cell line was 
required. We aimed to increase the homogeneity of the cell line by selecting 
against cells that poorly express RBV-P using FACS, which can isolate 
thousands of cells with the same expression profiles from a given population. 
The levels of GFP expression in the RBV-P expressing cell line was assessed 
in comparison to the parental A549/pr(ISRE).GFP cell line. In the presence of 
RBV-P and IFNα, a fluorescent profile similar to that of unactivated 
A549/pr(ISRE).GFP cells should be observed, as the IFN signalling pathway 
would be inhibited. The GFP expression profile of the A549/pr(ISRE).GFP 
population exhibited a clear shift in fluorescence following IFNα treatment, 
where one clear peak is observed (Figure 6.8A). As expected, 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells treated only with IFNα exhibited the 
same profile as the parental cell line (Figure 6.8B). When Dox treatment is 
included to induce RBV-P expression, there is a clear decrease in fluorescence, 
although a second lesser peak of high fluorescence was observed (Figure 
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6.8C), where a sub-population of cells exhibiting high GFP expression was 
present. FACS was used to select for the population of cells that, in the 
presence of Dox and IFNα, expressed low levels of GFP. The expression profile 
of these sorted cells exhibited a more defined peak of low fluorescence (Figure 
6.8D). However, although reduced, the second peak of cells expressing high 
levels of GFP was not eradicated. 
 
Figure 6.8: Optimization of viral IFN antagonist expression through FACS 
To maximize the inhibitory effect of viral IFN antagonists on the IFN signalling pathway, we 
sought to optimize the fluorescent signal window through FACS. The parental 
A549/pr(ISRE).GFP cells were analyzed for GFP expression following incubation with and 
without IFNα to establish the original signal window of the IFN signaling assay (A). Cell lines 
expressing the IFN antagonist of Rabies virus (B-D) were then either left untreated or treated 
with Dox, followed by incubation with IFNα and subjected to FACS analysis on the basis of GFP 
fluorescence. Cells treated with both Dox and IFNα (C) were sorted, and those expressing the 
lowest levels of GFP isolated. The GFP fluorescent profile of sorted cells in the presence of Dox 
and IFNα is shown (D). 
  
100# 101# 102# 103# 104#
+ IFNα 






100# 101# 102# 103# 104# 100# 101# 102# 103# 104#
+ IFNα + Dox 
100# 101# 102# 103# 104#
+ IFNα + Dox 
Unsorted Sorted 
GFP (530/40) GFP (530/40) 
A 
B C D 
	   157 
We previousliy utilized multiple rounds of lentivirus transduction to 
optimize the A549/pr(ISRE).GFP cell line. Therefore, we used the same 
approach to reduce the heterogeneity of the A549/pr(ISRE).GFP.Tet-One-RBV-
P cell line, which were subjected to six rounds of lentivirus transduction. We 
used FACS to compare GFP expression in cells that had undergone 1 and 6 
rounds of transduction. Following IFNα treatment, the GFP expression profiles 
observed in A549/pr(ISRE).GFP cells (Figure 6.9A), and 
A549/pr(ISRE).GFP.Tet-One-RBV-P cells, which had undergone 1 (Figure 
6.9B) or 6 (Figure 6.9C) lentiviral transductions all exhibited high levels of GFP 
fluorescence, producing a single defined peak. Following Dox induction of RBV-
P expression, A549/pr(ISRE).GFP.Tet-One-RBV-P cells that had been 
transduced once with lentivirus again displayed 2 peaks (Figure 6.9D). 
Interestingly, A549/pr(ISRE).GFP.Tet-One-RBV-P cells that had been 
transduced 6 times displayed a single peak comparable to that observed in 
untreated A549/pr(ISRE).GFP cells (Figure 6.9E). Only a slight shoulder was 
observed however, where a small number of cells continued to express high 
levels of GFP. 
  




















Figure 6.9: Optimization of viral IFN antagonist expression through repeated lentivirus 
transduction 
To optimize the inhibitory effect of RBV-P expression on the IFN signalling assay, we sought to 
maximize the fluorescent signal window through repeated lentivirus transduction of cells. The 
parental reporter cell line (A549/pr(ISRE).GFP) (A) was transduced once or 6 times with 
lentivirus containing the gene encoding RBV-P. Cells were then either left untreated (B&C) or 
treated with Dox (D&E), followed by incubation with IFNα. All cells were subjected to FACS 
analysis on the basis of GFP fluorescence. 
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6.3 Summary 
 Validation of the A549/pr(ISRE).GFP.RBV-P cell line in the IFN signalling 
reporter assay potentiated a successful primary screening campaign against 
16,000 compounds, which identified 56 putative hits. Following potency 
assessment of these hits through dose-response screening, all 56 compounds 
exhibited inactivity or some degree of autofluorescence and as such were 
categorized as false positive hits. With the aim of developing a less complex 
assay that required a single cell line for HTS, we developed a derivative of the 
A549/pr(ISRE).GFP cell line where the expression of RBV-P was under the 
control of a Dox inducible promoter. Although functional protein resulted from 
Dox treatment of this cell line, heterogeneous expression resulted in 
inconsistent levels of IFN signalling pathway inhibition within the population. 
Therefore, using FACS, we sought to select for cells expressing functional 
antagonist that was successfully blocking IFN signalling. As this did not 
sufficiently optimize the cell lines, they were transduced a further 5 times with 
lentivirus containing the inducible integration cassette. Through repeated 
rounds of lentivirus transduction, we have successfully optimized the 
A549/pr(ISRE).GFP.Tet-One-RBV-P cell line, resulting in the production of a 
population with more homogeneous expression of RBV-P. These results further 
support repeated rounds of lentivirus transduction as a method to achieve an 
optimal signal window, potentiating successful optimization of an assay for use 
in HTS. 
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7. Discussion 
 Through the use of GFP reporter cell lines, we successfully developed 
and validated two cell-based assays to identify modulators of the IFN induction 
and signalling pathways. We performed a robust phenotypic HTS with the IFN 
induction reporter assay, which has the potential to target all components 
involved in RIG-I-induced, IRF3-dependent IFN induction. The screen identified 
2 compounds, StA-IFN-1 and StA-IFN-4 that specifically inhibit IFN induction. 
The potency of these compounds is in the micromolar range, and along with 
other dose-response parameters for hill slope, and maximum and minimum 
percentage effects, are broadly comparable to the IKKβ inhibitor, TPCA-1. We 
did not know the cellular targets of StA-IFN-1 and StA-IFN-4, as the assay used 
to identify them was phenotypic. Therefore, we instigated target deconvolution 
studies to characterize their target(s), which is discussed below. 
 
7.1 Target deconvolution 
 Data mining and target set enrichment can be a powerful tool to direct 
target deconvolution. Although not crucial for clinical approval of a candidate 
drug (Perola, 2010), target elucidation of a hit compound can be valuable to 
medicinal chemistry to further optimize the compound in terms of potency and 
specificity. We identified that StA-IFN-1 and StA-IFN-4 were novel in their ability 
to inhibit IFN induction through the use of SciFinder database searches and so 
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extended the investigation into the cellular targets of StA-IFN-1 and StA-IFN-4 
through preliminary target deconvolution studies. 
7.1.1 StA-IFN-4 
 StA-IFN-4 is a novel inhibitor of IFN induction, as SciFinder database 
searches against its structure gave no indication as to the compound’s 
mechanism of action or cellular target within the pathway. Although a patent 
detailing a compound with 74% similarity to StA-IFN-4 has been published, it 
details the use of Imidazo pyridines as GABA receptor agonists (Fang et al., 
2011, Goodacre et al., 2006). To characterize the antagonistic action of StA-
IFN-4 in IFN induction, we first assessed its effect on IRF3. We discovered that 
StA-IFN-4 is a potent inhibitor of IRF3 phosphorylation and subsequent nuclear 
translocation, suggesting that the cellular target of StA-IFN-4 must be at, or 
upstream, of IRF3 phosphorylation. To investigate this further, we assessed the 
affect of StA-IFN-4 on the kinases TBK1, and IKKε, which are responsible for 
IRF3 phosphorylation. In contrast to the IRF3 experiments conducted in A549 
cells, where SeV activated IFN induction, StA-IFN-4 had no impact on the levels 
of IRF3, TBK1 or IKKε phosphorylation where IFN induction in HACAT cells was 
activated by Poly(I:C). Although the difference in cell line may have a causal 
role in the differences observed in pIRF3 levels, the most likely reason for this 
discrepancy is the nature of the inducer used to activate the IFN induction 
pathway. As poly(I:C) is introduced to cells in liposomes via transfection, it is a 
potent activator of TLR3-dependent IFN induction (Naumann et al., 2013, 
Matsumoto and Seya, 2008). SeV Cantell on the other hand is a well-
characterized ligand of RIG-I (Martinez-Gil et al., 2013). This difference would 
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suggest that the cellular target of StA-IFN-4 is upstream of TRAF3 recruitment, 
as this is where the signalling cascades instigated by TLR3 and RIG-I converge 
(Figure 7.1). Therefore, StA-IFN-4 could target MAVS or RIG-I. Additionally, it 
could target the cellular regulators of these signalling molecules such as 
TRIM25, PP1α, PP1γ and TRAF 2, 5 and 6 (Gack et al., 2009, Wies et al., 
2013, Liu et al., 2013). In order to strengthen the kinase data, the experiment 
should be repeated to test RIG-I and TRL3-dependent kinase activity in parallel, 
















Figure 7.1: TL3- and RIG-I-dependent activation of IRF3. 
Poly(I:C) induced activation of IRF3 signals through TLR3 and TRIF, whereas SeV is sensed by 
RIG-I, and induces IRF3 phosphorylation through MAVS. TRIF- and MAVS-dependent 













	   163 
 To further investigate the activity of StA-IFN-4 upstream of TRAF3, co-
immunoprecipitation (IP) experiments could be utilised. As RIG-I-dependent IFN 
induction relies on the dephosphorylation of RIG-I by PP1 proteins, this 
interaction could be studied through IP of RIG-I followed by western blotting for 
PP1α and PP1γ (Wies et al., 2013). The levels of phosphorylated RIG-I could 
be examined in the presence and absence of StA-IFN-4. Furthermore, the 
interaction between RIG-I and its regulator TRIM25 can be detected through IP 
experiments (Gack et al., 2007). If, in the presence of StA-IFN-4, this interaction 
were undetectable, it would suggest that the target is either of these two 
proteins or upstream effector molecules such as PP1 proteins. Likewise, the 
association of MAVS with TRIM25, and MAVS CARD with RIG-I CARD could 
be studied using IP to assess these interactions in the presence of StA-IFN-4 
(Castanier et al., 2012, Nistal-Villan et al., 2010).  
As a result of this preliminary investigation into the target of StA-IFN-4, 
we have identified that it is acting at, or upstream, of IRF3 phosphorylation. 
Furthermore, it is suggested that StA-IFN-4 is acting upon RIG-I, MAVS or their 
modulators, as no inhibition of TLR3-dependent IFN induction was observed. 
Further deconvolution studies are required to verify the exact cellular target of 
StA-IFN-4. Other approaches that could be used for this are discussed below 
(7.1.3). 
7.1.2 StA-IFN-1 
 As with StA-IFN-4, we carried out SciFinder searches of published patent 
and research literature relating to the structure of StA-IFN-1, which revealed 
that it is also a novel antagonist of IFN induction. These searches did not 
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highlight its specific mode of action in the IFN induction pathway. In fact, 
literature relating to this compound was limited to an 87% similar molecule 
identified as binding to BRPF1, a transcriptional scaffolding protein (Zhu and 
Caflisch, 2016), and a molecule with ~70% similarity patented as an inhibitor of 
tyrosine kinases involved in angiogenesis (Arnold et al., 2002). In contrast to 
StA-IFN-4, StA-IFN-1 did not potently inhibit IRF3 phosphorylation of nuclear 
translocation. Although we cannot rule out the possibility that StA-IFN-1 is 
acting downstream of IRF3 nuclear translocation, by inhibiting IFNβ 
enhanceosome assembly for example, we postulated that its target might be 
elsewhere in the IFN induction pathway. The compound with 70% similarity 
identified through SciFinder suggests that StA-IFN-1 may be a kinase inhibitor. 
It may therefore inhibit a kinase involved in the NF-κB branch of the IFN 
induction cascade, such as TAK-1, IKKβ or IKKα (Israel, 2010). To investigate 
this further, the impact of StA-IFN-1 on the nuclear translocation of NF-κB 
subunits could be assessed via immunofluorescent microscopy (Unterholzner et 
al., 2011). Additionally, as NF-κB activation is dependent on the proteasomal 
degradation of IκBα (Li et al., 2000), the levels of this cellular effector in the 
presence of StA-IFN-1 could also be monitored. More specifically, as TAK-1 is 
responsible for IKKβ phosphorylation in the course of NF-κB activation (Israel, 
2010), monitoring the levels of pIKKβ in the presence of StA-IFN-1 could 
indicate that TAK-1 is the cellular target. However, it is worth noting that TAK-1 
is a serine kinase, and the 70% similar compound identified is responsible for 
inhibiting tyrosine kinases.  
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 As a result of this preliminary study into the cellular target of StA-IFN-1, 
we have identified that, unlike StA-IFN-4, it is not a potent inhibitor of IRF3 
phosphorylation or nuclear translocation. Although StA-IFN-1 may inhibit 
downstream events in the IRF3 branch of the IFN induction cascade, it is likely 
that it may also target elsewhere such as the NF-κB branch of IFN induction. 
Structural similarity searches suggest that StA-IFN-1 may be a kinase inhibitor 
and as such may target TAK-1, IKKβ or IKKα. Further target deconvolution 
studies will be necessary to verify the exact cellular target of StA-IFN-1. The 
approaches that could be used for this are discussed below (7.1.3). 
7.1.3 Further approaches to target deconvolution. 
 Although a case-independent systematic approach to target 
deconvolution is yet to be established, there are numerous methods that can be 
employed to identify the target of a hit molecule. Through the characterisation of 
StA-IFN-1 and StA-IFN-4 we had identified that the latter acts at or upstream of 
IRF3 phosphorylation. Here, we will discuss 3 methods that could be employed 
to elucidate the exact targets of StA-IFN-1 and StA-IFN-4. 
7.1.3.1 Functional screening of IFN induction pathway effector molecules 
A targeted approach that could be used to identify the cellular targets of 
StA-IFN-1 and StA-IFN-4 is the use of expression vectors encoding signalling 
factors involved in the IFN induction pathway. This approach has been 
successfully applied to identify the cellular targets of the viral IFN antagonists 
expressed by Vaccinia virus and Poxvirus. The overexpression of MAVS 
activates the IFN induction pathway (Unterholzner et al., 2011). In the presence 
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of an IFN antagonist acting at or downstream of MAVS, induction is inhibited. 
However, if the target of the antagonist is upstream of MAVS, induction is 
unimpeded. As such, this provides a convenient method for target identification 
and could be applied to test StA-IFN-4. If the target of StA-IFN-4 is MAVS, IFN 
induction would be blocked. If, on the other hand, StA-IFN-4 inhibits RIG-I or a 
regulator of MAVS or RIG-I, then IFN will be induced as normal. Similarly, this 
approach has been used to identify the cellar target of IFN antagonists acting 
upon the NF-κB branch of IFN induction. Ectopic overexpression of IKKα, IKKβ, 
and TRAF6 induce the expression of a luciferase gene under the control of an 
NF-κB dependent promoter (DiPerna et al., 2004). If a molecule targets 
downstream of these signalling molecules, luciferase expression will be 
impeded. This approach could also be applied to StA-IFN-1 to establish 
whether it targets the NF-κB branch of the IFN induction pathway and indicate 
its point of action. However, to date, this method has only been used to identify 
the target of overexpressed viral proteins following the overexpression of 
cellular signalling molecules. It remains to be seen therefore whether it is a 
suitable method for small molecule target deconvolution, as the compound may 
not be potent enough to interfere with the pathway to a detectable level. 
7.1.3.2 Global approaches to target deconvolution 
Historically, target deconvolution has involved affinity-based approaches 
based on immunoprecipitation and chromatography (Reviewed by Lomenick et 
al., 2010, Titov and Liu, 2012, McFedries et al., 2013). Although a powerful 
approach, it relies on the conjugation of a small molecule to an affinity tag such 
as biotin, or a solid matrix such as agarose, which can reduce the activity of the 
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compound. More recently, a technique has been developed, which negates the 
need for small molecule conjugation. Drug affinity responsive target stability 
(DARTS) suggests that when bound to a ligand (small molecule), the stability of 
a protein is increased, and thus is less susceptible to protease cleavage 
(Lomenick et al., 2010, Lomenick et al., 2009). For target deconvolution of StA-
IFN-1 and StA-IFN-4, cell lysates would be incubated with or without the 
compounds. As the compounds were identified through a phenotypic screen 
where the IFN induction pathway was activated, the cell lysates should be taken 
from both activated and unactivated cells. Following protease digestion, protein 
samples are separated on 1-dimensional SDS-PAGE gels, which are then 
stained with Silver staining or Coomassie blue for example (Figure 7.2A). Visual 
analysis of the differences in the banding patterns between the two samples 
can identify changes in the abundance of specific proteins, which can then be 
identified by LC-MS. If protein levels are too low to assess visually, direct LC-
MS followed by subtractive analysis of results from the two samples and other 
label-free approaches could be utilized (Wiener et al., 2004). 
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Figure 7.2: Schematic representation of two global approaches to target deconvolution. 
DARTS relies on the decreased protease susceptibility of the binding partner upon small 
molecule binding (A) whereas affinity chromatography-based target elucidation requires the 
small molecule to be immobilized in order to capture its interaction partner (B). (Adapted from 
Lomenick et al., 2010) 
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One of the most commonly used approaches to target elucidation is 
affinity-chromatography (Titov and Liu, 2012, McFedries et al., 2013). Cell 
lysates are incubated with affinity-tagged compound followed by standard 
immunoprecipitation protocols and LC-MS or western blotting to identify the 
bound proteins (Figure 7.2B). As these approaches rely on the conjugation of a 
small molecule to an affinity tag such as biotin, or a solid matrix such as 
agarose, these methods require considerable knowledge of SAR relating to the 
compound as to not ablate activity once immobilised. To determine the regions 
of StA-IFN-1 and StA-IFN-4 that may be amenable to conjugation, we tested 
molecules with high levels of similarity to the parental compounds and 
fragments of the structures. These experiments suggest that the acetyl indole of 
StA-IFN-1 and the dichloro pyridazinone of StA-IFN-4 are crucial for their 
inhibitory activity. Therefore, in order to use affinity chromatography to elucidate 
the target of StA-IFN-1, a biotin affinity-tag could be attached to the pyrazolone 
structure. Loss of this group did not ablate the activity of StA-IFN-1, although it 
was reduced. Similarly, the pyridopyrimidine group of StA-IFN-4 appeared 
dispensable, and as such a biotin tag could be attached here. In order to 
maximize the knowledge pertaining to mode of action, SAR and potentiate 
target elucidation, medicinal chemistry to optimize the potency of StA-IFN-1 and 
StA-IFN-4 may be necessary before affinity-based approaches to target 
deconvolution are utilized. 
As a result of preliminary investigations into the targets of StA-IFN-1 and 
StA-IFN-4, we have identified StA-IFN-4 as a potent inhibitor of IRF3-dependent 
IFN induction. As such, StA-IFN-4 could be targeting RIG-I, MAVS or one of 
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their effector molecules. The reduced activity of StA-IFN-1 in comparison to 
StA-IFN-4 against IRF3 activation suggests that its cellular target may be 
involved in the NF-κB branch of IFN induction. To further elucidate the cellular 
targets of these compounds, various approaches can be employed ranging 
from targeted IP analysis and signalling molecule activity studies to more global 
methods such as DARTS and affinity chromatography. 
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7.2 Applications of IFN induction inhibitors 
 The IFN response is a potent first line of cellular defence against 
invading pathogens. However, aberrant activation of IFN induction and 
signalling either as a result of persistent viral infection or autoimmunity has 
potentially devastating effects. Compounds that inhibit IFN induction have 
potential uses in the clinic as therapeutics to treat diseases associated with 
dysfunction in the IFN system. Furthermore, IFN induction inhibitors could have 
applications in the biotechnology industry for the production of live-attenuated 
viral vaccines and oncolytic viruses, and could also be powerful tools for use in 
the research environment. 
Inhibitors of the IFN response can be used to increase the growth of IFN 
sensitive viruses, including oncolytic viruses and live-attenuated viral vaccines 
(Jackson et al., 2016, Cataldi et al., 2015, Stewart et al., 2014). We assessed 
the replication of BunVΔNSs, a recombinant virus lacking its viral IFN antagonist 
(Weber et al., 2002), in the presence of StA-IFN-1 and StA-IFN-4. BunVΔNSs 
has a reduced plaque size in cell culture, whereas in the presence of TPCA-1, 
plaque size is increased by 6-fold. The plaque size in the presence of both StA-
IFN-1 and StA-IFN-4 significantly increased to almost 2-fold, and although 
marginal, these results are promising for further compound optimization. Due to 
its potent inhibition of IRF3, it was interesting that only a marginal increase in 
plaque size was observed in the presence of StA-IFN-4. We demonstrated that 
the lack of potency of StA-IFN-4 on BunVΔNSs plaque size was a result of 
instability in tissue culture, causing a rapid loss of compound activity. Therefore, 
to increase the stability of StA-IFN-4 medicinal chemistry is required. BunV is 
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sensed by RIG-I and has also been shown to activate PKR, which induces NF-
κB and IRF1-dependent pathways and also has direct antiviral activity 
(Streitenfeld et al., 2003). Therefore, to further assess StA-IFN-1 and StA-IFN-4 
for their ability to increase the growth of IFN sensitive viruses, plaque assays 
using viruses known to activate specific PRRs, such as IAV PR8 (Hale et al., 
2008), could be used. 
To the best of our knowledge, there are no known chemical antagonists 
of MAVS, and only one chemical modulator of RIG-I activity. Bufalin, an FDA 
approved cardiac glycoside, appears to inhibit the ATPase activity of RIG-I by 
increasing the intracellular sodium concentration (Ye et al., 2011). If StA-IFN-4 
specifically inhibits RIG-I or MAVS, it has various potential uses. For example, it 
could provide a straightforward method to transiently inhibit RIG-I or MAVS in a 
research environment. To achieve knockdown such as this currently, the use of 
expensive reagents such as short-interfering RNA, or the lengthy development 
of stable cell lines is required (Jiang et al., 2012, Schmolke et al., 2012, 
Spengler et al., 2015). Furthermore, knowledge regarding the mode of binding 
of a molecule specific to RIG-I could be used to highlight the mechanistic 
differences between RLRs. Targeting of RIG-I, MAVS or any their regulatory 
molecules such as TRIM25, PP1α or PP1γ, suggests that StA-IFN-4 could be a 
clinical candidate for use in the treatment of diseases associated with RLR 
dysfunction such as AGS, SMS and SLE (Buers et al., 2016, Rice et al., 2014, 
del Toro Duany et al., 2015, Miner and Diamond, 2014). 
As the precise target of StA-IFN-1 remains unknown, we can only 
speculate as to its specific application. If it does act in the NF-κB branch of IFN 
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induction, StA-IFN-1 has potential applications in the treatment of cancers and 
the aforementioned production of IFN sensitive viruses. Due to the involvement 
of NF-κB in the regulation of many cellular pathways, it has been the target of 
many drug discovery programs, and as such hundreds of modulators have 
already been identified (Ahmad et al., 2013, Herrington et al., 2015, Gilmore 
and Herscovitch, 2006). 
The potential uses of IFN induction inhibitors are numerous, ranging from 
clinical treatments to basic research tools. StA-IFN-1 and StA-IFN-4 although 
specifically inhibiting IFN induction require further characterization and 
medicinal chemistry to improve their potency before they can be considered 
NMEs. 
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7.3 Design and optimization of cell-based assays for 
HTS 
 The use of cell-based assays in HTS has increased dramatically in 
recent years due to their potential to indicate more biologically relevant 
characteristics of test compounds (Clemons et al., 2014). Due to the sensitivity 
of cells and the potential for variation within a population, optimization is crucial 
for an assay to be successful. Below, we will discuss some of the aspects 
involved in the successful development of phenotypic and targeted cell-based 
assays. 
7.3.1 Phenotypic assays 
 We successfully used a phenotypic fluorescent assay in HTS following 
the development of a reporter cell-line to monitor IFN induction. The IFN 
induction assay performed exceptionally following optimization achieving Z’ 
factors of >0.6 and S/B ratios >3, which are above pre-set industry standards 
(Iversen et al., 2006, Zhang, 1999). Although a S/B ratio of 3 may be regarded 
as relatively low in comparison to other reporter systems such as luciferase, 
where the S/B ratio can range from 79 to >11,000 (Guo et al., 2014, Martínez-
Gil et al., 2012, Patel et al., 2012), the Z’ factors achieved by these assays 
ranged between 0.3 and 0.7. Therefore, the excellent Z’ factors achieved by our 
assays are comparable to those of reporter assays associated with a large 
signal window. 
Typically, a high S/B ratio giving a larger signal window is advantageous 
to HTS and although an accurate and sensitive method (Zhang et al., 2012), the 
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use of enzyme reporters such as firefly and Renilla luciferase have been 
associated with compound interference from screening libraries (Auld et al., 
2008). Therefore, we believed that the use of GFP as a reporter would give rise 
to a more robust assay, less amenable to off-target compound interference. 
Although there remains the possibility that compounds in screening libraries 
could interfere with the generation of a fluorescent reporter signal, no detection 
method is capable of differentiating between real activity and interference 
(Gribbon and Sewing, 2003). That being said, the inclusion of a secondary 
reference signal could increase the robustness of an assay (Cali et al., 2008). 
For example, we could have included a constitutively expressed fluorophore in 
the IFN induction assay. The expression of mCherry for example, with excitation 
and emission wavelengths distinct from the GFP signal being assayed (Kremers 
et al., 2011), would potentiate the differentiation between test and control 
signals. This could reduce the false positive hit rate of the primary diversity 
screen by identifying compounds that interfere with signal generation, such as 
translational inhibitors, as both signals would be affected. Nevertheless, the IFN 
induction assay was optimized and validated as suitable for use in an HTS, 
where we successfully identified two specific inhibitors. 
We also validated the IFN signalling assay for use in HTS following cell 
line optimization and assay development. Prior to optimization, both the IFN 
induction and signalling assays had comparable levels of variability, although 
the initial S/B ratio of the A549/pr(ISRE).GFP cell line was below 2. Therefore, 
we sought to increase the signal window of the IFN signalling assay, theorizing 
that repeated rounds of lentivirus transduction could achieve this. Different 
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methods for the titration of lentivirus stock show inconsistency (Geraerts et al., 
2006), and as such they cannot be quantified in the same way as infectious 
viruses. The same principle of multiplicity of infection (MOI) can be applied, 
where plaque-forming units is substituted for transducing units. Working on the 
principle that one lentivirus results in one integration event per cell, applying the 
Poisson distribution suggests that only 62% of cells will be successfully 
transduced from an MOI of 1 (Fields et al., 2013). By increasing the rounds of 
lentivirus transduction, we effectively increase the MOI. Thus, following multiple 
rounds of transduction, each cell in the population should have at least one 
integration event. For the A549/pr(ISRE).GFP cell line, multiple rounds of 
lentiviral transduction followed by FACS significantly increased S/B ratio, 
potentiating the successful optimization and validation of the IFN signalling 
assay for HTS. Due to the excellent performance of the IFN induction and 
signalling assays in HTS, they have the potential to be used in HCS, where 
multiplexing of assays is potentiated (Nichols, 2006). As such, the IFN induction 
and signalling assays could be combined into one cell line. To achieve this, one 
of the promoters would need to drive the expression of a distinct fluorophore, 
such as the aforementioned mCherry. HCS is a powerful approach and 
multiplexing the IFN induction and signalling assays potentiates the screening 
of a compound library against both assays simultaneously, immediately 
allowing the identification of compounds acting specifically upon either pathway. 
Phenotypic assays are powerful tools for use in HTS as they not only 
indicate the biological activity of a test compound, but also, as we have 
demonstrated, have the potential to identify compounds with distinct targets. 
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The IFN induction assay was successfully optimized and validated for use in an 
HTS where it identified two specific inhibitors. The IFN signalling assay was 
also optimized and validated as suitable for HTS, and as such could be used to 
identify modulators of the IFN signalling pathway. Both GFP reporter assays 
produce excellent Z’ factors comparable to other reporter assays such as 
luciferase-based systems. 
7.3.2 Targeted cell-based assays 
As the IFN induction and signalling assays were successfully optimized 
and validated for use in HTS, we postulated that we could expand the assays 
and develop a platform to target viral IFN antagonists. We developed and 
validated an assay using the IFN signalling reporter cell line, in which RBV-P 
was constitutively expressed. The function of RBV-P antagonising IFN 
signalling results in the inhibition of GFP expression, and therefore, a 
compound that modulates RBV-P function will result in a restoration of GFP 
signal. We successfully performed an in-house HTS of 16,000 small molecules 
that performed well and remained robust throughout, identifying 56 putative hit 
compounds that resulted in an increase in GFP signal. During dose-response 
screening, all putative hits were eliminated as they either displayed inactivity or 
autofluorescence. As the A549/pr(ISRE).GFP.RBV-P cell line expresses high 
levels of RBV-P, we hypothesised that it may be saturating the IFN signalling 
pathway. Thus, a small molecule at a relatively low concentration of 11.42 µM 
may simply not be potent enough to modulate the protein-protein interaction of 
RBV-P with STATs (Kuenemann et al., 2016, Bakail and Ochsenbein, 2016). 
Therefore, the case may be that RBV-P is simply not a druggable target. If the 
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binding of RBV-P to STAT molecules is very rapid and highly stable, a small 
molecule may not be able to disrupt the interaction. A possible solution to this 
would be to alter the order in which the assay is performed. RBV-P binds only to 
phosphorylated STAT molecules (Wiltzer et al., 2014, Brzozka et al., 2006), 
which occurs only upon IFN signalling pathway activation. Therefore, compound 
treatment of the cells prior to IFNα treatment would allow for their binding to 
RBV-P and blockage of the interaction with phosphorylated STAT upon 
activation of IFN signalling. As small molecule compound libraries require 
constant upkeep and maintenance, an additional consideration as to why no 
modulators of RBV-P function were identified may be the size and age of the 
library used. The Maybridge library at just 16,000 compounds has undergone 
countless freeze-thaw cycles, which could expedite compound loss. A study by 
Kozikowski et al demonstrated that although not due to considerable levels of 
compound degradation, loss was observed following just 5 freeze-thaw cycles, 
most probably due to compound precipitation (Kozikowski et al., 2003). 
To simplify the assay to require only one cell line, and have greater 
control over the levels of RBV-P expressed, we further developed this assay 
format with a derivative of the IFN signalling reporter cell line where RBV-P 
gene expression is under the control of a Dox inducible promoter. Initially, the 
expressed viral protein did not fully block the IFN signalling pathway. We 
hypothesized that this was due to inconsistent levels of RBV-P expression 
within the cell population, and confirmed this through immunofluorescent 
microscopy illustrating that RBV-P and GFP expression were indeed 
heterogeneous and appeared mutually exclusive. Additionally, the 
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corresponding FACS profile of this cell line showed 2 distinct sub-populations. 
As with the parental A549/pr(ISRE).GFP cell line, we successfully optimized the 
inducible expression cell line through multiple rounds of lentivirus transduction 
followed by FACS. Although requiring further characterization, we have 
optimized the inducible RBV-P assay, and demonstrated a straightforward 
method by which an HTS appropriate assay, targeting a specific viral protein, 
can be developed. Furthermore, the inducible assay format can be applied to a 
variety of viral IFN antagonists, including those of high containment category 
viruses, as whole, live virus is not required. This may be a more favourable 
approach for pharmaceutical companies to adopt, as it does not require 
expensive high containment facilities. An interesting option for further expansion 
of the assay would be through the use of a dual reporter cell line as previously 
discussed, where the IFNβ promoter drives the expression of GFP and another 
fluorophore is under the control of the MxA promoter. Thus, when used in HTS, 
it could potentiate the simultaneous detection of hit compounds that modulate 
the IFN induction or signalling functions of a viral IFN antagonist. 
We have successfully expanded the IFN signalling assay to develop an 
screening platform to target viral IFN antagonists, which could identify 
compounds with potential uses as antiviral drugs. Through the use of an 
inducible expression system and multiple rounds of lentivirus transduction, we 
have demonstrated the flexibility of this assay format, and highlighted 
approaches that potentiate successful assay optimization. 
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7.4 Concluding remarks 
 With the primary aim of developing a fluorescent-based phenotypic 
assay for use in HTS to identify novel modulators of the IFN response, we 
instigated a campaign of optimization of two reporter assays to monitor the 
activity of the IFN induction and IFN signalling pathways. Through successful 
optimization and validation, the IFN induction assay was used in an HTS 
against 15,667 small molecules that culminated in the identification of 2 specific 
IFN induction inhibitors. Although not inconsequential, StA-IFN-1 is arguably 
less interesting in comparison to StA-IFN-4, which appears to target the IFN 
induction pathway upstream of TRAF3, potentially directed against RIG-I or 
MAVS. Both compounds warrant further investigation and chemical optimization 
to improve potency and pinpoint their mode of action. Nevertheless, they 
provide an exciting starting point for the development of novel therapeutics 
against RLR-associated diseases and as chemical tools to expedite the growth 
of live-attenuated viral vaccines and oncolytic viruses. 
We also demonstrate the optimization of the signal window of a 
fluorescent assay through the use of multiple lentiviral transduction and FACS. 
Additionally, we extended the IFN signalling assay to incorporate the 
expression of the RBV IFN antagonist and demonstrate the development of a 
target-specific fluorescent assay through the use if an inducible expression 
system. This assay can be easily manipulated to target the IFN antagonists of 
different clinically relevant viruses, including those typically requiring high 
containment facilities. 
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